Compounds comprising fibroblast activating protein ligands and uses thereof

By developing FAP inhibitors with specific cyclic peptide structures, the problems of inefficiency and poor selectivity of existing FAP inhibitors in diagnosis and treatment are solved, and the efficient inhibition and therapeutic effect of FAP is achieved, especially in cancer and In other FAP-related diseases.

CN118930608APending Publication Date: 2024-11-123B PHARM GMBH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411047674.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-09-20
Filing Date
2020-07-08
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing FAP inhibitors and targeted therapies have problems with low efficiency, poor selectivity and stability in diagnosis and treatment, making it difficult to effectively inhibit FAP activity, especially in cancer and other diseases, especially because FAP in lesion cells and High expression in tissues leads to poor treatment results.

Method used

A compound containing a specific cyclic peptide structure has been developed to form a potent FAP inhibitor by binding to the FAP active site, with a pIC50 value preferably equal to or greater than 6.0, which can effectively inhibit FAP activity and be used in diagnosis and treatment. The agent is delivered to the lesion cells and tissues expressing FAP.

Benefits of technology

It achieves efficient inhibition of FAP, improves the selectivity and stability of treatment, can be effectively delivered to lesion cells and tissues, and enhances the therapeutic effect on cancer and other FAP-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930608A_ABST
    Figure CN118930608A_ABST
Patent Text Reader

Abstract

# imgabs0 # The present invention relates to compounds comprising fibroblast activating protein ligands and uses thereof, in particular to compounds comprising a cyclic peptide of formula (I) wherein each and any of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is an amino acid residue and Yc is the structure of formula (X) and uses thereof, and in particular to compounds comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1 and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese invention patent application No. 202080062641.3, filed on July 8, 2020, entitled “Compounds containing fibroblast activation protein ligands and their uses”. Technical Field

[0002] The present invention relates to compounds; fibroblast activation protein (FAP) inhibitors; compositions comprising the compounds and inhibitors, respectively; the compounds, inhibitors, and compositions, respectively, for use in methods for diagnosing a disease; the compounds, inhibitors, and compositions, respectively, for use in methods for treating a disease; the compounds, inhibitors, and compositions, respectively, for use in methods for diagnosing and treating a disease (also referred to as "thera(g)nosis" or "thera(g)nostics"); the compounds, inhibitors, and compositions, respectively, for use in methods for delivering effectors to tissues expressing FAP; methods of using the compounds, inhibitors, and compositions, respectively, for diagnosing a disease; methods of using the compounds, inhibitors, and compositions, respectively, for treating a disease; methods of using the compounds, inhibitors, and compositions, respectively, for diagnosing a disease (also referred to as "thera(g)nosis" or "thera(g)nostics"); methods of using the compounds, inhibitors, and compositions, respectively, for delivering effectors to tissues expressing FAP. Background Art

[0003] Despite a growing number of treatment options, cancer remains the second leading cause of death worldwide. Treatment strategies have primarily focused on targeting malignant cancer cells themselves, while neglecting the ever-present tumor microenvironment (TME) that limits the access of cancer therapeutics (Valkenburg et al., Nat Rev Clin Oncol, 2018, 15:366). The TME is part of the tumor mass and contains not only a heterogeneous population of cancer cells but also a variety of resident and infiltrating host cells, secreted factors, and extracellular matrix proteins (Quail et al., Nat Med, 2013, 19:1423). The predominant cell type found within the TME is cancer-associated fibroblasts (CAFs) (Kalluri et al., Nat Rev Cancer, 2016, 16:582). Many different cell types have been described as the source and origin of CAFs, such as fibroblasts, mesenchymal stem cells, smooth muscle cells, epithelial-derived cells, or endothelial cells (Madar et al., Trends Mol Med, 2013, 19:447). CAFs exhibit mesenchymal-like characteristics and are often the predominant cell type in solid tumor masses. CAFs are receiving increasing attention as players in tumor progression and homeostasis (Gascard, et al., Genes Dev, 2016, 30:1002; LeBleu, et al., Dis Model Mech, 2018, 11).

[0004] In recent years, fibroblast activation protein (FAP) has become widely known as a marker for CAFs (Shiga et al., Cancers (Basel), 2015, 7:2443; Pure et al., Oncogene, 2018, 37:4343; Jacob et al., Curr Mol Med, 2012, 12:1220). Due to the ubiquitous presence of CAFs and stroma within tumors, FAP has been found to be a suitable marker for radiopharmaceutical diagnosis and a suitable target for radiopharmaceutical therapy (Siveke, J Nucl Med, 2018, 59:1412).

[0005] Fibroblast activation protein alpha (FAP) is a type II transmembrane serine protease and a member of the S9 prolyl oligopeptidase family (Park et al., J Biol Chem, 1999, 274:36505). Its closest family member, DPP4, shares 53% homology with FAP. Like other DPPases (DPP4, DPP7, DPP8, and DPP9), FAP possesses post-proline exopeptidase activity. Furthermore, FAP possesses endopeptidase activity, similar to prolyl oligopeptidase / endopeptidase (POP / PREP). The FAP gene is highly conserved across species. The extracellular domain of human FAP shares 90% amino acid sequence identity with mouse and rat FAP. Mouse FAP shares 97% sequence identity with rat FAP.

[0006] Structurally, FAP is a 760-amino acid transmembrane protein consisting of a short N-terminal cytoplasmic tail (6 amino acids), a single transmembrane domain (20 amino acids), and a 734-amino acid extracellular domain (Aertgeerts et al., J Biol Chem, 2005, 280:19441). This extracellular domain consists of an eight-bladed β-helix and an α / β hydrolase domain. The catalytic triad, comprising Ser624, Asp702, and His734, is located at the interface of the β-helix and hydrolase domains. The active site is accessible through a central pore in the β-helix domain or through a narrow cavity between the β-helix and hydrolase domains. FAP monomers are inactive, but form active homodimers and heterodimers with DPP4 (Ghersi et al., Cancer Res, 2006, 66:4652). Soluble homodimeric FAP has also been described (Keane, et al., FEBS Open Bio, 2013, 4:43; Lee, et al., Blood, 2006, 107:1397).

[0007] FAP has dual enzymatic activity (Hamson et al., Proteomics Clin Appl, 2014, 8:454). Its dipeptidyl peptidase activity allows for the cleavage of two amino acids at the N-terminus following the proline residue. FAP substrates rapidly cleaved by its dipeptidyl peptidase activity include neuropeptide Y, peptide YY, substance P, and B-type natriuretic peptide. Collagen I and III, FGF21, and α2-antiplasmin have been shown to be cleaved by FAP's endopeptidase activity. Although FAP is unable to cleave native collagen, predigestion with other proteases, such as matrix metalloproteinases, facilitates further collagen cleavage by FAP. Collagen processing may affect the migratory ability of cancer cells. In addition to increasing cancer cell invasiveness through extracellular matrix remodeling, several other FAP-mediated tumor-promoting effects have been proposed, including proliferation and increased angiogenesis. Furthermore, interstitial expression of FAP has been associated with escape from immune surveillance in various cancers, suggesting a role in anti-tumor immunity (Pure, et al., Oncogene, 2018, 37:4343).

[0008] FAP is transiently expressed during normal development but is rarely expressed in healthy adult tissues. In transgenic mice, FAP has been shown to be expressed in adipose tissue, skeletal muscle, skin, bone, and pancreas (Pure et al., Oncogene, 2018, 37:4343; Roberts et al., J Exp Med, 2013, 210:1137). However, FAP knockout mice have a healthy phenotype, suggesting a redundant role under normal conditions (Niedermeyer et al., Mol Cell Biol, 2000, 20:1089). FAP is highly upregulated in mesenchymal cells at sites of active tissue remodeling, including wound healing, fibrosis, arthritis, atherosclerosis, and cancer (Pure et al., Oncogene, 2018, 37:4343).

[0009] Using the monoclonal antibody F19, FAP expression was first reported in 1990, in the tumor stroma of 90% of epithelial cancers (Garin-Chesa et al., Proc Natl Acad Sci USA, 1990, 87:7235; Rettig et al., Cancer Res, 1993, 53:3327). FAP-expressing stromal cells were further characterized as cancer-associated fibroblasts (CAFs) and cancer-associated pericytes (Cremasco et al., Cancer Immunol Res, 2018, 6:1472). FAP expression has also been reported on malignant epithelial cells, but its significance remains to be determined (Pure et al., Oncogene, 2018, 37:4343). Table 1 below is excerpted from Busek et al. (Busek, et al., Front Biosci (Landmark Ed), 2018, 23:1933), which summarizes the expression of FAP in various malignant tumors, indicating the tumor type and cell expression.

[0010] Table 1: FAP expression in human malignancies (from Busek et al.)

[0011]

[0012]

[0013]

[0014] FAP expression in CAFs has been shown in nearly all carcinomas and sarcomas (Pure, et al., Oncogene, 2018, 37:4343; Busek, et al., Front Biosci (Landmark Ed), 2018, 23:1933). Furthermore, CAFs are present in hematological malignancies (Raffaghello, et al., Oncotarget, 2015, 6:2589). Therefore, the use of FAP as a therapeutic target is not limited to certain tumor entities.

[0015] Many CAFs expressing FAP have been described to be associated with poor prognosis. Across a wide range of human tumor indications, FAP expression has been described to be associated with higher tumor grade and poorer overall survival (Pure, et al., Oncogene, 2018, 37:4343).

[0016] As described above, FAP present in the tumor microenvironment and cells expressing FAP have been shown to significantly influence tumor progression (Hanahan, et al., Cancer Cell, 2012, 21:309). In addition, as described below, due to its relatively selective expression in tumors, FAP is considered a suitable target for therapeutic and diagnostic agents (Siveke, J Nucl Med, 2018, 59:1412; Christiansen, et al., Neoplasia, 2013, 15:348; Zi, et al., Mol Med Rep, 2015, 11:3203).

[0017] Soon after its discovery, FAP was exploited as a therapeutic target for cancer. To this day, various strategies have been explored, including, for example, inhibition of FAP enzymatic activity, ablation of FAP-positive cells, or targeted delivery of cytotoxic compounds.

[0018] In 2007, Point Therapeutics developed the FAP and DPP4 inhibitor Talabostat (Val-boro-Pro, PT-100) (e.g., as described in U.S. Patent No. 6,890,904, WO9916864). Pennisi et al. (Pennisi, et al., Br J Haematol, 2009, 145:775) observed reduced tumor growth in animal models of multiple myeloma and in syngeneic mouse models of cancer. In addition, several other prolyl boronic acid derivatives have been developed and reported as putative selective inhibitors of FAP. These derivatives exhibit instability in aqueous environments at physiological pH (Coutts, et al., J Med Chem, 1996, 39:2087) and have nonspecific reactivity with other enzymes.

[0019] WO 2008 / 116054 discloses hexapeptide derivatives, wherein the compounds contain a C-terminal bis-amino or boronic acid functional group.

[0020] US2017 / 0066800 discloses pseudopeptide inhibitors effective against FAP, such as M83. These inhibitors were evaluated in lung and colon cancer xenografts in immunodeficient mice. Tumor growth inhibition was observed (Jackson et al., Neoplasia, 2015, 17:43). These pseudopeptides inhibit the activity of prolyl oligopeptidases (POP / PREP) and FAP, thus precluding their use as specific therapeutic FAP inhibitors.

[0021] US 2008 / 280856 discloses a nanomolar boronic acid-based inhibitor that exhibits bispecific inhibition of FAP and PREP, thereby precluding its use as a specific therapeutic FAP inhibitor.

[0022] Cyclic peptide-based FAP inhibitors are disclosed, for example, in WO 2016 / 146174 and WO 2006 / 042282. WO 2016 / 146174 discloses peptides for the diagnosis and treatment of FAP-expressing tumors, exhibiting specificity for FAP while not recognizing its closely related homolog, DPP4. WO 2006 / 042282 discloses polypeptides for the treatment of melanoma, demonstrating inhibitory effects on melanoma growth and metastasis in nude mice.

[0023] WO 99 / 75151 and WO 01 / 68708 disclose humanized FAP monoclonal antibody F19 (sibrotuzumab). Furthermore, WO 99 / 57151 and WO 01 / 68708 disclose anti-FAP antibody F19 and humanized versions thereof. Development methods involve, for example, the generation of high-affinity, species-cross-reactive, FAP-specific scFvs that are converted to bivalent derivatives (Brocks et al., Mol Med, 2001, 7:461). In Phase I and II clinical trials, sibrotuzumab demonstrated specific tumor accumulation in patients with metastatic colorectal cancer, but failed to demonstrate measurable therapeutic activity, with only 2 of 17 patients achieving stable disease (Hofheinz et al., Onkologie, 2003, 26:44). This F19 antibody has not been shown to block any cellular or protease function of FAP, which may explain the lack of therapeutic effect (Hofheinz, et al., Onkologie, 2003, 26:44; Scott, et al., Clin Cancer Res, 2003, 9:1639).

[0024] US2018 / 022822 discloses novel molecules that specifically bind to human FAP and its epitopes, as humanized antibodies and chimeric antigen receptors (CARs), which can be used to treat diseases and conditions induced by FAP. Treatment of mice bearing orthotopic syngeneic MC38 colorectal tumors with anti-FAP antibodies reduced tumor diameter and the number of metastases. WO 2012 / 020006 discloses glycoengineered antibodies with modified oligosaccharides in the Fc region. Subsequently, bispecific antibodies specific for FAP and DR5 were developed according to WO 2014 / 161845. These antibodies induced tumor cell apoptosis in in vitro and in vivo preclinical tumor models with FAP-positive stroma (Brunker et al., Mol Cancer Ther, 2016, 15:946). WO 2015 / 118030 describes antibody-drug conjugates and immunotoxins targeting FAP. While the anti-hu / moFAP hu36:cytolysin ADC candidates demonstrated in vitro toxicity and in vivo tumor growth inhibition following administration, it is unclear whether these antibodies can inhibit FAP activity.

[0025] Jansen et al. (Jansen, et al., J Med Chem, 2014, 57:3053; Jansen, et al., ACSMed Chem Lett, 2013, 4:491) described small molecule FAP inhibitors based on (4-quinolinyl)glycyl-2-cyanopyrrolidine that exhibit low nanomolar inhibitory potency and high selectivity for related DPPs and PREPs and are disclosed in WO 2013 / 107820. However, these compounds are structurally unrelated to the compounds of the present invention and include a warhead that results in covalent binding to FAP.

[0026] In recent years, several radiopharmaceutical approaches to targeting FAP have been developed and are exemplarily described herein.

[0027] WO 2010 / 036814 discloses small molecule inhibitors of FAP that are useful as therapeutic agents by inhibiting FAP enzymatic activity or as radiopharmaceuticals by binding to FAP.

[0028] WO 2019 / 083990 discloses imaging and radiotherapy agents based on small molecule FAP inhibitors described by Jansen et al. (Jansen, et al., J Med Chem, 2014, 57:3053; Jansen, et al., ACS Med Chem Lett, 2013, 4:491). In addition, several authors have described imaging of FAP inhibitors based on the work of Jansen et al. (Jansen, et al., J Med Chem, 2014, 57:3053; Jansen, et al., ACS Med Chem Lett, 2013, 4:491) and the selective uptake of radiotherapeutic agents in tumors of cancer patients (Lindner, et al., J Nucl Med, 2018, 59:1415; Loktev, et al., J Nucl Med, 2018, 59:1423; Giesel, et al., J Nucl Med, 2019, 60:386; Loktev, et al., J Nucl Med, 2019, Mar 8 (epub ahead of print); Giesel, et al., Eur J Nucl Med Mol Imaging, 2019, 46:1754; Kratochwil ...23; Giesel, et al., J Nucl Med, 2019, 60:386; Loktev, et al., J Nucl Med, 2019, Mar 8 (epub ahead of print); Giesel, et al., Eur J Nucl Med Mol Imaging, 2019, 46:1 Med, 2019, 60:801).

[0029] right 131 Clinical evaluation of an I-labeled humanized form of the F19 antibody (sibrotuzumab) showed selective uptake by tumors rather than normal tissues in patients with colorectal cancer or non-small cell lung cancer (Scott, et al., Clin Cancer Res, 2003, 9:1639). This may be due to the long circulation time of the antibody, making it unsuitable for diagnostic, therapeutic, or theranostic methods involving radionuclides.

[0030] WO 2011 / 040972 discloses high-affinity antibodies that recognize human and murine FAP antigens as potent radioimmunoconjugates. ESC11 IgG1 induces downregulation and internalization of surface FAP (Fischer et al., Clin Cancer Res, 2012, 18:6208). WO 2017 / 211809 discloses tissue-targeted thorium-227 complexes in which the targeting moiety is specific for FAP. However, the long circulation time of antibodies makes them unsuitable for diagnostic, therapeutic, or theranostic methods involving radionuclides.

[0031] FAP has also been described in diseases other than oncology indications, examples of which are listed below.

[0032] Fibroblast-like synoviocytes in rheumatoid arthritis joints show significantly increased expression of FAP (Bauer et al., Arthritis Res Ther, 2006, 8:R171; Milner et al., Arthritis Res Ther, 2006, 8:R23). In rheumatoid arthritis, interstitial cells play a crucial role in organizing the synovial tissue structure by producing extracellular matrix components, recruiting infiltrating immune cells, and secreting inflammatory mediators. There is considerable evidence supporting the role of these cells in driving inflammation and perpetuating joint damage (Bartok et al., Immunol Rev, 2010, 233:233; Turner et al., Curr Opin Rheumatol, 2015, 27:175). In rheumatoid arthritis, FAP plays a pathological role in cartilage turnover, at least by promoting proteoglycan loss and subsequent cartilage degradation (Bauer, et al., Arthritis Res Ther, 2006, 8: R171; Waldele, et al., Arthritis Res Ther, 2015, 17: 12). Therefore, it can be used as a marker for patient stratification, for the assessment and follow-up of treatment success, or as a therapeutic target (Bauer, et al., Arthritis Res Ther, 2006, 8: R171). In mice, FAP was expressed in the presence of 1% FAP. 99m SPECT / CT imaging of Tc-labeled anti-FAP antibodies demonstrated therapeutic response (van der Geest, et al., Rheumatology (Oxford), 2018, 57:737; Laverman, et al., J Nucl Med, 2015, 56:778; van der Geest, et al., J Nucl Med, 2017, 58:151).

[0033] Furthermore, FAP is not only considered a marker of activated fibroblasts in response to injury (Tillmanns et al., Int J Cardiol, 2013, 168:3926), but is also a key player in the wound healing process (Ramirez-Montagut et al., Oncogene, 2004, 23:5435). Jing et al. demonstrated a time-dependent course of FAP expression changes after burns in rats (Jing et al., Nan Fang Yi Ke Da Xue Xue Bao, 2013, 33:615). Inhibiting FAP activity in reactive wound fibroblasts in keloid scars (common benign fibroproliferative reticular dermal lesions) may provide a therapeutic option to prevent disease progression (Dienus et al., Arch Dermatol Res, 2010, 302:725).

[0034] In fibrotic diseases, FAP expression is observed to be upregulated, such as in idiopathic pulmonary fibrosis, Crohn's disease, and liver fibrosis. In an in vitro model of Crohn's disease (a chronic intestinal inflammatory disease characterized by excessive and unbalanced extracellular matrix (ECM) deposition), FAP expression was observed to be upregulated. FAP inhibition reestablishes extracellular matrix homeostasis (Truffi, et al., Inflamm Bowel Dis, 2018, 24:332). Egger et al. (Egger, et al., Eur J Pharmacol, 2017, 809:64) also made similar observations using a mouse model of pulmonary fibrosis. FAP inhibition leads to a reduction in fibrotic pathology. FAP is also expressed in tissue remodeling areas of chronically injured livers (Wang et al., Front Biosci, 2008, 13:3168), and FAP expression in hepatic stellate cells correlates with the histological severity of liver disease (Gorrell et al., Adv Exp Med Biol, 2003, 524:235). Therefore, FAP is also a promising target for the treatment of liver fibrosis (Lay et al., Front Biosci (Landmark Ed), 2019, 24:1).

[0035] FAP is expressed in atherosclerotic lesions and is upregulated in activated vascular smooth muscle cells (Monslow et al., Circulation, 2013, 128:A17597). Monslow et al. demonstrated that targeted inhibition of FAP in atherosclerotic lesions can reduce overall lesion burden, inhibit inflammatory cell homing, and increase lesion stability through its ability to alter lesion architecture by favoring matrix-rich lesions over inflammation. Importantly, most atherosclerotic lesions share a common pathogenic feature: atherosclerotic lesions are initiated by rupture of atherosclerotic plaques (Davies et al., Br Heart J, 1985, 53:363; Falk, Am J Cardiol, 1989, 63:114e). Rupture of the fibrous cap in advanced atherosclerotic plaques is a key trigger for acute coronary syndromes, which can lead to myocardial infarction and sudden cardiac death. One of the key events that promotes plaque instability is the degradation of the fibrous cap, which exposes the potentially thrombotic plaque core to the bloodstream, leading to thrombosis and subsequent vascular occlusion (Farb et al., Circulation, 1996, 93:1354; Virmani et al., J Am Coll Cardiol, 2006, 47:C13). Brokopp et al. demonstrated that FAP contributes to the breakdown of type I collagen in the fibrous cap (Brokopp et al., Eur Heart J, 2011, 32:2713). Radiolabeled tracers have been developed and shown to be suitable for imaging atherosclerosis (Meletta et al., Molecules, 2015, 20:2081). Summary of the Invention

[0036] The problem underlying the present invention is to provide compounds suitable as diagnostic and / or pharmaceutical agents, in particular when conjugated to a diagnostically and / or therapeutically active effector. Another problem underlying the present invention is to provide compounds suitable as diagnostic and / or pharmaceutical agents, in particular when conjugated to a diagnostically and / or therapeutically active effector, such that the compounds are potent inhibitors of FAP activity; preferably, the pIC50 of the compounds is equal to or greater than 6.0. Another problem underlying the present invention is to provide compounds suitable as diagnostic and / or pharmaceutical agents in the diagnosis and / or treatment of diseases, in particular when conjugated to a diagnostically and / or therapeutically active effector, wherein the diseased cells and / or diseased tissue express FAP. A further problem underlying the present invention is to provide compounds suitable for delivering diagnostically and / or therapeutically effective agents, respectively, to diseased cells and / or diseased tissue, more particularly to diseased cells and / or diseased tissue expressing FAP, preferably wherein the diseased tissue comprises or contains cancer-associated fibroblasts. Furthermore, the present invention is based on the problem of providing methods for diagnosing a disease, methods for treating and / or preventing a disease, and methods for combined diagnosis and treatment of a disease; preferably, such a disease involves cells and / or tissue expressing FAP, more particularly diseased cells and / or diseased tissue expressing FAP, preferably said diseased tissue comprising or containing cancer-associated fibroblasts. Another problem underlying the present invention is to provide methods for identifying individuals who may or may not respond to a treatment for a disease, and methods for selecting individuals from a group of individuals who may or may not respond to a treatment for a disease. Furthermore, the present invention is based on the problem of providing pharmaceutical compositions containing compounds having the characteristics described above. Furthermore, the present invention is based on the problem of providing kits suitable for use in any of the above methods.

[0037] There is a need for compounds suitable as diagnostic and / or pharmaceutical agents, particularly when conjugated to a diagnostically and / or therapeutically active effector. Furthermore, there is a need for compounds suitable as diagnostic and / or pharmaceutical agents, particularly when conjugated to a diagnostically and / or therapeutically active effector, such that the compound is a potent inhibitor of FAP activity; preferably, the compound has a pIC50 of 6.0 or greater. Furthermore, there is a need for compounds suitable as diagnostic and / or pharmaceutical agents in the diagnosis and / or treatment of diseases, particularly when conjugated to a diagnostically and / or therapeutically active effector, wherein the diseased cells and / or diseased tissue express FAP. Furthermore, there is a need for compounds suitable for delivering diagnostically and / or therapeutically effective agents to diseased cells and / or diseased tissue, more particularly diseased cells and / or diseased tissue expressing FAP, preferably wherein the diseased tissue comprises or contains cancer-associated fibroblasts. Additionally, there is a need for methods for diagnosing a disease, methods for treating and / or preventing a disease, and methods for combining the diagnosis and treatment of a disease; preferably, such a disease involves cells and / or tissue expressing FAP, more particularly diseased cells and / or diseased tissue expressing FAP, preferably diseased tissue comprising or containing cancer-associated fibroblasts. Furthermore, there is a need for methods for identifying individuals who may or may not respond to treatment for a disease, and methods for selecting individuals from a group of individuals who may or may not respond to treatment for a disease. Furthermore, there is a need for pharmaceutical compositions containing compounds having the above-described characteristics. Furthermore, there is a need for kits suitable for use in any of the above-described methods. The present invention addresses these needs.

[0038] These and other problems are solved by the subject matter of the appended claims.

[0039] These and other problems on which the present invention is based are also solved by the following embodiments.

[0040] Embodiment 1. A compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1,

[0041]

[0042] in:

[0043] The peptide sequences are drawn from left to right in the direction of N-terminus to C-terminus.

[0044] Xaa1 is the residue of an amino acid of formula (II),

[0045]

[0046] in:

[0047] R 1a is –NH-,

[0048] R 1b is H or CH3,

[0049] n=0 or 1,

[0050] The N-terminal modification group A is covalently linked to the nitrogen atom of Xaa1,

[0051] The carbonyl group of Xaa1 is covalently linked to the nitrogen of Xaa2.

[0052] and the sulfur atom of Xaa1 is covalently linked to Yc as a thioether;

[0053] Xaa2 is the residue of an amino acid of formula (III), (IV) or (XX),

[0054]

[0055] in:

[0056] R 2a 、R 2b and R 2c are each independently selected from (C1-C2)alkyl and H, wherein said (C1-C2)alkyl may be substituted by a substituent selected from OH, NH2, halogen, (C5-C7)cycloalkyl,

[0057] p = 0, 1, or 2

[0058] v = 1 or 2

[0059] w = 1, 2, or 3, and

[0060] The amino acid of formula (IV) may be substituted at ring positions 3 and 4 as shown by one or two substituents selected from methyl, OH, NH2 and F;

[0061] Xaa3 is the residue of an amino acid of formula (V) or (XX),

[0062]

[0063] in:

[0064] X 3 Selected from CH2, CF2, CH-R 3b , S, O and NH,

[0065] p = 1 or 2

[0066] v = 1 or 2

[0067] w=1, 2 or 3,

[0068] R 3a is H, methyl, OH, NH2 or F,

[0069] R 3b is methyl, OH, NH2 or F;

[0070] Xaa4 is the residue of an amino acid of formula (VI),

[0071]

[0072] in:

[0073] R 4a Selected from H, OH, COOH, CONH2, X 4 and -NH-CO-X 4 , where X 4 is selected from (C1-C6)alkyl, (C5-C6)aryl and (C5-C6)heteroaryl, and X 4 may be substituted by one or two substituents selected from methyl, CONH2, halogen, NH2 and OH;

[0074] q=1, 2 or 3, wherein optionally, one or both hydrogens of said 1, 2 or 3 CH2 groups are each and independently substituted by methyl, ethyl, (C5-C6)aryl or (C5-C6)heteroaryl,

[0075] R 4b is methyl or H;

[0076] Xaa5 is an amino acid residue of structure (VII),

[0077]

[0078] in:

[0079] R 5 selected from OH and NH2, and

[0080] r = 1, 2, or 3;

[0081] Xaa6 is an amino acid selected from aromatic L-α-amino acids and heteroaromatic L-α-amino acids;

[0082] Xaa7 is an aminothiol or amino acid residue of formula (IX),

[0083]

[0084] in:

[0085] R 7a -CO-, -COOH, -CONH2, -CH2-OH, -(CO)-NH-R 7b 、-(CO)-(NR 7c )-R 7b or H, where R7b and R 7c are each and independently (C1-C4)alkyl, and

[0086] t is 1 or 2;

[0087] Yc is a structure of formula (X),

[0088]

[0089] It connects the S atom of Xaa1 and the S atom of Xaa7 while forming two thioether bonds, thereby forming a cyclic structure of formula (XXI),

[0090]

[0091] in:

[0092] The substitution pattern of the aromatic group in formula (X) is ortho, meta or para,

[0093] n=0 or 1,

[0094] t = 1 or 2,

[0095] Y 1 is CH or N,

[0096] Y 2 Is N or CR c1 ,

[0097] R c1 is H or CH2-R c2 ,as well as

[0098] R c2 is a structure of formula (XI), (XII) or (XXII),

[0099]

[0100] in:

[0101] R c3 and R c4 are each and independently selected from H and (C1-C4)alkyl, and

[0102] u=1, 2, 3, 4, 5 or 6,

[0103] x and y are each and independently selected from 1, 2 or 3, and

[0104] X=O or S,

[0105] Wherein in formula (XI) and (XXII), one of the nitrogen atoms is connected to R c1 -CH2-, and in formula (XII), -X- is connected to Rc1 -CH2-; and

[0106] Wherein the N-terminal modification group A is a protecting group Abl or amino acid Aaa.

[0107] Embodiment 2. A compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1,

[0108]

[0109] in:

[0110] The peptide sequences are drawn from left to right in the direction of N-terminus to C-terminus.

[0111] Xaa1 is the residue of an amino acid of formula (II),

[0112]

[0113] in:

[0114] R 1a It is -NH-,

[0115] R 1b is H or CH3,

[0116] n=0 or 1,

[0117] The N-terminal modification group A is covalently linked to the nitrogen atom of Xaa1,

[0118] The carbonyl group of Xaa1 is covalently linked to the nitrogen of Xaa2.

[0119] and the sulfur atom of Xaa1 is covalently linked to Yc as a thioether;

[0120] Xaa2 is the residue of an amino acid of formula (III), (IV) or (XX),

[0121]

[0122] in:

[0123] R 2a 、R 2b 、R 2c are each independently selected from (C1-C2)alkyl and H, wherein said (C1-C2)alkyl may be substituted by a substituent selected from OH, NH2, halogen, (C5-C7)cycloalkyl,

[0124] p = 0, 1, or 2

[0125] v = 1 or 2

[0126] w = 1, 2, or 3, and

[0127] The amino acid of formula (IV) may be substituted at ring positions 3 and 4 as shown by one or two substituents selected from methyl, OH, NH2 and F;

[0128] Xaa3 is the residue of an amino acid of formula (V) or (XX),

[0129]

[0130] in:

[0131] X 3 Selected from CH2, CF2, CH-R 3b , S, O and NH,

[0132] p = 1 or 2

[0133] v = 1 or 2

[0134] w=1, 2 or 3,

[0135] R 3a is H, methyl, OH, NH2 or F,

[0136] R 3b is methyl, OH, NH2 or F;

[0137] Xaa4 is the residue of an amino acid of formula (VI),

[0138]

[0139] in:

[0140] R 4a Selected from H, OH, COOH, CONH2, X 4 and -NH-CO-X 4 , where X 4 is selected from (C1-C6)alkyl, (C5-C6)aryl and (C5-C6)heteroaryl, and X 4 may be substituted by one or two substituents selected from methyl, CONH2, halogen, NH2 and OH;

[0141] q=1, 2 or 3, wherein optionally, one or both hydrogens of said 1, 2 or 3 CH2 groups are each and independently substituted by methyl, ethyl, (C5-C6)aryl or (C5-C6)heteroaryl,

[0142] R 4b is methyl or H;

[0143] Xaa5 is an amino acid residue of structure (VII),

[0144]

[0145] in:

[0146] R 5 selected from OH and NH2, and

[0147] r = 1, 2, or 3;

[0148] Xaa6 is an amino acid selected from aromatic L-α-amino acids and heteroaromatic L-α-amino acids;

[0149] Xaa7 is an aminothiol or amino acid residue of formula (IX),

[0150]

[0151] in:

[0152] R 7a Yes –CO-XXX, -COOH, -CONH2, -CH2-OH, -(CO)-NH-R 7b 、-(CO)-(NR 7c )-R 7b or H, wherein XXX is an amino acid or peptide that forms an amide bond with the carbonyl carbon atom,

[0153] where R 7b and R 7c are each and independently (C1-C4)alkyl,

[0154] wherein the amino acid or the peptide is optionally substituted with a Z group, and

[0155] t is 1 or 2;

[0156] Yc is a structure of formula (X),

[0157]

[0158] It connects the S atom of Xaa1 and the S atom of Xaa7 while forming two thioether bonds, thereby forming a cyclic structure of formula (XXI),

[0159]

[0160] in:

[0161] The substitution pattern of the aromatic group in formula (X) is ortho, meta or para,

[0162] n=0 or 1,

[0163] t = 1 or 2,

[0164] Y 1 is CH or N,

[0165] Y 2 Is N or CR c1 ,

[0166] R c1 is H or CH2-R c2 ,as well as

[0167] R c2 is a structure of formula (XI), (XII) or (XXII),

[0168]

[0169] in:

[0170] R c3 and R c4 are each and independently selected from H and (C1-C4)alkyl,

[0171] R c5 is an H or Z group, and

[0172] u=1, 2, 3, 4, 5 or 6,

[0173] x and y are each and independently 1, 2 or 3, and

[0174] X=O or S,

[0175] Wherein in formula (XI) and (XXII), one of the nitrogen atoms is connected to R c1 -CH2-, and in formula (XII), -X- is connected to R c1 -CH2-;

[0176] as well as

[0177] wherein the N-terminal modification group A is a protecting group Abl or an amino acid Aaa, wherein the amino acid Aaa is optionally substituted with a Z group; and

[0178] Each Z group comprises a chelating agent and an optional linker.

[0179] Embodiment 3. The compound according to embodiment 2, wherein

[0180] R c5 is a Z group comprising a chelating agent and an optional linker,

[0181] R 7a Is -CO-XXX, -COOH, -CONH2, -CH2-OH, -(CO)-NH-R 7b 、-(CO)-(NR 7c )-R 7b or H, where R7b and R 7c Each and independently is (C1-C4)alkyl, XXX is an amino acid or a peptide that forms an amide bond with the carbonyl carbon atom, wherein the amino acid or the peptide is not substituted by a Z group comprising a chelator and an optional linker; and

[0182] If the N-terminal modification group A is the amino acid Aaa, the amino acid Aaa is not substituted by the Z group comprising a chelator and an optional linker,

[0183] Preferably, the compound comprises only one Z group, wherein the Z group comprises a chelating agent and an optional linker.

[0184] Embodiment 4. The compound according to any one of Embodiments 2 and 3, wherein:

[0185] R 7a Other than -CO-XXX, where XXX is an amino acid or peptide that forms an amide bond with the carbonyl carbon atom, and

[0186] If the N-terminal modification group A is the amino acid Aaa, the amino acid Aaa is not substituted by the Z group comprising the chelator and the optional linker.

[0187] Embodiment 5. The compound according to embodiment 2, wherein:

[0188] R 7a is -CO-XXX, wherein XXX is an amino acid or a peptide forming an amide bond with the carbonyl carbon atom, wherein said amino acid or said peptide is substituted with a Z group comprising a chelator and optionally a linker,

[0189] R c1 or R c5 is H, and

[0190] If the N-terminal modification group A is the amino acid Aaa, the amino acid Aaa is not substituted by the Z group comprising a chelator and an optional linker,

[0191] Preferably, the compound comprises only one Z group, wherein the Z group comprises a chelating agent and an optional linker.

[0192] Embodiment 6. The compound according to embodiment 2, wherein:

[0193] The N-terminal modification group A is an amino acid Aaa substituted with a Z group comprising a chelator and an optional linker,

[0194] R c1 or R c5 is H, and

[0195] R7a Is -CO-XXX-COOH, -CONH2, -CH2-OH, -(CO)-NH-R 7b 、-(CO)-(NR 7c )-R 7b or H, where R 7b and R 7c each and independently is a (C1-C4)alkyl group, XXX is an amino acid or a peptide that forms an amide bond with the carbonyl carbon atom, wherein the amino acid or the peptide is not substituted by a Z group comprising a chelator and an optional linker,

[0196] Preferably, the compound comprises only one Z group, wherein the Z group comprises a chelating agent and an optional linker.

[0197] Embodiment 7. The compound according to embodiment 6, wherein R 7a Different from -CO-XXX, where XXX is an amino acid or peptide which forms an amide bond with the carbonyl carbon atom.

[0198] Embodiment 8. The compound according to any one of embodiments 2, 6 and 7, wherein the amino acid Aaa is a D-amino acid residue or an L-amino acid residue, each of which has structure (XIV):

[0199]

[0200] in:

[0201] R a2 is selected from (C1-C6)alkyl, modified (C1-C6)alkyl, (C1-C3)alkyl, modified (C1-C3), (C3-C8)carbocycle, aryl, heteroaryl and (C3-C8)heterocycle, wherein in the modified (C1-C6)alkyl, one -CH2- group is replaced by -S- or -O-, and in the modified (C1-C3)alkyl, one H is replaced by OH, F or COOH, or two H are replaced by F, and wherein R a3 is a Z group.

[0202] Embodiment 9. A compound according to any one of embodiments 1, 2, 3, 4 and 5, wherein the protecting group Abl is selected from R a1 -C(O)-、R a1 -S(O2)-、R a1 -NH-C(O)- and R a1 -OC(O)-; where R a1is (C1-C8)alkyl optionally substituted by up to two substituents each and independently selected from OH, F, COOH, (C3-C8)cycloalkyl, aryl, heteroaryl and (C3-C8)heterocycle, and wherein in the (C1-C8)alkyl, one -CH2- group is optionally replaced by -S- or -O-.

[0203] Embodiment 10. The compound according to embodiment 9, wherein the protecting group Abl is R a1 -C(O)- or R a1 -S(O2)-, and R a1 is (C1-C6)alkyl, wherein optionally one -CH2- group is replaced by -S- or -O-.

[0204] Embodiment 11. The compound according to embodiment 10, wherein the protecting group Abl is hexanoyl or pentylsulfonyl, preferably the protecting group Abl is hexanoyl.

[0205] Embodiment 12. The compound according to any one of embodiments 1, 2, 3, 4 and 5, wherein the amino acid Aaa is a D-amino acid residue or an L-amino acid residue, each of which has structure (XIV):

[0206]

[0207] in:

[0208] R a2 is selected from (C1-C6)alkyl, modified (C1-C6)alkyl, (C1-C3)alkyl, modified (C1-C3)alkyl, (C3-C8)carbocycle, aryl, heteroaryl and (C3-C8)heterocycle, wherein in the modified (C1-C6)alkyl, one -CH2- group is replaced by -S- or -O-, and in the modified (C1-C3)alkyl, one H is replaced by OH, F or COOH, or two H are replaced by F,

[0209] where R a3 Preferred is H or acetyl.

[0210] Embodiment 13. The compound according to embodiment 12, wherein R a2 It is C 1-6 alkyl, and the C 1- One -CH2- group at C6 is replaced by -S-.

[0211] Embodiment 14. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13, preferably 12 to 13, wherein Aaa is selected from the amino acid residues of Nle, nle, Met and met, and derivatives thereof.

[0212] Embodiment 15. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, wherein Xaa1 is a D-amino acid residue selected from cys, hcy and pen, or Xaa1 is an L-amino acid residue selected from Cys, Hcy and Pen.

[0213] Embodiment 16. The compound according to embodiment 15, wherein Xaa1 is Cys.

[0214] Embodiment 17. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16, wherein Xaa2 is an amino acid residue selected from Pro, Gly, Nmg and derivatives thereof.

[0215] Embodiment 18. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17, wherein Xaa3 is an amino acid residue selected from Pro, Hyp, Tfp, Cfp, Dmp, Aze and Pip and derivatives thereof.

[0216] Embodiment 19. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18, wherein Xaa4 is an amino acid residue selected from Thr, Hse, Asn, Gln and Ser and derivatives thereof.

[0217] Embodiment 20. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19, wherein Xaa5 is an amino acid residue selected from Gln and Glu and derivatives thereof.

[0218] Embodiment 21. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20, wherein Xaa6 is an amino acid residue of any one of formula (VIIIa), (VIIIb), (VIIIc) and (VIIId):

[0219]

[0220] in:

[0221] R 6a and R 6bare each and independently selected from H, methyl, ethyl, propyl and isopropyl,

[0222] R 6c represents 0 to 3 substituents, each such substituent being individually and independently selected from Cl, F, Br, NO2, NH2, CN, CF3, OH, OR 6d and C1-C4 alkyl,

[0223] R 6d is selected from methyl, ethyl, propyl and isopropyl, and

[0224] s is 0 or 1.

[0225] Embodiment 22. The compound according to embodiment 21, wherein Xaa6 is an amino acid residue of any one of formulae (VIIIa), (VIIIb), (VIIIc) and (VIIId):

[0226]

[0227] in:

[0228] R 6a and R 6b Each is H,

[0229] R 6c represents 0 to 2 substituents, each such substituent being individually and independently selected from Cl, F, Br, NO2, NH2, CN, CF3, OH, OR 6d and methyl,

[0230] R 6d is selected from methyl, ethyl, propyl and isopropyl, and

[0231] s is 0.

[0232] Embodiment 23. The compound according to any one of embodiments 21 to 22, wherein Xaa6 is an amino acid residue selected from Phe, Ocf, Ppa, Thi, 1Ni, Otf and Mpa and derivatives thereof.

[0233] Embodiment 24. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23, wherein Xaa7 is an aminothiol residue selected from Cys, Cysol, AET, Hcy, cys and hcy.

[0234] Embodiment 25. The compound according to embodiment 24, wherein Xaa7 is an aminothiol residue selected from Cys, Cysol and AET.

[0235] Embodiment 26. A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25, wherein the compound is of formula (LI), (LII), (LIII) or (LIV):

[0236]

[0237] Embodiment 27. A compound according to claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25, preferably according to any one of claims 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25, wherein the compound comprises the structure of formula (LI), (LII), (LIII) or (LIV):

[0238]

[0239] Embodiment 28. A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 and 27, wherein R c2 is a structure of any one of formulae (XXIIa), (XIb) and (XIIa):

[0240]

[0241] where R c4 is H or methyl, and

[0242] u=1, 2, 3, 4 or 5,

[0243] In formula (XIb) and (XXIIa), any nitrogen atom is connected to R c1 -CH2-, and in formula (XIIa), -S- is connected to R c1 -CH2-.

[0244] Embodiment 29. A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28, wherein Yc is a structure of formula (XIII):

[0245]

[0246] Embodiment 30. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 and 29, wherein Yc comprises an NH group, preferably a reactive NH group, wherein the NH group allows the conjugation of a moiety to Yc, preferably the NH group is composed of the structure R c2 Provided, where R c2 is a structure selected from any one of formulae (XXIb), (XIc) and (XIIb):

[0247]

[0248] where R c4 is H or methyl, and

[0249] u=1, 2, 3, 4 or 5.

[0250] Embodiment 31. Compounds according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30, wherein structure R c2 Having formula (XXIIb) or (XIIc):

[0251]

[0252] Embodiment 32. A compound according to any one of embodiments 30 to 31, wherein the compound comprises a Z group, wherein the Z group is covalently linked to Yc, preferably covalently linked to a structure of formula (X), wherein the Z group comprises a chelating agent and an optional linker.

[0253] Embodiment 33. The compound according to embodiment 32, wherein the Z group is covalently linked to R c2 , forming a structure of any one of formula (XXIIc), (XId) and (XIId):

[0254]

[0255] where R c4 is H or methyl, and

[0256] u=1, 2, 3, 4 or 5.

[0257] Embodiment 34. A compound according to any one of embodiments 32 to 33, wherein the Z group comprises a linker, wherein the linker covalently links the chelator to Yc, preferably to R c2 .

[0258] Embodiment 35. The compound according to embodiment 34, wherein the covalent bond between Yc and the linker, preferably R c2 The covalent bond between the α-Hydroxy-L-pyrrolidone and the linker is an amide.

[0259] Embodiment 36. The compound according to any one of embodiments 34 to 35, wherein the chelator is covalently attached to the linker, wherein the covalent bond is selected from an amide bond, a urea bond, a carbamate bond, an ester bond, an ether bond, a thioether bond, a sulfonamide, a triazole, and a disulfide bond.

[0260] Embodiment 37. A compound according to any one of embodiments 32, 33, 34, 35 and 36, preferably a compound according to any one of claims 34, 35 and 36, wherein the linker is selected from Ttds, O2Oc, Apac, Gly, Bal, Gab, Mamb, Pamb, Ppac, 4Amc, Inp, Sni, Rni, Nmg, Cmp, PEG6, PEG12 and other PEG-amino acids, most preferably Ttds, O2Oc, Apac, 4Amc, PEG6 and PEG12.

[0261] Embodiment 38. The compound according to any one of embodiments 32 to 33, wherein the chelating agent is covalently linked to Yc, preferably to R c2 Covalently linked.

[0262] Embodiment 39. The compound according to embodiment 38, wherein the chelator is directly linked to Yc.

[0263] Embodiment 40. The compound according to any one of embodiments 38 to 39, wherein the Z group is free of any linker.

[0264] Embodiment 41. A compound according to any one of embodiments 38, 39 and 40, wherein the covalent bond between Yc and the chelating agent, preferably R c2 The covalent bond with the chelating agent is an amide.

[0265] Embodiment 42. Compounds according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, preferably embodiments 32, 33, 34, 35, 36, 37, The compound of any one of 38, 39, 40 and 41, wherein the chelating agent is selected from DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOTP, sarcophagine, FSC, NETA, H4octapa, Pycup, N x S 4-x (N4, N2S2, N3S), Hynic, 99m Tc(CO)3-chelating agents, more preferably DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, CB-TE2A, DFO, THP, N4, and most preferably DOTA, DOTAGA, NOTA and NODAGA.

[0266] Embodiment 43. Compounds according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 and 42, preferably according to claims 1, 2, 3, 4, 5, 6, 7, 8, 12, 13 , 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 and 42, wherein the N-terminal modification group A is the amino acid Aaa, and wherein the compound comprises a Z group covalently linked to the amino acid Aaa, wherein the Z group comprises a chelator and an optional linker.

[0267] Embodiment 44. The compound according to embodiment 43, wherein said Z group comprises a linker, wherein said linker covalently links said chelator to said amino acid Aaa, preferably to the α-nitrogen of said amino acid Aaa.

[0268] Embodiment 45. The compound according to embodiment 44, wherein the covalent bond between said linker and said α-nitrogen of said amino acid Aaa is an amide.

[0269] Embodiment 46. The compound according to any one of embodiments 44-45, wherein the chelator is covalently attached to the linker, wherein the covalent bond is selected from the group consisting of an amide bond, a urea bond, a carbamate bond, an ester bond, an ether bond, a thioether bond, a sulfonamide, a triazole, and a disulfide bond.

[0270] Embodiment 47. A compound according to any one of embodiments 43, 44, 45 and 46, wherein the linker is selected from Ttds, O2Oc, Apac, Gly, Bal, Gab, Mamb, Pamb, Ppac, 4Amc, Inp, Sni, Rni, Nmg, Cmp, PEG6, PEG12 and other PEG-amino acids, most preferably Ttds, O2Oc, Apac, 4Amc, PEG6 and PEG12, and preferably the linker amino acid is selected from Ttds, O2Oc and PEG6.

[0271] Embodiment 48. The compound according to any one of embodiments 43, 44, 45, 46 and 47, wherein said chelator is covalently linked to said amino acid Aaa.

[0272] Embodiment 49. The compound according to embodiment 48, wherein said chelator is directly linked to said amino acid Aaa.

[0273] Embodiment 50. The compound according to any one of embodiments 48 to 49, wherein the Z group is free of any linker.

[0274] Embodiment 51. The compound according to any one of embodiments 48, 49 and 50, wherein the covalent bond between the amino acid Aaa and the chelator is an amide.

[0275] Embodiment 52. The compound according to any one of embodiments 43, 44, 45, 46, 47, 48, 49, 50 and 51, wherein the chelating agent is selected from DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOTP, sarcophagine, FSC, NETA, H4octapa, Pycup, N x S 4-x (N4, N2S2, N3S), Hynic, 99mTc(CO)3-chelating agents, more preferably DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, CB-TE2A, DFO, THP, N4, and most preferably DOTA, DOTAGA, NOTA and NODAGA.

[0276] Embodiment 53. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 and 52, preferably according to claim 1, 2 , 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, and 42, wherein an amino acid or peptide is linked to Xaa7, wherein a majority of the amino acids of the peptide are charged or polar, and the net charge of the peptide is -2, -1, 0, +1, or +2.

[0277] Embodiment 54. The compound according to embodiment 53, wherein the peptide is selected from the peptides of formula (XXXa to XXXf):

[0278] Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16 (XXXa)

[0279] Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15 (XXXb)

[0280] Xaa10-Xaa11-Xaa12-Xaa13-Xaa14 (XXXc)

[0281] Xaa10-Xaa11-Xaa12-Xaa13 (XXXd)

[0282] Xaa10-Xaa11-Xaa12 (XXXe)

[0283] Xaa10-Xaa11 (XXXf)

[0284] in:

[0285] Xaa10 is Asp, asp, Bal, Gly, Gab, Ser, Nmg, Bhf, Lys, Ttds, or Bhk,

[0286] Xaa11 is His, his, Lys, Ttds, Arg, Ape or Ala,

[0287] Xaa12 is Phe, Nmf, Tic, Aic, Ppa, Mpa, Amf, Nmf, phe, Lys, Ape, Ttds and Ppa,

[0288] Xaa13 is Arg, Lys, Ape, Ttds or arg,

[0289] Xaa14 is Asp, Ala, asp, Lys, Ape, or Ttds,

[0290] Xaa15 is Ttds, Ape, or Lys, and

[0291] Xaa16 is Lys or Ape,

[0292] wherein, optionally,

[0293] Xaa11 and Xaa12 together form a single amino acid selected from Gab, Pamb, Cmp, Pamb, Mamb, and optionally

[0294] Xaa10, Xaa11 and Xaa12 together form a single amino acid selected from Gab, Pamb, Cmp, Pamb and Mamb,

[0295] With the proviso that in said peptides of formula (XXXa to XXXf), Ape, if present, is the C-terminal component.

[0296] Embodiment 55. The compound according to any one of embodiments 53 to 54, wherein the amino acid attached to Xaa7 is Xaa10 according to claim 46, preferably the amino acid attached to Xaa7 is Asp, asp, Bal, Gly, Gab, Ser, Nmg, Bhf, Lys, Ape, Ttds or Bhk.

[0297] Embodiment 56. The compound according to any one of embodiments 53 to 55, wherein the Z group is covalently linked to the peptide, preferably to the C-terminal amino acid of the peptide, wherein the Z group comprises a chelator and optionally a linker.

[0298] Embodiment 57. A compound according to embodiment 56, wherein the Z group is covalently linked to the C-terminal amino acid of the peptide, preferably covalently linked to the C-terminal amino acid of any one of the peptides of formula (XXXa), (XXXb), (XXXc), (XXXd), (XXXe) and (XXXf).

[0299] Embodiment 58. The compound according to any one of embodiments 53, 54 and 55, wherein the Z group is covalently linked to the amino acid attached to Xaa7, wherein the Z group comprises a chelator and optionally a linker.

[0300] Embodiment 59. A compound according to any one of embodiments 53, 54, 55, 56, 57 and 58, wherein the Z group comprises a linker, wherein the linker covalently links the chelator to the amino acid attached to Xaa7, preferably in the absence of a peptide attached to Xaa7, or the linker covalently links the chelator to the C-terminal amino acid of the peptide, preferably to the C-terminal amino acid of any one of the peptides of formula (LI), (LII), (LIII) and (LIV).

[0301] Embodiment 60. The compound according to embodiment 59, wherein the covalent bond is an amide bond.

[0302] Embodiment 61. The compound according to any one of embodiments 59 to 60, wherein the chelator is covalently attached to the linker, wherein the covalent bond is selected from an amide bond, a urea bond, a carbamate bond, an ester bond, an ether bond, a thioether bond, a sulfonamide, a triazole, and a disulfide bond.

[0303] Embodiment 62. A compound according to any one of embodiments 59, 60 and 61, wherein the linker is selected from Ttds, O2Oc, Apac, Gly, Bal, Gab, Mamb, Pamb, Ppac, 4Amc, Inp, Sni, Rni, Nmg, Cmp, PEG6, PEG12 and other PEG-amino acids.

[0304] Embodiment 63. A compound according to embodiment 62, wherein the linker is selected from Ttds, O2Oc, Apac, 4Amc, PEG6 and PEG12.

[0305] Embodiment 64. A compound according to any one of embodiments 56, 57 and 58, wherein the chelator is covalently linked to the amino acid linked to Xaa7, or the chelator is covalently linked to the C-terminal amino acid of the peptide, preferably to the C-terminal amino acid of any one of the peptides of formula (LI), (LII), (LIII) and (LIV).

[0306] Embodiment 65. A compound according to embodiment 64, wherein the chelator is directly linked to the amino acid linked to Xaa7, or directly linked to the C-terminal amino acid of the peptide, preferably directly linked to the C-terminal amino acid of any of the peptides of formula (LI), (LII), (LIII) and (LIV).

[0307] Embodiment 66. The compound according to any one of embodiments 64 to 65, wherein the Z group is free of any linker.

[0308] Embodiment 67. A compound according to any one of embodiments 64, 65 and 66, wherein the covalent bond between the chelator and the amino acid attached to Xaa7, and the covalent bond between the chelator and the C-terminal amino acid of the peptide, preferably the C-terminal amino acid of any one of the peptides of formula (LI), (LII), (LIII) and (LIV), is an amide bond.

[0309] Embodiment 68. The compound according to any one of embodiments 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 and 67, wherein the chelating agent is selected from DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOTP, sarcophagine, FSC, NETA, H4octapa, Pycup, N x S 4-x (N4, N2S2, N3S), Hynic, 99m Tc(CO)3-chelating agents, more preferably DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, CB-TE2A, DFO, THP, N4, and most preferably DOTA, DOTAGA, NOTA and NODAGA.

[0310] Embodiment 69. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67 and 68, wherein the compound is selected from:

[0311] Diastereomers of the formula:

[0312]

[0313] and the diastereomers of the formula:

[0314]

[0315] Stereocenters where the stereochemistry is unspecified (indicated by an asterisk *) are each and independently of the other in the R- or S-configuration.

[0316] Embodiment 70. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, and 69, wherein the compound is selected from:

[0317] The compound of the formula H-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-Ttds-Lys(Bio)-NH2(3BP-2881)

[0318]

[0319] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-2974)

[0320]

[0321] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-2975)

[0322]

[0323] The compound of the formula H-met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-2976)

[0324]

[0325] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-Ttds-Lys(DOTA)-NH2(3BP-3105)

[0326]

[0327] The compound of the formula DOTA-Ttds-Nle-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3168)

[0328]

[0329] The compound of the formula DOTA-Ttds-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3169)

[0330]

[0331] The compound of the formula DOTA-Ttds-Leu-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3172)

[0332]

[0333] The compound of the formula Ac-Met-[cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3175)

[0334]

[0335] The compound of the formula Ac-met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3187)

[0336]

[0337] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Nmf-Arg-Asp-NH2(3BP-3188)

[0338]

[0339] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Tic-Arg-Asp-NH2(3BP-3189)

[0340]

[0341] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Aic-Arg-Asp-NH2(3BP-3190)

[0342]

[0343] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Ppa-Arg-Asp-NH2(3BP-3191)

[0344]

[0345] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Mpa-Arg-Asp-NH2(3BP-3192)

[0346]

[0347] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Thi-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3193)

[0348]

[0349] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-Ala-Phe-Arg-Asp-NH2(3BP-3195)

[0350]

[0351] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Ala-Arg-Asp-NH2(3BP-3196)

[0352]

[0353] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Ala-NH2(3BP-3198)

[0354]

[0355] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-NH2(3BP-3200)

[0356]

[0357] The compound of the formula Ac-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3202)

[0358]

[0359] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Amf-Arg-Asp-NH2(3BP-3203)

[0360]

[0361] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-his-Phe-Arg-Asp-NH2(3BP-3210)

[0362]

[0363] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-phe-Arg-Asp-NH2(3BP-3211)

[0364]

[0365] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-arg-Asp-NH2(3BP-3212)

[0366]

[0367] The compound of the formula Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-asp-NH2(3BP-3213)

[0368]

[0369] The compound of the formula Ac-Met-[Cys(3MeBn)-Gly-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3214)

[0370]

[0371] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Nmf-Arg-Ttds-Lys(DOTA)-NH2(3BP-3275)

[0372]

[0373] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-phe-Arg-Ttds-Lys(DOTA)-NH2(3BP-3276)

[0374]

[0375] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Ppa-arg-Ttds-Lys(DOTA)-NH2(3BP-3277)

[0376]

[0377] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-NH2(3BP-3288)

[0378]

[0379] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-Arg-NH2(3BP-3299)

[0380]

[0381] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-Gab-Arg-NH2(3BP-3300)

[0382]

[0383] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-Pamb-Arg-NH2(3BP-3301)

[0384]

[0385] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-Cmp-Arg-NH2(3BP-3302)

[0386]

[0387] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Pamb-Arg-NH2(3BP-3303)

[0388]

[0389] The compound of the formula DOTA-Ttds-Nle-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-NH2(3BP-3319)

[0390]

[0391] The compound of the formula DOTA-Ttds-Nle-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-NH2(3BP-3320)

[0392]

[0393] The compound of the formula DOTA-Ttds-Nle-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-Pamb-Arg-NH2(3BP-3321)

[0394]

[0395] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-Mamb-Arg-NH2(3BP-3324)

[0396]

[0397] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-NH2(3BP-3349)

[0398]

[0399] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Bal-OH (3BP-3371)

[0400]

[0401] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-Ttds-Lys(DOTA)-NH2(3BP-3395)

[0402]

[0403] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-Ttds-Lys(DOTA)-NH2(3BP-3396)

[0404]

[0405] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Bhk(DOTA)-OH(3BP-3397)

[0406]

[0407] The compound of the formula DOTA-Ttds-Nle-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Bal-OH (3BP-3398)

[0408]

[0409] The compound of the formula DOTA-Ttds-Nle-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3401)

[0410]

[0411] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-Ape(DOTA)(3BP-3403)

[0412]

[0413] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-Ttds-Ape(DOTA)(3BP-3404)

[0414]

[0415] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Otf-Cys]-NH2(3BP-3409)

[0416]

[0417] The compound of the formula: Amyl NH-urea-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3425)

[0418]

[0419] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3426)

[0420]

[0421] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3476)

[0422]

[0423] The compound of the formula Hex-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Bhk(DOTA-Ttds)-OH(3BP-3489)

[0424]

[0425] The compound of the formula: Pentyl-SO2-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2 (3BP-3514)

[0426]

[0427] The compound of the formula Hex-[Cys(2Lut)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3518)

[0428]

[0429] The compound of the formula Hex-[Cys(3Lut)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3519)

[0430]

[0431] The compound of the formula Hex-[Cys(tMeBn(DOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-3555)

[0432]

[0433] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-1Ni-Cys]-OH(3BP-3650)

[0434]

[0435] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Bal-OH (3BP-3651)

[0436]

[0437] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-NH2(3BP-3652)

[0438]

[0439] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Glu-Phe-Cys]-NH2(3BP-3653)

[0440]

[0441] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-AET](3BP-3654)

[0442]

[0443] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Gly-OH(3BP-3656)

[0444]

[0445] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Gab-OH (3BP-3657)

[0446]

[0447] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Ser-OH (3BP-3658)

[0448]

[0449] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Nmg-OH(3BP-3659)

[0450]

[0451] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Bhf-OH(3BP-3660)

[0452]

[0453] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Mpa-Cys]-OH(3BP-3664)

[0454]

[0455] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-OH (3BP-3665)

[0456]

[0457] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Nmg-Pro-Thr-Gln-Phe-Cys]-OH(3BP-3678)

[0458]

[0459] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Hyp-Thr-Gln-Phe-Cys]-OH(3BP-3679)

[0460]

[0461] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Otf-Cys]-OH(3BP-3680)

[0462]

[0463] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-asp-NH2(3BP-3681)

[0464]

[0465] The compound of the formula: Pentyl-SO2-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-3690)

[0466]

[0467] The compound of the formula: Pentyl-SO2-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Glu-Phe-Cys]-OH (3BP-3691)

[0468]

[0469] The compound of the formula: Pentyl-SO2-[Cys(tMeBn(DOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3692)

[0470]

[0471] The compound of the formula Hex-[Cys(tMeBn(InDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-NH2(3BP-3712)

[0472]

[0473] The compound of the formula Hex-[Cys(tMeBn(InDOTA-AET))-Pro-Pro-Thr-Gln-Phe-AET](3BP-3713)

[0474]

[0475] The compound of the formula Hex-[Cys(tMeBn(InDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Gly-OH(3BP-3714)

[0476]

[0477] The compound of the formula Hex-[Cys(tMeBn(InDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Nmg-OH(3BP-3715)

[0478]

[0479] The compound of the formula Hex-[Cys(tMeBn(InDOTA-AET))-Nmg-Pro-Thr-Gln-Phe-Cys]-OH(3BP-3716)

[0480]

[0481] The compound of the formula: Pentyl-SO2-[Cys(tMeBn(InDOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3717)

[0482]

[0483] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Bal-NH2(3BP-3736)

[0484]

[0485] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Nmg-NH2(3BP-3737)

[0486]

[0487] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Nmg-Pro-Thr-Gln-Phe-Cys]-NH2(3BP-3744)

[0488]

[0489] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cysol](3BP-3767)

[0490]

[0491] The compound of the formula Hex-[Cys(tMeBn(InDOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-3770)

[0492]

[0493] The compound of the formula Hex-[Cys(tMeBn(DOTA-PP))-Nmg-Pro-Thr-Gln-Phe-Cys]-OH (3BP-3771)

[0494]

[0495] The compound of the formula Hex-[Cys-(tMeBn(H-O2Oc-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3967)

[0496]

[0497] The compound of the formula H-Ahx-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3980)

[0498]

[0499] The compound of the formula Hex-[Cys-(tMeBn(H-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3981)

[0500]

[0501] The compound of the formula Hex-[Cys-(tMeBn(H-O2Oc-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-4003)

[0502]

[0503] The compound of the formula H-Ahx-Ttds-Nle-[Cys-(tMeBn(DOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-4004)

[0504]

[0505] The compound of the formula Hex-[Cys-(tMeBn(N4Ac-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4063)

[0506]

[0507] The compound of the formula Hex-[Cys-(tMeBn(N4Ac-O2Oc-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4088)

[0508]

[0509] The compound of the formula Hex-[Cys-(tMeBn(H-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4089)

[0510]

[0511] The compound of the formula Hex-[D-Cys-(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4109)

[0512]

[0513] The compound of the formula N4Ac-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-OH (3BP-4161)

[0514]

[0515] The compound of the formula Hex-[Cys-(tMeBn(NODAGA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4162)

[0516]

[0517] The compound of the formula Hex-[Cys-(tMeBn(N4Ac-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4168)

[0518]

[0519] The compound of the formula Hex-[Cys-(tMeBn(N4Ac-O2Oc-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4169)

[0520]

[0521] The compound of the formula Hex-[Cys-(tMeBn(Bio-Ttds-Ttds-Ttds-Ttds-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4170)

[0522]

[0523] The compound of the formula Hex-[Cys-(tMeBn(H-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4181)

[0524]

[0525] The compound of the formula Hex-[Cys(tMeBn(ATTO488-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-4182)

[0526]

[0527] The compound of the formula Hex-[Cys-(tMeBn(GaNODAGA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4184)

[0528]

[0529] The compound of the formula Hex-[Cys-(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4186)

[0530]

[0531] The compound of the formula Hex-[Cys-(tMeBn(DTPA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4214)

[0532]

[0533] The compound of the formula N4Ac-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4219)

[0534]

[0535] The compound of the formula N4Ac-PEG6-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-OH (3BP-4221)

[0536]

[0537] The compound of the formula N4Ac-Glu-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-OH (3BP-4222)

[0538]

[0539] The compound of the formula Hex-[Cys-(tMeBn(DTPA-O2Oc-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4224)

[0540]

[0541] The compound of the formula N4Ac-Efa-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-OH (3BP-4243)

[0542]

[0543] The compound of the formula N4Ac-gGlu-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4245)

[0544]

[0545] The compound of the formula N4Ac-Glu(AGLU)-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-4246)

[0546]

[0547] The compound of the formula N4Ac-gGlu-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-OH (3BP-4247)

[0548]

[0549] The compound of the formula N4Ac-Glu(AGLU)-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-OH(3BP-4249)

[0550]

[0551] The compound of the formula Hex-[Cys-(tMeBn(DOTA-AET))-Pro-Pro-Thr-Glu-Phe-Cys]-OH (3BP-4250)

[0552]

[0553] The compound of the formula Hex-[Cys-(tMeBn(NODAGA-O2Oc-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4251)

[0554]

[0555] The compound of the formula N4Ac-Glu(AGLU)-Glu(AGLU)-Ttds-Nle-[Cys-(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-OH(3BP-4266)

[0556]

[0557] The compound of the formula Hex-[Cys-(tMeBn(N4Ac-Ttds-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4299)

[0558]

[0559] The compound of the formula Hex-[Cys-(tMeBn(N4Ac-PEG6-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4300)

[0560]

[0561] The compound of the formula Hex-[Cys-(tMeBn(H-SAc-Ser-Ser-Ser-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4301)

[0562]

[0563] The compound of the formula Hex-[Cys-(tMeBn(H-Asp-Asp-Cys-Ttds-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4302)

[0564]

[0565] The compound of the formula Hex-[Cys-(tMeBn(H-Asp-Asp-Cys-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4303)

[0566]

[0567] The compound of the formula Hex-[Cys-(tMeBn(H-SAc-Ser-Ser-Ser-Ttds-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4308)

[0568]

[0569] The compound of the formula Hex-[Cys-(tMeBn(DTPA2-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4309)

[0570]

[0571] The compound of the formula Hex-[Cys-(tMeBn(NOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4310)

[0572]

[0573] The compound of the formula Hex-[Cys-(tMeBn(H-HYNIC-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4342)

[0574]

[0575] The compound of the formula Hex-[Cys-(tMeBn(NOTA-Ttds-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4344)

[0576]

[0577] The compound of the formula Hex-[Cys-(tMeBn(DTPA2-Ttds-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4352)

[0578]

[0579] The compound of the formula Hex-[Cys-(tMeBn(DTPA2-PEG6-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4353)

[0580]

[0581] The compound of the formula Hex-[Cys-(tMeBn(DTPABzl-Glutar-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4366)

[0582]

[0583] The compound of the formula Hex-[Cys(tMeBn(LuDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-Gab-Arg-Ttds-Lys(AF488)-NH2(3BP-4372)

[0584]

[0585] The compound of the formula Hex-[Cys(tMeBn(LuDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-Gab-Arg-Ttds-Ttds-Ttds-Lys(AF488)-NH2(3BP-4373)

[0586]

[0587] The compound of the formula Hex-[Cys-(tMeBn(H-HYNIC-Ttds--AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-4376)

[0588]

[0589] The compound of the formula Hex-[Cys-(tMeBn(PCTA--AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4379)

[0590]

[0591] The compound of the formula Hex-[Cys-(tMeBn(NOPO--AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4380)

[0592]

[0593] The compound of the formula Hex-[Cys-(tMeBn(HBED--AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4381)

[0594]

[0595] The compound of the formula Hex-[Cys-(tMeBn(DATA--AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4382)

[0596]

[0597] The compound of the formula DOTA-Ttds-Nle-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-4386)

[0598]

[0599] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-Ttds-Lys(DOTA)-NH2(3BP-4391)

[0600]

[0601] The compound of the formula DOTA-Ttds-Nle-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-Ttds-Lys(DOTA)-NH2(3BP-4392)

[0602]

[0603] and the compound of the formula DOTA-Ttds-Nle-[Cys(3MeBn)-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-Ttds-Lys(DOTA)-NH2(3BP-4393)

[0604]

[0605] 71. The compound of any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, and 70, wherein the compound is different from a compound selected from:

[0606] The compound of the formula Hex-[Cys(tMeBn(DOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-3554)

[0607] as well as

[0608] The compound of the formula Hex-[Cys(tMeBn(DOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3407)

[0609]

[0610] Embodiment 72. According to embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 and any one of the compounds of 71, wherein any S atom that can be oxidized, preferably the S atom of a thioether group, is present as -S-, -S(O)- or -S(O2)- or a mixture thereof.

[0611] Embodiment 73. A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 and 72, wherein the compound binds to fibroblast activation protein (FAP).

[0612] Embodiment 74. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, and 73, wherein the compound comprises a diagnostically active nuclide or a therapeutically active nuclide.

[0613] Embodiment 75. The compound according to embodiment 74, wherein the compound is different from the compound selected from the group consisting of:

[0614] The compound of the formula Hex-[Cys(tMeBn(InDOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3590)

[0615]

[0616] The compound of the formula Hex-[Cys(tMeBn(LuDOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3591)

[0617]

[0618] The compound of the formula Hex-[Cys(tMeBn(GaDOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3592)

[0619]

[0620] The compound of the formula Hex-[Cys(tMeBn(EuDOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-Asp-NH2(3BP-3661)

[0621]

[0622] The compound of the formula Hex-[Cys(tMeBn(InDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-3623)

[0623]

[0624] The compound of the formula Hex-[Cys(tMeBn(LuDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-3624)

[0625]

[0626] The compound of the formula Hex-[Cys(tMeBn(EuDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-3662)

[0627] as well as

[0628] The compound of the formula Hex-[Cys(tMeBn(GaDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH(3BP-3949)

[0629]

[0630] The compound of the formula Hex-[Cys-(tMeBn(CuDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4293)

[0631]

[0632] The compound of the formula Hex-[Cys-(tMeBn(ZnDOTA-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH (3BP-4343)

[0633]

[0634] Embodiment 76. The compound according to any one of embodiments 74 and 75, wherein the diagnostically active nuclide is a diagnostically active radionuclide.

[0635] Embodiment 77. The compound according to embodiment 76, wherein the diagnostically active radionuclide is selected from 43 Sc, 44 Sc, 51 Mn, 52 Mn, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 94m Tc, 99m Tc, 111 In, 152 Tb, 155 Tb, 201 Tl, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1, preferably 43 Sc, 44 Sc, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 99m Tc,111 In, 152 Tb, 155 Tb, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1, most preferably 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 In, 18 F. 123 I and 124 I.

[0636] Embodiment 78. The compound according to embodiment 76, wherein the therapeutically active nuclide is a therapeutically active radionuclide.

[0637] Embodiment 79. The compound according to embodiment 78, wherein the therapeutically active radionuclide is selected from 47 Sc, 67 Cu, 89 Sr. 90 Y. 153 Sm, 149 Tb, 161 Tb, 177 Lu, 186 Re、 188 Re、 212 Pb, 213 Bi, 223 Ra, 225 Ac, 226 Th, 227 Th, 131 I. 211 At, preferred 47 Sc, 67 Cu, 90 Y. 177 Lu, 188 Re、 212 Pb, 213 Bi, 225 Ac, 227 Th, 131 I. 211 At, the best 90 Y. 177 Lu, 225 Ac, 227 Th, 131 I and 211 At.

[0638] Embodiment 80. According to embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, The compound of any one of 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 and 79, wherein the compound interacts with fibroblast activation protein (FAP), preferably with human FAP having the amino acid sequence of SEQ ID NO: 1 or a homolog thereof, wherein the amino acid sequence of the homolog has at least 85% identity to the amino acid sequence of SEQ ID NO: 1.

[0639] Embodiment 81. The compound according to embodiment 80, wherein said compound is an inhibitor of said fibroblast activation protein (FAP).

[0640] Embodiment 82. According to embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 4, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, and 81, wherein the compound has a pIC for human FAP of SEQ ID NO: 1 50 The value is ≥6.0, preferably ≥7.0, and most preferably ≥8.0.

[0641] Embodiment 83. Use of a method for diagnosing a disease according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, and 82.

[0642] Embodiment 84. The compound for use according to embodiment 83, wherein the disease is a disease involving upregulated expression of fibroblast activation protein (FAP), preferably fibroblast activation protein (FAP).

[0643] Embodiment 85. Compound for use according to any one of embodiments 83 to 84, wherein the disease involves cells showing upregulated expression of fibroblast activation protein (FAP), preferably a diseased tissue containing cells showing upregulated expression of fibroblast activation protein (FAP), more preferably a disease involving tumor-associated fibroblasts.

[0644] Embodiment 86. Compound for use according to any one of embodiments 83 to 85, wherein the disease is a neoplasm, preferably a cancer or a tumor.

[0645] Embodiment 87. The compound for use according to embodiment 86, wherein the neoplasms, cancers and tumors are each and independently selected from solid tumors, epithelial tumors, bladder cancer, breast cancer, cervical cancer, colorectal cancer, bile duct cancer, endometrial cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumors, head and neck cancer, liver cancer, lung cancer, melanoma, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, salivary gland cancer, sarcoma, squamous cell carcinoma and thyroid cancer.

[0646] Embodiment 88. The compound for use according to embodiment 87, wherein the neoplasms, cancers and tumors are each and independently selected from breast cancer, colorectal cancer, bile duct cancer, head and neck cancer, lung cancer, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma and squamous cell carcinoma.

[0647] Embodiment 89. Compound for use according to any one of embodiments 83 to 85, wherein the disease is selected from inflammatory diseases, cardiovascular diseases, autoimmune diseases and fibrotic diseases.

[0648] Embodiment 90. The compound for use according to embodiment 89, wherein the disease is an inflammatory disease.

[0649] Embodiment 91. The compound for use according to embodiment 90, wherein the disease is atherosclerosis, arthritis or rheumatoid arthritis.

[0650] Embodiment 92. The compound for use according to embodiment 91, wherein the disease is a cardiovascular disease.

[0651] Embodiment 93. The compound for use according to embodiment 92, wherein the disease is a cardiovascular disease involving atherosclerotic plaques.

[0652] Embodiment 94. The compound for use according to embodiment 93, wherein the disease is atherosclerotic lesions due to plaque rupture, acute coronary syndrome, myocardial infarction, thrombosis or vascular occlusion.

[0653] Embodiment 95. The compound for use according to embodiment 83, wherein the disease is a fibrotic disease.

[0654] Embodiment 96. The compound for use according to embodiment 95, wherein the disease is selected from idiopathic pulmonary fibrosis, Crohn's disease and liver fibrosis.

[0655] Embodiment 97. Compound for use according to any one of embodiments 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 and 96, wherein the compound comprises a diagnostically active nuclide, preferably a diagnostically active radionuclide.

[0656] Embodiment 98. Compound for use according to embodiment 97, wherein the diagnostically active nuclide is selected from 43 Sc, 44 Sc, 51 Mn, 52 Mn, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 94m Tc, 99m Tc, 111 In, 152 Tb, 155 Tb, 201 Tl, 203 Pb, 18 F. 76 Br, 77 Br,123 I. 124 I. 125 1, preferably 43 Sc, 44 Sc, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 99m Tc, 111 In, 152 Tb, 155 Tb, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1, and more preferably 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 In, 18 F. 123 I and 124 I.

[0657] Embodiment 99. The compound for use according to any one of embodiments 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97 and 98, wherein the diagnostic method is an imaging method.

[0658] Embodiment 100. The compound for use according to embodiment 98, wherein the imaging method is selected from scintigraphy, single photon emission computed tomography (SPECT) and positron emission tomography (PET).

[0659] Embodiment 101. A compound for use according to any one of embodiments 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100, wherein the method comprises administering a diagnostically effective amount of the compound to a subject, preferably a mammal, wherein the mammal is selected from the group consisting of humans, companion animals, pets and livestock, more preferably the subject is selected from the group consisting of humans, dogs, cats, horses and cows, and most preferably the subject is a human.

[0660] Embodiment 102. The use of the method for treating a disease according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, and 82.

[0661] Embodiment 103. The compound for use according to embodiment 102, wherein the disease is a disease involving upregulated expression of fibroblast activation protein (FAP), preferably fibroblast activation protein (FAP).

[0662] Embodiment 104. A compound for use according to any one of embodiments 102 to 103, wherein the disease involves cells showing upregulated expression of fibroblast activation protein (FAP), preferably a diseased tissue containing cells showing upregulated expression of fibroblast activation protein (FAP), more preferably a disease involving tumor-associated fibroblasts.

[0663] Embodiment 105. Compound for use according to any one of embodiments 102 to 104, wherein the disease is a neoplasm, preferably a cancer or a tumor.

[0664] Embodiment 106. The compound for use according to embodiment 105, wherein the neoplasms, cancers and tumors are each and independently selected from solid tumors, epithelial tumors, bladder cancer, breast cancer, cervical cancer, colorectal cancer, bile duct cancer, endometrial cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumors, head and neck cancer, liver cancer, lung cancer, melanoma, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, salivary gland cancer, sarcoma, squamous cell carcinoma and thyroid cancer.

[0665] Embodiment 107. The compound for use according to embodiment 106, wherein the neoplastic neoplasms, cancers and tumors are each and independently selected from breast cancer, colorectal cancer, bile duct cancer, head and neck cancer, lung cancer, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma and squamous cell carcinoma.

[0666] Embodiment 108. The compound for use according to any one of embodiments 102, 103 and 104, wherein the disease is selected from inflammatory diseases, cardiovascular diseases, autoimmune diseases and fibrotic diseases.

[0667] Embodiment 109. The compound for use according to embodiment 108, wherein the disease is an inflammatory disease.

[0668] Embodiment 110. The compound for use according to embodiment 109, wherein the disease is atherosclerosis, arthritis or rheumatoid arthritis.

[0669] Embodiment 111. Compound for use according to embodiment 108, wherein the disease is cardiovascular disease.

[0670] Embodiment 112. The compound for use according to embodiment 111, wherein the disease is a cardiovascular disease involving atherosclerotic plaques.

[0671] Embodiment 113. The compound for use according to embodiment 112, wherein the disease is atherosclerotic lesions due to plaque rupture, acute coronary syndrome, myocardial infarction, thrombosis or vascular occlusion.

[0672] Embodiment 114. The compound for use according to embodiment 108, wherein the disease is a fibrotic disease.

[0673] Embodiment 115. The compound for use according to embodiment 114, wherein the disease is selected from idiopathic pulmonary fibrosis, Crohn's disease and liver fibrosis.

[0674] Embodiment 116. Compound for use according to any one of embodiments 102, 103, 104 and 105, wherein said compound comprises a therapeutically active nuclide, preferably a therapeutically active radionuclide.

[0675] Embodiment 117. Compound for use according to embodiment 116, wherein the therapeutically active nuclide is selected from 47 Sc, 67 Cu, 89 Sr. 90 Y. 153 Sm, 149 Tb, 161 Tb, 177 Lu, 186 Re、 188 Re、 212 Pb, 213 Bi, 223 Ra, 225 Ac,226 Th, 227 Th, 131 I. 211 At, preferred 47 Sc, 67 Cu, 90 Y. 177 Lu, 188 Re、 212 Pb, 213 Bi, 225 Ac, 227 Th, 131 I. 211 At, and most preferably 90 Y. 177 Lu, 225 Ac, 227 Th, 131 I and 211 At.

[0676] Embodiment 118. A compound for use according to any one of embodiments 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116 and 117, wherein the method comprises administering a therapeutically effective amount of the compound to a subject, preferably a mammal, wherein the mammal is selected from the group consisting of humans, companion animals, pets and livestock, more preferably the subject is selected from the group consisting of humans, dogs, cats, horses and cows, and most preferably the subject is a human.

[0677] Embodiment 119. Use of a method for identifying an individual according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 9, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, and 82, wherein the individual may or may not respond to treatment for the disease, wherein the method for identifying the individual comprises using a compound according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 1, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 and 82 for performing a diagnostic method, preferably performing a method for diagnosing a disease as described in any one of embodiments 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 and 101.

[0678] Embodiment 120. Use of a method for selecting an individual from a group of individuals according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 , 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, and 82, wherein the individual may be responsive or nonresponsive to treatment for the disease, wherein the method for selecting an individual from a group of individuals comprises using a compound according to embodiments 1, 2 , 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 6 0, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 and 82 are compounds for performing a diagnostic method, preferably performing a method for diagnosing a disease as described in any one of Embodiments 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 and 101.

[0679] Embodiment 113. Use of a method according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 for stratifying a group of individuals into individuals who are likely to respond to a treatment for a disease and individuals who are likely not to respond to a treatment for a disease. , 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, and 82, wherein the method of stratifying a group of individuals comprises using a compound according to the embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 and 82 are compounds for performing a diagnostic method, preferably performing a method for diagnosing a disease as described in any one of embodiments 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 and 101.

[0680] Embodiment 122. Compound for use according to any one of embodiments 119, 120 and 121, wherein the disease is a disease involving upregulated expression of fibroblast activation protein (FAP), preferably fibroblast activation protein (FAP).

[0681] Embodiment 123. A compound for use according to any one of embodiments 119, 120, 121 and 122, wherein the disease involves cells showing upregulated expression of fibroblast activation protein (FAP), preferably a diseased tissue containing cells showing upregulated expression of fibroblast activation protein (FAP), more preferably a disease involving tumor-associated fibroblasts.

[0682] Embodiment 124. Compound for use according to any one of embodiments 119, 120, 121, 122 and 123, wherein the disease is a neoplasm, preferably a cancer or a tumor.

[0683] Embodiment 125. The compound for use according to embodiment 124, wherein the neoplasm, cancer or tumor is each and independently selected from solid tumors, epithelial tumors, bladder cancer, breast cancer, cervical cancer, colorectal cancer, bile duct cancer, endometrial cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumors, head and neck cancer, liver cancer, lung cancer, melanoma, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, salivary gland cancer, sarcoma, squamous cell carcinoma and thyroid cancer.

[0684] Embodiment 126. The compound for use according to embodiment 125, wherein the neoplasms, cancers and tumors are each and independently selected from breast cancer, colorectal cancer, bile duct cancer, head and neck cancer, lung cancer, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma and squamous cell carcinoma.

[0685] Embodiment 127. Compound for use according to any one of embodiments 119, 120, 121, 122 and 123, wherein the disease is selected from inflammatory diseases, cardiovascular diseases, autoimmune diseases and fibrotic diseases.

[0686] Embodiment 128. The compound for use according to embodiment 127, wherein the disease is an inflammatory disease.

[0687] Embodiment 129. The compound for use according to embodiment 128, wherein the disease is atherosclerosis, arthritis or rheumatoid arthritis.

[0688] Embodiment 130. The compound for use according to embodiment 129, wherein the disease is a cardiovascular disease.

[0689] Embodiment 131. Compound for use according to embodiment 130, wherein the disease is a cardiovascular disease involving atherosclerotic plaques.

[0690] Embodiment 132. Compound for use according to embodiment 131, wherein the disease is atherosclerotic lesions due to plaque rupture, acute coronary syndrome, myocardial infarction, thrombosis or vascular occlusion.

[0691] Embodiment 133. The compound for use according to embodiment 127, wherein the disease is a fibrotic disease.

[0692] Embodiment 134. Compound for use according to embodiment 1335, wherein the disease is selected from idiopathic pulmonary fibrosis, Crohn's disease and liver fibrosis.

[0693] Embodiment 135. The compound for use according to any one of embodiments 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 and 134, wherein the diagnostic method is an imaging method.

[0694] Embodiment 136. The compound for use according to embodiment 135, wherein the imaging method is selected from scintigraphy, single photon emission computed tomography (SPECT) and positron emission tomography (PET).

[0695] Embodiment 137. Compound for use according to any one of embodiments 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135 and 136, wherein the compound comprises a diagnostically active nuclide, preferably a diagnostically active radionuclide.

[0696] Embodiment 138. Compound for use according to embodiment 137, wherein the diagnostically active nuclide is selected from 43 Sc, 44 Sc, 51 Mn, 52 Mn, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 94m Tc, 99m Tc, 111 In, 152 Tb, 155 Tb, 201 Tl, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1, preferably 43 Sc, 44 Sc, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 99m Tc, 111In, 152 Tb, 155 Tb, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1, and most preferably 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 In, 18 F. 123 I and 124 I.

[0697] Embodiment 139. A method for delivering an effector to a fibroblast activation protein (FAP), preferably a human fibroblast activation protein (FAP) according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 , 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, and 82, wherein the effector is selected from the group consisting of a diagnostically active agent and a therapeutically active agent.

[0698] Embodiment 140. The compound for use according to embodiment 139, wherein the effector is selected from the group consisting of a diagnostically active nuclide and a therapeutically active nuclide.

[0699] Embodiment 141. The compound for use according to embodiment 140, wherein the diagnostically active nuclide is a diagnostically active radionuclide.

[0700] Embodiment 142. Compound for use according to embodiment 141, wherein the diagnostically active radionuclide is selected from 43 Sc, 44 Sc, 51 Mn, 52 Mn, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 94mTc, 99m Tc, 111 In, 152 Tb, 155 Tb, 201 Tl, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1, preferably 43 Sc, 44 Sc, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 99m Tc, 111 In, 152 Tb, 155 Tb, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1, most preferably 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 In, 18 F. 123 I and 124 I.

[0701] Embodiment 143. A compound for use according to any one of embodiments 139, 140, 141 and 142, wherein the Fibroblast Activation Protein (FAP) is expressed by cells, preferably by fibroblasts, mesenchymal stem cells, smooth muscle cells, cells of epithelial origin, or endothelial cells, more preferably by human fibroblasts, mesenchymal stem cells, smooth muscle cells, cells of epithelial origin, or endothelial cells, most preferably by human fibroblasts, mesenchymal stem cells, smooth muscle cells, cells of epithelial origin, or endothelial cells that show upregulated expression of Fibroblast Activation Protein (FAP).

[0702] Embodiment 144. The compound for use according to embodiment 143, wherein the cell is contained in or is part of a tissue, preferably a diseased tissue of a diseased individual.

[0703] Embodiment 145. A compound for use according to embodiment 144, wherein the disease involves cells showing upregulated expression of fibroblast activation protein (FAP), preferably a diseased tissue containing cells showing upregulated expression of fibroblast activation protein (FAP), more preferably a disease involving tumor-associated fibroblasts.

[0704] Embodiment 146. Compound for use according to any one of embodiments 144 to 145, wherein the disease is a neoplasm, preferably a cancer or a tumor.

[0705] Embodiment 147. A compound for use according to embodiment 146, wherein the neoplasms, cancers and tumors are each and independently selected from solid tumors, epithelial tumors, bladder cancer, breast cancer, cervical cancer, colorectal cancer, bile duct cancer, endometrial cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumors, head and neck cancer, liver cancer, lung cancer, melanoma, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, salivary gland cancer, sarcoma, squamous cell carcinoma and thyroid cancer.

[0706] Embodiment 148. The compound for use according to embodiment 147, wherein the neoplasms, cancers and tumors are each and independently selected from breast cancer, colorectal cancer, bile duct cancer, head and neck cancer, lung cancer, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma and squamous cell carcinoma.

[0707] Embodiment 149. Compound for use according to any one of embodiments 144 to 145, wherein the disease is selected from inflammatory diseases, cardiovascular diseases, autoimmune diseases and fibrotic diseases.

[0708] Embodiment 150. The compound for use according to embodiment 149, wherein the disease is an inflammatory disease.

[0709] Embodiment 151. The compound for use according to embodiment 150, wherein the disease is atherosclerosis, arthritis or rheumatoid arthritis.

[0710] Embodiment 152. The compound for use according to embodiment 149, wherein the disease is a cardiovascular disease.

[0711] Embodiment 153. The compound for use according to embodiment 152, wherein the disease is a cardiovascular disease involving atherosclerotic plaques.

[0712] Embodiment 154. The compound for use according to embodiment 153, wherein the disease is atherosclerotic lesions due to plaque rupture, acute coronary syndrome, myocardial infarction, thrombosis or vascular occlusion.

[0713] Embodiment 155. The compound for use according to embodiment 149, wherein the disease is a fibrotic disease.

[0714] Embodiment 156. The compound for use according to embodiment 155, wherein the disease is selected from idiopathic pulmonary fibrosis, Crohn's disease and liver fibrosis.

[0715] Embodiment 157. The compound for use according to embodiment 140, wherein the therapeutically active nuclide is a therapeutically active radionuclide.

[0716] Embodiment 158. Compound for use according to embodiment 157, wherein the therapeutically active radionuclide is selected from 47 Sc, 67 Cu, 89 Sr. 90 Y. 153 Sm, 149 Tb, 161 Tb, 177 Lu, 186 Re、 188 Re、 212 Pb, 213 Bi, 223 Ra, 225 Ac, 226 Th, 227 Th, 131 I. 211 At, preferred 47 Sc, 67 Cu, 90 Y. 177 Lu, 188 Re、 212 Pb, 213 Bi, 225 Ac, 227 Th, 131 I. 211 At, the best 90 Y. 177 Lu, 225 Ac, 227 Th, 131 I and 211 At.

[0717] Embodiment 159. The compound for use according to any one of embodiments 157 to 158, wherein the Fibroblast Activation Protein (FAP) is expressed by cells, preferably by fibroblasts, mesenchymal stem cells, smooth muscle cells, cells of epithelial origin, or endothelial cells, more preferably by human fibroblasts, mesenchymal stem cells, smooth muscle cells, cells of epithelial origin, or endothelial cells, most preferably by human fibroblasts, mesenchymal stem cells, smooth muscle cells, cells of epithelial origin, or endothelial cells that show upregulated expression of Fibroblast Activation Protein (FAP).

[0718] Embodiment 160. The compound for use according to embodiment 159, wherein the cell is contained in or is part of a tissue, preferably a diseased tissue of a diseased individual.

[0719] Embodiment 161. A compound for use according to embodiment 160, wherein the disease involves cells showing upregulated expression of fibroblast activation protein (FAP), preferably a diseased tissue containing cells showing upregulated expression of fibroblast activation protein (FAP), more preferably a disease involving tumor-associated fibroblasts.

[0720] Embodiment 162. Compound for use according to any one of embodiments 159, 160 and 161, wherein the disease is a neoplasm, preferably a cancer or a tumor.

[0721] Embodiment 163. A compound for use according to embodiment 162, wherein the neoplasms, cancers and tumors are each and independently selected from solid tumors, epithelial tumors, bladder cancer, breast cancer, cervical cancer, colorectal cancer, bile duct cancer, endometrial cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumors, head and neck cancer, liver cancer, lung cancer, melanoma, mesothelioma, neuroendocrine tumors and carcinomas, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, salivary gland cancer, sarcoma, squamous cell carcinoma and thyroid cancer.

[0722] Embodiment 164. A composition, preferably a pharmaceutical composition, wherein the composition comprises the compound according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 , 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 and 82, and a pharmaceutically acceptable excipient.

[0723] Embodiment 165. A composition according to embodiment 164 for use in any method as defined in any one of the preceding claims.

[0724] Embodiment 166. A method for diagnosing a disease in a subject, wherein the method comprises administering to the subject a diagnostically effective amount of an agent according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 , 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, and 82.

[0725] Embodiment 167. The method according to embodiment 166, wherein said compound comprises a diagnostically active agent, whereby said agent is preferably a radionuclide.

[0726] Embodiment 168. A method for treating a disease in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a drug according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, and 82.

[0727] Embodiment 169. The method according to embodiment 168, wherein said compound comprises a therapeutically active agent, whereby said agent is preferably a radionuclide.

[0728] Embodiment 170. The method according to any one of embodiments 166, 167, 168 and 169, wherein the disease is a disease involving upregulated expression of fibroblast activation protein (FAP), preferably fibroblast activation protein (FAP).

[0729] Embodiment 171. A method according to any one of embodiments 166, 167, 168, 169 and 170, wherein the disease involves cells showing upregulated expression of fibroblast activation protein (FAP), preferably a diseased tissue containing cells showing upregulated expression of fibroblast activation protein (FAP), more preferably a disease involving tumor-associated fibroblasts.

[0730] Embodiment 172. The method according to any one of embodiments 166, 167, 168, 169, 170 and 171, wherein the disease is selected from neoplasms, preferably cancer or tumors, and inflammatory diseases, cardiovascular diseases, autoimmune diseases and fibrotic diseases.

[0731] Embodiment 173. A kit comprising the invention according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 , 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 and 82, one or more optional excipients and optionally one or more devices, wherein the device is selected from a labeling device, a purification device, a manipulation device, a radiation protection device, an analytical device or an administration device.

[0732] Embodiment 174. A kit according to embodiment 173 for use in any method as defined in any of the preceding claims.

[0733] More particularly, the problem on which the present invention is based is solved in a first aspect by a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A linked to Xaa1,

[0734]

[0735] in:

[0736] The peptide sequences are drawn from left to right in the N-terminal to C-terminal direction.

[0737] Xaa1 is an amino acid residue of formula (II),

[0738]

[0739] in:

[0740] R 1a It is -NH-,

[0741] R 1b is H or CH3,

[0742] n=0 or 1,

[0743] The N-terminal modification group A is covalently linked to the nitrogen atom of Xaa1,

[0744] The carbonyl group of Xaa1 is covalently linked to the nitrogen of Xaa2.

[0745] and the sulfur atom of Xaa1 is covalently linked to Yc as a thioether;

[0746] Xaa2 is the residue of an amino acid of formula (III), (IV) or (XX),

[0747]

[0748] in:

[0749] R 2a 、R 2b and R 2c are each independently selected from (C1-C2)alkyl and H, wherein said (C1-C2)alkyl may be substituted by a substituent selected from OH, NH2, halogen, (C5-C7)cycloalkyl,

[0750] p = 0, 1, or 2

[0751] v = 1 or 2

[0752] w = 1, 2, or 3, and

[0753] The amino acid of formula (IV) may be substituted at ring positions 3 and 4 as shown by one or two substituents selected from methyl, OH, NH2 and F;

[0754] Xaa3 is the residue of an amino acid of formula (V) or (XX),

[0755]

[0756] in:

[0757] X 3 Selected from CH2, CF2, CH-R 3b , S, O and NH,

[0758] p = 1 or 2

[0759] v = 1 or 2

[0760] w=1, 2 or 3,

[0761] R 3a is H, methyl, OH, NH2 or F,

[0762] R 3b is methyl, OH, NH2 or F;

[0763] Xaa4 is the residue of an amino acid of formula (VI),

[0764]

[0765] in:

[0766] R 4a Selected from H, OH, COOH, CONH2, X 4and –NH-CO-X 4 , where X 4 is selected from (C1-C6)alkyl, (C5-C6)aryl and (C5-C6)heteroaryl, and X 4 may be substituted by one or two substituents selected from methyl, CONH2, halogen, NH2 and OH;

[0767] q=1, 2 or 3, wherein optionally, one or both hydrogens of these 1, 2 or 3 CH2 groups are each and independently substituted by methyl, ethyl, (C5-C6)aryl or (C5-C6)heteroaryl,

[0768] R 4b is methyl or H;

[0769] Xaa5 is an amino acid residue of structure (VII),

[0770]

[0771] in:

[0772] R 5 selected from OH and NH2, and

[0773] r = 1, 2, or 3;

[0774] Xaa6 is an amino acid selected from aromatic L-α-amino acids and heteroaromatic L-α-amino acids;

[0775] Xaa7 is an aminothiol or amino acid residue of formula (IX),

[0776]

[0777] in:

[0778] R 7a are –CO-, -COOH, -CONH2, -CH2-OH, -(CO)-NH-R 7b 、-(CO)-(NR 7c )-R 7b or H, where R 7b and R 7c are each and independently (C1-C4)alkyl, and

[0779] t is 1 or 2;

[0780] Yc is a structure of formula (X),

[0781]

[0782] It connects the S atom of Xaa1 and the S atom of Xaa7 while forming two thioether bonds, thereby forming a cyclic structure of formula (XXI),

[0783]

[0784] in:

[0785] The substitution pattern of the aromatic group in formula (X) is ortho, meta or para,

[0786] n=0 or 1,

[0787] t = 1 or 2,

[0788] Y 1 is CH or N,

[0789] Y 2 Is N or CR c1 ,

[0790] R c1 is H or CH2-R c2 ,as well as

[0791] R c2 is a structure of formula (XI), (XII) or (XXII),

[0792]

[0793] in:

[0794] R c3 and R c4 are each and independently selected from H and (C1-C4)alkyl, and

[0795] u=1, 2, 3, 4, 5 or 6,

[0796] x and y are each and independently 1, 2 or 3, and

[0797] X=O or S,

[0798] Wherein in formula (XI) and (XXII), one of the nitrogen atoms is connected to R c1 -CH2-, and in formula (XII), -X- is connected to R c1 -CH2-; and

[0799] Wherein the N-terminal modification group A is a protecting group Abl or amino acid Aaa.

[0800] More specifically, the problem on which the present invention is based is solved in a second aspect by the use of a compound according to the first aspect, including any embodiment thereof, in a method for diagnosing a disease.

[0801] More specifically, the problem on which the present invention is based is solved in a third aspect by the use of a compound according to the first aspect, including any embodiment thereof, in a method for treating a disease.

[0802] More specifically, the problem on which the present invention is based is solved in a fourth aspect by the use of a compound according to the first aspect, including any embodiment thereof, in a method for identifying an individual, wherein the individual may or may not respond to a treatment for a disease, wherein the method for identifying an individual comprises performing a diagnostic method using a compound according to the first aspect, including any embodiment thereof.

[0803] More specifically, the problem on which the present invention is based is solved in a fifth aspect by the use of a compound according to the first aspect, including any embodiment thereof, in a method for selecting an individual from a group of individuals, wherein the individual may or may not respond to a treatment for a disease, wherein the method for selecting an individual from a group of individuals comprises performing a diagnostic method using a compound according to the first aspect, including any embodiment.

[0804] More specifically, the problem on which the present invention is based is solved in a sixth aspect by the use of a compound according to the first aspect, including any embodiment thereof, in a method for stratifying a group of individuals into individuals who are likely to respond to a treatment for a disease and into individuals who are likely to not respond to a treatment for a disease, wherein the method for stratifying a group of individuals comprises performing a diagnostic method using a compound according to the first aspect, including any embodiment thereof.

[0805] More specifically, the problem on which the present invention is based is solved in a seventh aspect by a composition, preferably a pharmaceutical composition, comprising a compound according to the first aspect, including any embodiment thereof, and a pharmaceutically acceptable excipient.

[0806] More specifically, the problem on which the present invention is based is solved in an eighth aspect by a method for diagnosing a disease in an individual, wherein said method comprises administering to said individual a diagnostically effective amount of a compound according to the first aspect, including any embodiment thereof.

[0807] More specifically, the problem on which the present invention is based is solved in a ninth aspect by a method for treating a disease in an individual, wherein said method comprises administering to said individual a therapeutically effective amount of a compound according to the first aspect, including any embodiment thereof.

[0808] More specifically, the problem on which the present invention is based is solved in a tenth aspect by a kit comprising a compound according to the first aspect, including any embodiment thereof, one or more optional excipients and optionally one or more devices, wherein the device is selected from a labeling device, a purification device, a manipulation device, a radiation protection device, an analysis device or an administration device.

[0809] One skilled in the art will recognize that a or the compound of the present invention is any compound disclosed herein, including but not limited to any compound described in any of the above embodiments and any of the following embodiments.

[0810] One skilled in the art will recognize that one or the methods of the present invention is any method disclosed herein, including but not limited to any method described in any of the above embodiments and any of the following embodiments.

[0811] One skilled in the art will recognize that a or the composition of the present invention is any composition disclosed herein, including but not limited to any composition described in any of the above embodiments and any of the following embodiments.

[0812] One skilled in the art will recognize that a or the kit of the present invention is any kit disclosed herein, including but not limited to any kit described in any of the above embodiments and any of the following embodiments.

[0813] The present invention is based on the surprising discovery of the inventors that the compounds of the invention, more particularly cyclic peptides thereof, provide highly specific binding of compounds comprising such cyclic peptides to fibroblast activation protein (FAP), since no FAP-specific cyclic peptide-based inhibitors with nanomolar affinity have been described to date.

[0814] Furthermore, the present invention is based on the surprising discovery that a chelating agent can be attached to the cyclic peptide directly or indirectly (i.e., using a linker) at three different positions. The first position is Yc having the structure of formula (X), which connects the S atom of Xaa1 and the S atom of Xaa7 to form two thioether bonds; the second position is Aaa attached to Xaa1 of the cyclic peptide of formula (I), and the third position is an amino acid or peptide attached to Xaa7. Surprisingly, the attachment of such a chelating agent does not significantly affect the binding of the compounds of the invention to FAP and the inhibitory properties of the compounds of the invention against FAP. In one embodiment, the present invention relates to a cyclic peptide of formula (I), wherein the chelating agent (Z group) is attached only at one of the first, second, or third positions as defined above. It is also within the scope of the present invention that the chelating agent is attached to the cyclic peptide of formula (I) at any combination of the first, second, and third positions as defined above. More specifically, the present invention also relates to compounds of formula (I) wherein the Z group is attached to the first and second positions as defined above, compounds of formula (I) wherein the Z group is attached to the first and third positions as defined above, compounds of formula (I) wherein the Z group is attached to the second and third positions as defined above, and compounds of formula (I) wherein the Z group is attached to the first, second, and third positions as defined above. These compounds comprising two or three Z groups may be realized in any embodiment of the invention disclosed herein.

[0815] Finally, the inventors have discovered that the compounds of the present invention are surprisingly stable in plasma and surprisingly useful as imaging agents as well as being effective in shrinking tumors.

[0816] As preferably used herein, the expression alkyl refers each and independently to a saturated straight or branched hydrocarbon radical, usually accompanied by a modifier specifying the number of carbon atoms it may contain. For example, the expression (C1-C6)alkyl refers each and independently to any of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methyl-butyl, 1-ethyl-propyl, 3-methyl-butyl, 1,2-dimethyl-propyl, 2-methyl-butyl, 1,1-dimethyl-propyl, 2,2-dimethylpropyl, n-hexyl, 1,1-dimethyl-butyl and any other isomer of an alkyl group containing six saturated carbon atoms.

[0817] In one embodiment and as preferably used herein, (C1-C2)alkyl refers each and independently to any of methyl and ethyl.

[0818] In one embodiment and as preferably used herein, (C1-C3)alkyl refers each and independently to any of methyl, ethyl, n-propyl and isopropyl.

[0819] In one embodiment and as preferably used herein, (C1-C4)alkyl refers each and independently to any of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

[0820] In one embodiment and as preferably used herein, (C1-C6)alkyl each and independently refers to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 2-methyl-butyl, 3-methyl-butyl, 3-pentyl, 3-methyl-but-2-yl, 2-methyl-but-2-yl, 2,2-dimethylpropyl, n-hexyl, 2-hexyl, 2-methyl-pentyl, 3- Any of methyl-pentyl, 4-methyl-pentyl, 3-hexyl, 2-ethyl-butyl, 2-methyl-pent-2-yl, 2,2-dimethyl-butyl, 3,3-dimethyl-butyl, 3-methyl-pent-2-yl, 4-methyl-pent-2-yl, 2,3-dimethyl-butyl, 3-methyl-pent-3-yl, 2-methyl-pent-3-yl, 2,3-dimethyl-but-2-yl and 3,3-dimethyl-but-2-yl.

[0821] In one embodiment and as preferably used herein, (C1-C8)alkyl refers to a saturated or unsaturated straight or branched chain hydrocarbon group having 1 to 8 carbon atoms. Representative (C1-C8)alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 2-methyl-butyl, 3-methyl-butyl, 3-pentyl, 3-methyl-but-2-yl, 2-methyl-but-2-yl, 2,2-dimethylpropyl, n-hexyl, 2-hexyl, 2-methyl-pentyl, 3-methyl-pentyl, 4-methyl-pentyl, 3-hexyl, 2-ethyl-butyl, 2-methyl-pent-2-yl, 2,2-dimethyl-butyl, 3,3-dimethyl-butyl, 3-methyl-pent-2-yl, 4-methyl-pent-2-yl, 2,3- dimethyl-butyl, 3-methyl-pentan-3-yl, 2-methyl-pentan-3-yl, 2,3-dimethyl-butan-2-yl, 3,3-dimethyl-butan-2-yl, n-heptyl, 2-heptyl, 2-methyl-hexyl, 3-methyl-hexyl, 4-methyl-hexyl, 5-methyl-hexyl, 3-heptyl, 2-ethyl-pentyl, 3-ethyl-pentyl, 4-heptyl, 2-methyl-hexan-2-yl, 2,2-dimethyl-pentyl, 3,3-dimethyl-pentyl, 4,4-dimethyl-pentyl, 3-methyl-hexan-2-yl, 4-methyl-hexan-2-yl, 5-methyl-hexan-2-yl, 2,3-dimethyl-pentyl, 2,4-dimethyl 2-ethyl-2-methyl-butyl, 4-methyl-hexan-3-yl, 5-methyl-hexan-3-yl, 2-ethyl-3-methyl-butyl, 2,3-dimethyl-pentan-2-yl, 2,4-dimethyl-pentan-2-yl, 3,3-dimethyl-pentan-2-yl, 4,4-dimethyl-pentan-2-yl, 2,2,3-trimethyl-butyl, 2,3,3-trimethyl-butyl, 2,3,3-trimethyl-butan-2-yl, n-octyl, 2-octyl, 2-methyl-heptyl, 3-methyl-heptyl, 4-methyl-heptyl, 5-methyl-heptyl, 6-methyl-heptyl, 4-Dimethyl-hexyl, 5-Methyl-heptyl, 6-Methyl-heptyl, 2,3-Dimethyl-hexyl, 2,4-Dimethyl-hexyl, 2,5-Dimethyl-hexyl, 3,4-Dimethyl-hexyl, 3,5-Dimethyl-hexyl, 3,4-Dimethyl-hexyl, 4,5-Dimethyl-heptyl, 2,3-Dimethyl-hexan-1-yl, 2,4-Dimethyl-hexan-1-yl, 2,5-Dimethyl-hexan-1-yl, 3,4-Dimethyl-hexan-1-yl, 3,5-Dimethyl-hexan-1-yl, 3,5-dimethyl-hexan-1-yl, 3-methyl-heptan-3-yl, 2-ethyl-2-methyl-1-yl, 3-ethyl-3-methyl-1-yl, 4-methyl-heptan-3-yl, 5-methyl-heptan-3-yl, 6-methyl-heptan-3-yl, 2-ethyl-3-methyl-pentyl, 2-ethyl-4-methyl-pentyl, 3-ethyl-4-methyl-pentyl, 2,3-dimethyl-hexan-2-yl, 2,4-dimethyl-hexan-2-yl, 2,5-dimethyl-hexan-2-yl, 3,3-dimethyl-hexan- 2-yl, 3,4-dimethyl-hexan-2-yl, 3,5-dimethyl-hexan-2-yl, 4,4-dimethyl-hexan-2-yl, 4,5-dimethyl-hexan-2-yl, 5,5-dimethyl-hexan-2-yl, 2,2,3-trimethyl-pentyl, 2,2,4-trimethyl-pentyl, 2,3,3-trimethyl-pentyl, 2,3,4-trimethyl-pentyl, 2,4,4-trimethyl-pentyl, 3,3,4-trimethyl-pentyl, 3,4,4-trimethyl-pentyl, 2,3,3-trimethyl- Pentan-2-yl, 2,3,4-trimethyl-pentan-2-yl, 2,4,4-trimethyl-pentan-2-yl, 3,4,4-trimethyl-pentan-2-yl, 2,2,3,3-tetramethyl-butyl, 3,4-dimethyl-hexan-3-yl, 3,5-dimethyl-hexan-3-yl, 4,4-dimethyl-hexan-3-yl, 4,5-dimethyl-hexan-3-yl, 5,5-dimethyl-hexan-3-yl, 3-ethyl-3-methyl-pentan-2-yl, 3-ethyl-4-methyl-pentan-2-yl, 3-ethyl -hexan-3-yl, 2,2-diethyl-butyl, 3-ethyl-3-methyl-pentyl, 4-ethyl-hexan-3-yl, 5-methyl-hept-3-yl, 2-ethyl-3-methyl-pentyl, 4-methyl-hept-4-yl, 3-methyl-hept-4-yl, 2-methyl-hept-4-yl, 3-ethyl-hexan-2-yl, 2-ethyl-2-methyl-pentyl, 2-isopropyl-pentyl, 2,2-dimethyl-hexan-3-yl, 2,2,4-trimethyl-pentan-3-yl and 2-ethyl-3-methyl-pentyl. (C1-C8)alkyl may be unsubstituted or substituted with one or more groups including, but not limited to, (C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2, and -CN; wherein each R' is independently selected from -(C1-C8)alkyl and aryl.

[0822] The expression alkylene, as preferably used herein, refers to a saturated straight-chain or branched hydrocarbon radical in which two substitution points are specified. Simple alkyl chains in which the two substitution points are at the greatest distance from each other, such as methane-1,1-diyl, ethane-1,2-diyl, propane-1,3-diyl, butane-1,4-diyl and pentane-1,5-diyl, are also known as methylene (which is also known as methane-1,1-diyl), ethylene (which is also known as ethane-1,2-diyl), propylene (which is also known as propane-1,3-diyl), butylene (which is also known as butane-1,4-diyl) and pentylide (which is also known as pentane-1,5-diyl).

[0823] In one embodiment and as preferably used herein, (C1-C 10 ) alkylene each and independently refers to methylene, ethane-1,2-diyl, propane-1,3-diyl, propane-1,2-diyl, butane-1,4-diyl, butane-1,3-diyl, butane-1,2-diyl, 2-methyl-propane-1,2-diyl, 2-methyl-propane-1,3-diyl, pentane-1,5-diyl, pentane-1,4-diyl, pentane-1,3-diyl, pentane-1,2-diyl, pentane-2,3-diyl, pentane-2,4-diyl Any of a C1-C1 diyl group, any other isomer having 5 carbon atoms, a hexane-1,6-diyl group, any other isomer having 6 carbon atoms, a heptane-1,7-diyl group, any other isomer having 7 carbon atoms, an octane-1,8-diyl group, any other isomer having 8 carbon atoms, a nonane-1,9-diyl group, any other isomer having 9 carbon atoms, a decane-1,10-diyl group, and any other isomer having 10 carbon atoms, preferably (C1-C1 10 )Alkylene each and independently refers to any one of methylene, ethane-1,2-diyl, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl, hexane-1,6-diyl, heptane-1,7-diyl, octane-1,8-diyl, nonane-1,9-diyl and decane-1,10-diyl. (C1-C 10 )alkylene may be unsubstituted or substituted by one or more groups including, but not limited to, (C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2, and -CN; wherein each R' is individually and independently selected from -(C1-C8)alkyl and aryl.

[0824] In one embodiment and as preferably used herein, (C3-C8)cycloalkyl refers each and independently to any one of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

[0825] In one embodiment and as preferably used herein, (C5-C7)cycloalkyl each and independently refers to any one of cyclopentyl, cyclohexyl and cycloheptyl.

[0826] In one embodiment and as preferably used herein, (C3-C8) carbocycle refers to a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated non-aromatic carbocycle. Representative (C3-C8) carbocycles include, but are not limited to, any of -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-cycloheptadienyl, -1,3,5-cycloheptatrienyl, -cyclooctyl and -cyclooctadienyl. The (C3-C8)carbocycle may be unsubstituted or substituted by one or more groups including, but not limited to, (C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2 and -CN; wherein each R' is independently selected from -(C1-C8)alkyl and aryl.

[0827] In one embodiment and as preferably used herein, (C3-C8)carbocyclo refers to a (C3-C8)carbocyclic group as defined above wherein one of the carbocyclic hydrogen atoms is replaced by a bond.

[0828] In one embodiment and as preferably used herein, "aryl" refers to a carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and anthracenyl.

[0829] In one embodiment and as preferably used herein, (C5-C6)aryl refers to a carbocyclic aromatic group comprising 5 or 6 carbon atoms. The carbocyclic aromatic group may be unsubstituted or substituted by one or more groups including, but not limited to, -(C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2 and -CN; wherein each R' is independently selected from -(C1-C8)alkyl and aryl.

[0830] In one embodiment, and as preferably used herein, "heteroaryl" refers to a heterocyclic aromatic group. Examples of heteroaryl groups include, but are not limited to, furan, thiophene, pyridine, pyrimidine, benzothiophene, benzofuran, and quinoline.

[0831] In one embodiment and as preferably used herein, (C5-C6)heteroaryl refers to a heterocyclic aromatic group consisting of 5 or 6 ring atoms, at least one of which is different from carbon, preferably nitrogen, sulfur or oxygen. The heterocyclic aromatic group may be unsubstituted or substituted by one or more groups including, but not limited to, -(C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2 and -CN; wherein each R' is individually and independently selected from -(C1-C8)alkyl and aryl.

[0832] In one embodiment and as preferably used herein, (C3-C8)heterocyclo refers to a (C3-C8)heterocyclic group as defined above in which one of the carbocyclic hydrogen atoms is replaced by a bond. The (C3-C8)heterocyclic ring may be unsubstituted or substituted by up to six groups including (C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2 and -CN; wherein each R' is independently and individually selected from -(C1-C8)alkyl and aryl.

[0833] In one embodiment and as preferably used herein, arylene refers to an aryl group having two covalent bonds and can be in the ortho, meta, or para configuration, as shown in the following structure:

[0834]

[0835] Wherein phenyl can be unsubstituted or substituted by four groups, the groups including but not limited to (C1-C8) alkyl, -O-[(C1-C8) alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2 and -CN; wherein each R' is each and independently selected from -(C1-C8) alkyl and aryl.

[0836] In one embodiment and as preferably used herein, an atom for which an atomic mass number is not specified in any formula or any paragraph in this application, including the claims, is an unspecified isotopic composition, a naturally occurring isotopic mixture, or an individual isotope. This applies in particular to carbon, oxygen, nitrogen, sulfur, phosphorus, halogen, and metal atoms, including but not limited to C, O, N, S, F, P, Cl, Br, At, Sc, Cr, Mn, Co, Fe, Cu, Ga, Sr, Zr, Y, Mo, Tc, Ru, Rh, Pd, Pt, Ag, In, Sb, Sn, Te, I, Pr, Pm, Dy, Sm, Gd, Tb, Ho, Dy, Er, Yb, Tm, Lu, Sn, Re, Rd, Os, Ir, Au, Pb, Bi, Po, Fr, Ra, Ac, Th, and Fm.

[0837] In one embodiment and as preferably used herein, chelating agents are compounds capable of forming chelates, wherein the chelating agent is a compound, preferably a cyclic compound in which a metal or a moiety with an electronic interstitial or lone pair electron participates in the ring formation. More preferably, the chelating agent is a compound in which a single ligand occupies more than one coordination site at the central atom.

[0838] In one embodiment and as preferably used herein, a diagnostically active compound is a compound that is suitable or useful for diagnosing a disease.

[0839] In one embodiment and as preferably used herein, a diagnostic agent or a diagnostically active agent is a compound that is suitable or useful for diagnosing a disease.

[0840] In one embodiment and as preferably used herein, a therapeutically active compound is a compound that is suitable or useful for treating a disease.

[0841] In one embodiment and as preferably used herein, a therapeutic agent or therapeutically active agent is a compound that is suitable or useful for treating a disease.

[0842] In one embodiment and as preferably used herein, a theranostically active compound is a compound that is suitable or useful for the diagnosis and treatment of a disease.

[0843] In one embodiment and as preferably used herein, a theranostic agent or a theranostically active agent is a compound that is suitable or useful for the diagnosis and treatment of a disease.

[0844] In one embodiment and as preferably used herein, theranostics is a method for combined diagnosis and treatment of a disease; preferably, the combined diagnostically and therapeutically active compounds used in the theranostics are radiolabeled.

[0845] In one embodiment and as preferably used herein, treatment of a disease is the treatment and / or prevention of the disease.

[0846] In one embodiment and as preferably used herein, a disease involving FAP is a disease in which cells (including but not limited to fibroblasts) expressing (preferably in an upregulated manner) FAP and tissues expressing FAP or containing or comprising cells (e.g., fibroblasts) expressing FAP, preferably in an upregulated manner, are the cause of the disease and / or symptoms of the disease, respectively, or are part of the underlying pathology of the disease. Preferred FAP-expressing cells are cancer-associated fibroblasts (CAFs). In embodiments of the disease, preferably when used in conjunction with the treatment, management, and / or therapy of the disease, affecting the cells, tissue, and pathology, respectively, results in a cure, treatment, or amelioration of the disease and / or symptoms of the disease. In embodiments of the disease, preferably when used in conjunction with the diagnosis and / or performing a diagnosis of the disease, labeling of FAP-expressing cells and / or FAP-expressing tissues allows for the differentiation or distinction of the cells and / or tissues from healthy or non-FAP-expressing cells and / or healthy or non-FAP-expressing tissues. More preferably, this differentiation or distinction forms the basis for the diagnosis and performing a diagnosis, respectively. In an embodiment thereof, labeling refers to the direct or indirect interaction of a detectable label with a FAP-expressing cell and / or a FAP-expressing tissue or a tissue containing such a FAP-expressing cell; more preferably, such interaction involves or is based on the interaction of the label or a compound carrying such a label with FAP.

[0847] In one embodiment and as preferably used herein, the target cell is a cell that expresses FAP and is the cause of the disease and / or disease symptoms, or is part of the underlying pathology of the disease.

[0848] In one embodiment and as preferably used herein, non-target cells refer to cells that do not express FAP and / or are not the cause of the disease and / or disease symptoms, or are not part of the underlying pathology of the disease.

[0849] In one embodiment and as preferably used herein, a tumor is an abnormal new growth of cells. The cells in a tumor grow faster than normal cells and will continue to grow if not treated. Tumors can be benign or malignant.

[0850] In one embodiment and as preferably used herein, a tumor is a mass lesion, which may be benign or malignant.

[0851] In one embodiment and as preferably used herein, the cancer is a malignancy.

[0852] In one embodiment and as preferably used herein, a bond is the connection of two atoms of two independent parts. The preferred bond is a chemical bond or multiple chemical bonds. More preferably, the chemical bond is a covalent bond or multiple chemical bonds. Most preferably, the bond is a covalent bond or a coordination bond. As preferably used herein, an embodiment of a coordination bond is a bond or bond group that is achieved when a metal is bound by a chelating agent. Depending on the type of atoms connected and their atomic environment, different types of bonds are generated. These bond types are defined by the type of atomic arrangement generated by the bond. For example, the connection of a moiety containing an amine to a moiety containing a carboxylic acid results in a bond called an amide (also known as an amide bond, -CO-N-, -N-CO-). Those skilled in the art will recognize that this and the following examples of generating bonds are only typical examples and in no way limit the scope of this application. Those skilled in the art will recognize that the connection of a moiety containing an isothiocyanate to a moiety containing an amine produces a thiourea (also known as a thiourea bond, -N-CS-N-), and the connection of a moiety containing a C atom to a moiety containing a thiol group (-C-SH) produces a thioether (also known as a thioether bond, -CSC-). A non-limiting list of characteristic types of linkages and arrangements of their atoms that are preferred for use in combination with the chelators and linkers of the present invention is given in Table 2.

[0853] Table 2

[0854]

[0855] Examples of reactive groups used to form linkages between chelators and linkers, or directly between chelators and compounds of the invention, in some embodiments of the invention are summarized in Table 3. However, one skilled in the art will appreciate that the linkages that can be achieved in embodiments for forming conjugates of the invention are not limited to one of the linkages in Table 3, nor to the reactive groups that form such linkages.

[0856] Table 3

[0857] First reactive group Second reactive group Bond (type) amino carboxylic acid Amide amino Activated carboxylic acid Amide carboxylic acid amino Amide Thiol Michael acceptors (e.g., maleimide) sulfide bromine Thiol sulfide Isothiocyanates amino Thiourea Hydroxyl carboxylic acid ester Azide Alkynes triazole Thiol Thiol disulfide Thiol 2-Pyridine disulfide disulfide Isocyanates amino Carbamate bromine Hydroxyl ether

[0858] The following are reactive and functional groups that are used or suitable for forming linkages between moieties or structures used in embodiments of the conjugates of the present invention:

[0859] Primary or secondary amino groups, carboxylic acids, activated carboxylic acids, chlorine, bromine, iodine, thiol, hydroxyl, sulfonic acid, activated sulfonic acid, sulfonates such as mesylate or tosylate, Michael acceptors, strained alkene such as trans-cyclooctene, isocyanates, isothiocyanates, azides, alkynes, and tetrazines.

[0860] As preferably used herein, the term "activated carboxylic acid" refers to a carboxylic acid group having the general formula -CO-X, where X is a leaving group. For example, the activated form of the carboxylic acid group may include, but is not limited to, an acid chloride, a symmetrical or asymmetrical anhydride, and an ester. In some embodiments, the activated carboxylic acid group is an ester having pentafluorophenol, nitrophenol, benzotriazole, azabenzotriazole, thiophenol, or N-hydroxysuccinimide (NHS) as a leaving group.

[0861] As preferably used herein, the term "activated sulfonic acid" refers to a sulfonic acid group having the general formula -SO2-X, where X is a leaving group. For example, the activated form of the sulfonic acid may include, but is not limited to, a sulfonyl chloride or a sulfonic anhydride. In some embodiments, the activated sulfonic acid group is a sulfonyl chloride having chlorine as a leaving group.

[0862] In one embodiment and as preferably used herein, the term "mediating a linkage" refers to establishing a linkage or a type of linkage, preferably a linkage between two moieties. In preferred embodiments, the linkage and type of linkage are as defined herein.

[0863] Where reference is made to a range in this application represented by a lower integer and an upper integer (e.g., 1 to 4), such a range represents the lower integer, the upper integer, and any integer between the lower integer and the upper integer. To this extent, the range is effectively an individual disclosure of the integers. In the example, a range of 1 to 4 therefore means 1, 2, 3, and 4.

[0864] The compounds of the present invention generally comprise an amino acid sequence as provided herein. Conventional amino acids (also known as natural amino acids) are identified according to their standard three-letter codes and one-letter abbreviations, as shown in Table 4.

[0865] Table 4: Common amino acids and their abbreviations

[0866] amino acids 3-letter abbreviation 1-letter abbreviation Alanine Ala A Arginine Arg R Asparagine Asn N Aspartic acid Asp D Cysteine Cys C glutamate Glu E Glutamine Gln Q Glycine Gly G Histidine His H Isoleucine Ile I Leucine Leu L Lysine Lys K Methionine Met M Phenylalanine Phe F Proline Pro P Serine Ser S Threonine Thr T Tryptophan Trp W Tyrosine Tyr Y Valine Val V

[0867] Unconventional amino acids (also called non-natural amino acids) are any type of non-oligomeric compound that contains an amino group and a carboxyl group and that is not a conventional amino acid.

[0868] Examples of unconventional amino acids and other building blocks used to construct compounds of the invention are identified by their abbreviations or names in Table 5. The structures of some building blocks are depicted with exemplary reactants (e.g., carboxylic acid-like) for introducing the building blocks into peptides, or these building blocks are shown as residues fully connected to another structure, such as a peptide or an amino acid. The structures of the amino acids are shown as explicit amino acids, rather than amino acid residues (which are presented in the peptide sequence after execution in this way). For clarity, some larger chemical moieties consisting of more than one part are also shown.

[0869] Table 5: Abbreviations, names and structures of unnatural amino acids and other building blocks and chemical moieties

[0870]

[0871]

[0872]

[0873]

[0874]

[0875]

[0876]

[0877]

[0878]

[0879]

[0880]

[0881]

[0882]

[0883]

[0884]

[0885] It will be appreciated by those skilled in the art that the amino acid sequences of the peptides provided herein are described in a typical peptide sequence format. For example, the three letter codes for conventional amino acids, or the codes for unconventional amino acids, or the abbreviations for other components represent that the amino acids or components exist at specific positions in the peptide sequence. The code for each amino acid or component is connected to the code for the next and / or previous amino acid or component in the sequence by a hyphen (usually representing an amide bond).

[0886] In case an amino acid contains more than one amino and / or carboxyl group, all orientations of this amino acid are in principle possible, but in α-amino acids, preference is given to utilizing the α-amino and α-carboxyl groups, other preferred orientations being explicitly indicated.

[0887] For amino acids, in their abbreviations, the first letter indicates the stereochemistry of the C-α-atom (if applicable). For example, an uppercase first letter indicates the presence of the L-form of the amino acid in the peptide sequence, while a lowercase first letter indicates the presence of the D-form of the corresponding amino acid in the peptide sequence.

[0888] In one embodiment and as preferably used herein, an aromatic L-α-amino acid is any kind of L-α-amino acid comprising an aryl group.

[0889] In one embodiment and as preferably used herein, a heteroaromatic L-α-amino acid is any kind of L-α-amino acid comprising a heteroaryl group.

[0890] Those skilled in the art will recognize that if there is a stereocenter in the compounds disclosed herein, no matter whether this stereocenter is a part of an amino acid group or any other part or group of the compounds of this invention. Therefore, the present invention includes two possible stereoisomers and not only includes racemic compounds, but also includes independent enantiomers and / or diastereomers. When it is desired that the compound is a single enantiomer or diastereomer, it can be obtained by stereospecific synthesis or by splitting the final product or any convenient intermediate. The splitting of the final product, intermediate or starting material can be carried out by any suitable method known in the art. See, for example, " Stereochemistry of Organic Compounds " (Wiley-Interscience, 1994) by E.L. Eliel, S.H. Wilen and L.N. Mander.

[0891] In the present application, for the sake of convenience, in some cases, the structural formula of the compound represents a certain isomer, but the present invention includes all isomers, such as geometric isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers, etc. In the present application, for the sake of convenience, in some cases, the structural formula of the compound represents a certain isomer, but the present invention includes all isomers, such as geometric isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers, etc.

[0892] Unless indicated to the contrary, amino acid sequences are presented herein in N-terminal to C-terminal direction.

[0893] The derivatives of the amino acids constituting the peptides of the present invention may be as shown in Table 6. In any embodiment, one or more amino acids of the compound of the present invention are substituted with the corresponding preferred amino acid derivatives.

[0894] Table 6: Examples of preferred amino acid derivatives contained in the compounds of the present invention

[0895]

[0896] Linear peptides

[0897] A typical linear peptide is usually written from N-terminus to C-terminus as follows:

[0898] NT-Xaa1-Xaa2-Xaa3-Xaa4-…Xaan-CT;

[0899] in:

[0900] 1. Xaax is the abbreviation, descriptor or symbol for the amino acid or building block at position x of a particular sequence as shown in Table 5,

[0901] 2. NT is the N-terminal group, such as "H" (hydrogen of the free N-terminal amino group), or an abbreviation for a specific terminating carboxylic acid (such as "Ac" for acetic acid), or another chemical group or structural formula of a chemical group connected by a hyphen to the N-terminal amino acid code (Xaa1), and

[0902] 3. CT is the C-terminal group, which is usually an abbreviation of "OH" or "NH2" (as the terminal carboxylic acid or amide) or a specific terminating amine connected by a hyphen to the C-terminal amino acid code (Xaan).

[0903] Branched peptides with side chains modified by specific building blocks or peptides

[0904] A typical linear branched peptide is written from N-terminus to C-terminus as follows:

[0905] NT-Xaa1-Xaa2-Xaa3(NT-Xab1-Xab2-……Xabn)-……Xaan-CT

[0906] Statements 1 to 3 described for the linear peptide are applicable to the description of Xaax, NT and CT in the branched peptide backbone.

[0907] The position of the branch is specified by brackets following the abbreviation Xaax.The branch typically occurs at a lysine (Lys) residue (or analogue), meaning that the branch is attached to the side chain epsilon-amino function of the lysine via an amide bond.

[0908] The content in brackets describes the sequence / structure of the peptide branch "NT-Xab1-Xab2-...Xabn".

[0909] 1. Xabx is the abbreviation, descriptor or symbol for the amino acid or building block at position x of a particular sequence of a branch as shown in Table 3,

[0910] 2. NT is the N-terminal group, such as an abbreviation for a specific terminating carboxylic acid (e.g., "Ac" for acetic acid), or another chemical group or structural formula of a chemical group connected by a hyphen to the N-terminal amino acid code (Xab1), and

[0911] 3. The last building block of the branch Xabn connects the branch to the main chain by forming an amide bond between its own carboxyl function and the side chain amino function of this lysine (or similar residue).

[0912] Cyclic peptides

[0913] An exemplary general cyclic peptide is written from N-terminus to C-terminus as follows:

[0914] NT-Xaa1-[Xaa2-Xaa3-Xaa4-…Xaan]-CT;

[0915] Statements 1 to 3 above for the description of linear peptides apply to Xaax, NT, and CT in the backbone of the cyclic peptide. Features of the peptide ring are designated by square brackets.

[0916] 1. The left square bracket indicates the building block at whose side chain the loop begins (the loop-starting residue), and

[0917] 2. The right square bracket indicates a building block at whose side chain a loop terminates (loop-terminating residue).

[0918] The chemical nature of the connection between these two residues is:

[0919] 1. an amide bond, wherein, among those residues indicated, one residue contains an amino function (e.g. Lys) in its side chain and the other residue contains a carboxyl function (e.g. Glu) in its side chain, or

[0920] 2. Disulfide bonds, where those residues / amino acids indicated contain a sulfhydryl moiety (eg, Cys).

[0921] Cyclic peptides containing other cyclization elements (Yc)

[0922] A typical extended cyclic peptide written from N-terminus to C-terminus is shown below:

[0923] NT-Xaa1-[Xaa2(Yc)-Xaa3-Xaa4-…Xaan]-CT;

[0924] Wherein statements 1 to 3 in the description of linear peptides are applicable to the description of Xaax, NT and CT in the backbone of the cyclic peptide. In addition, Yc is a cyclization element. As in the case of cyclic peptides, the characteristics of the ring are specified by square brackets, which indicate the ring starting residue and the ring ending residue.

[0925] The parenthetical content adjacent to the ring starting residue specifies the cyclization element Yc in the extended peptide ring. The Yc element is connected to the side chain of the residue. In addition, the Yc element is connected to the side chain of the ring terminating residue. The chemical nature of the bond between any one of these residues and the Yc element depends on the side chain functional group of the corresponding amino acid Xaan. If the side chain of Xaan contains a sulfhydryl group (e.g., Cys), the bond is a thioether.

[0926] As a non-limiting example, the structure of Ac-[Cys(tMeBn(DOTA-PP))-Pro-Pro-Thr-Gln-Phe-Cys]-OH is shown below:

[0927]

[0928] in:

[0929] 1.Ac corresponds to NT in the general formula.

[0930] 2. Cys, Pro, Pro, Thr, Gln, Phe and Cys correspond to Xaa1 to Xaa7 in the general formula.

[0931] 3.OH corresponds to CT in the general formula.

[0932] 4. A left square bracket (,[') adjacent to the N-terminal cysteine ​​in the sequence indicates that the loop begins at this residue (loop start residue).

[0933] 5. A right square bracket (,]') adjacent to the N-terminal cysteine ​​in the sequence indicates that the loop terminates at this residue (loop-terminating residue).

[0934] 6. The tMeBn in brackets adjacent to the Cys residue indicated as the start residue refers to the cyclization element Yc. It is further bound to the Cys residue indicated as the loop terminator. The Yc element is linked to the residue via a thioether bond.

[0935] 7. The DOTA chelator is linked to the remaining attachment point of the tMeBn residue via a PP linker. For clarity, terms such as "Cys(tMeBn(DOTA-PP))" are included in the chemical structure listings in Table 2.

[0936] In one embodiment of the invention, an amino acid or peptide is linked to Xaa7, wherein the majority of the amino acids of the peptide are charged or polar, and the net charge of the peptide is -2, -1, 0, +1 or +2.

[0937] For the calculation of the peptide net charge, negatively charged amino acids are those carrying acidic groups such as -COOH or -SO3H in their side chains, and their net charge corresponds to the number of acidic groups, for example, Asp or Glu has a net charge of -1.

[0938] For this calculation, a positively charged amino acid is one that carries a basic group such as amino or -guanidino in its side chain and whose net charge corresponds to the number of basic groups, for example Lys or Arg has a net charge of +1.

[0939] Polar amino acids are amino acids with polar groups in their side chains. Examples of polar groups are CONH2, OH, F, Cl, CN, and heterocycles, such as the imidazole in histidine.

[0940] Polar amino acids have a net charge of 0. For some nitrogen-containing heterocycles, the net charge is assumed to be 0 in our calculations, but it is recognized that depending on the pH of the environment, they may be protonated in equilibrium and therefore have a positive charge to some extent.

[0941] The majority (50% or more) of the amino acids of the peptide are charged or polar.

[0942] Preferably, the positive or negative charges are sometimes separated by polar or nonpolar amino acids.

[0943] In some embodiments, the presence of a negatively charged amino acid is preferably at Xaa10.

[0944] In some embodiments, the presence of a positively charged amino acid is preferably at Xaa13, preferably Arg and arg.

[0945] According to the present invention, the compounds of the present invention may include a Z group. The Z group includes a chelating agent and an optional linker. As preferably used, a linker is an element, part or structure that separates two parts of a molecule. In the present invention, the linker group forms a covalent bond with both the chelating agent group and the corresponding part of the compounds of the present invention to which Z is attached. In principle, the linker group can be any chemical group that can form a bond with the chelating agent group and a part of the compounds of the present invention at a specified position.

[0946] An important property or feature of the linker is that it separates the chelator from the cyclic peptide portion of the compound of the invention. This is particularly important in cases where the target binding ability of the cyclic peptide is impaired by the close proximity of the chelator. However, the total linker length in its most extended conformer should not exceed Preferably no more than Most preferably no more than

[0947] In a preferred embodiment, the linker is -[X]a-, wherein a is an integer from 1 to 10, and each X is a separate building block that is independently linked to its neighbor in the sequence through a functional group selected from the group consisting of an amide bond, a urea bond, a carbamate bond, an ester bond, an ether bond, a thioether bond, a sulfonamide bond, a triazole bond, and a disulfide bond.

[0948] X1 is linked to the chelating agent and to X2 (if present), or to the compound of the invention at the indicated position. a With X a-1 (if present) and to the compound of the invention at the indicated position.

[0949] A more preferred type of linker group is represented by -[X] a - represents, wherein a is an integer from 1 to 10, preferably a is an integer from 1 to 8, 1 to 6, 1 to 5, 1 to 4 or 1 to 3, and each X is a separate building block that is independently linked to its adjacent group in the sequence through a functional group selected from the following: amide bond, urea bond, carbamate bond, ester bond, ether bond, thioether bond, sulfonamide bond, triazole and disulfide bond.

[0950] In one embodiment, the building block X has the general formula (8),

[0951]

[0952] in:

[0953] Fragment Lin 2 (if present) and the fragment Lin 3 (if present) are each independently selected from -CO-, -NR 10 -、-S-、-CO-NR 10 -、-CS-NR 10 -, -O-, -succinimide- and -CH2-CO-NR 10 -; The condition is Lin 2 or Lin 3 At least one of them is connected to R through a carbon atom 9 connection, and the nitrogen atoms of all nitrogen-containing fragments are connected to R 9 connect;

[0954] where R 10 is selected from hydrogen and (C1-C4)alkyl;

[0955] And R 9 Selected from -(C1-C 10)alkylene-、-(C3-C8)carbocycle-、-arylene-、-(C1-C 10 )alkylene-arylene-, -arylene-(C1-C 10 )alkylene-, -(C1-C 10 )alkylene-arylene-(C1-C 10 )alkylene-, -(C1-C 10 )alkylene-(C3-C8)carbocyclic-, -(C3-C8)carbocyclic-(C1-C 10 )alkylene-, -(C1-C 10 )alkylene-(C3-C8)carbocyclic-(C1-C 10 )alkylene-、-(C3-C8)heterocyclic-、(C1-C 10 )alkylene-(C3-C8)heterocycle-, -(C3-C8)heterocycle-(C1-C 10 )alkylene-, -(C1-C 10 )alkylene-(C3-C8)heterocyclic-(C1-C 10 )alkylene-、-(CH2CH2O) r - and -(CH2) s -(CH2CH2O) r -(CH2) t -;

[0956] and among them:

[0957] r is any integer from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

[0958] s is any integer from 0, 1, 2, 3, and 4; and

[0959] t is any integer from 0, 1, 2, 3, and 4.

[0960] Preferably, except for the bond between X1 and the chelating agent, the bond is an amide bond. More preferably, the building blocks X2 to X a Independently selected from amino acids, dicarboxylic acids, and diamines, the linkage to each being an amide.

[0961] In one embodiment, components X2 to X a Preferably, the amino acid is selected from conventional and unconventional amino acids. In one embodiment, the amino acid is selected from β-amino acids, γ-amino acids, δ-amino acids, ε-amino acids, and ω-amino acids. In a further embodiment, the amino acid is a cyclic amino acid or a linear amino acid. It will be understood by those skilled in the art that in the case of amino acids having stereocenters, all stereoisomeric forms can be used in building block X.

[0962] In one embodiment, components X2 to X a Preferably it is an amino acid, wherein the amino acid is selected from amino acids having different spacings between the amino group and the carboxyl group. Such amino acids can generally be represented as follows:

[0963]

[0964] It is within the scope of the present invention that such amino acids are not further substituted. However, it is also within the scope of the present invention that such amino acids are further substituted; preferably, such substitutions are CO-NH2 and / or Ac-NH-.

[0965] Representative of such amino acids (Structure 32) that can be used as building block X are glycine (Gly), beta-alanine (Bal), gamma-aminobutyric acid (GABA), aminovaleric acid, aminocaproic acid and homologues having up to 10 CH2 groups.

[0966] More preferred representatives of such amino acids (Structure 33) for use as building block X are 3-aminomethyl-benzoic acid, 4-aminomethyl-benzoic acid, anthranilic acid, 3-aminobenzoic acid and 4-aminobenzoic acid.

[0967] Related building blocks are diamines derived from amino acids (structure 32+33) by replacing NH2 with COOH, preferably used as building block X are diaminoethane, 1,3-diaminopropane, 1,4-diaminobutane, 1,5-diaminopentane, 3-aminomethylaniline, 4-aminomethylaniline, 1,2-diaminobenzene, 1,3-diaminobenzene and 1,4-diaminobenzene.

[0968] Related building blocks are dicarboxylic acids derived from amino acids (structure 32+33) by replacing COOH with NH2, more preferably used as building block X are malonic acid, succinic acid, glutaric acid, adipic acid, phthalic acid, terephthalic acid, isophthalic acid and 2,3 or 4-carboxyphenylacetic acid.

[0969] In a further embodiment, the amino acid is an amino acid containing a polyether (preferably as a backbone). Preferably, such a polyether is polyethylene glycol and consists of a maximum of 30 monomer units. Preferably, the amino acid containing such a polyether exhibits increased hydrophilicity compared to an amino acid not containing such a polyether. If incorporated into building block X and ultimately into linker group [X] a The result is generally an increase in hydrophilicity. Preferred embodiments of such amino acids are described below, wherein it is recognized that such amino acids may contain 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 ethylene oxide moieties:

[0970]

[0971] Preferred glycol-containing amino acids are Ttds (N-(3-{2-[2-(3-aminopropyloxy)-ethoxy]-ethoxy}-propyl)-succinic acid) and O2Oc ([2-(2-amino-ethoxy)-ethoxy]-acetic acid), which have the following structural formulas:

[0972]

[0973] In a preferred embodiment, the linker comprises an oligomer or monomer of only one specific amino acid selected from the group consisting of: Ttds, O2Oc, Apac, Gly, Bal, Gab, Mamb, Pamb, Ppac, 4Amc, Inp, Sni, Rni, Nmg, Cmp, PEG6, PEG12, PEG-amino acid, more preferably the linker is monomeric.

[0974] In another preferred embodiment, the linker comprises a building block X2 selected from Ttds, O2Oc, Apac, Gly, Bal, Gab, Mamb, Pamb, PEG6, PEG12 and PEG-amino acids, and another building block X1 that is directly bound to the amino nitrogen of X2 and is directly linked to the chelator via a bond selected from the group consisting of an amide bond, a urea bond, a carbamate bond, an ester bond, an ether bond, a thioether bond, a sulfonamide, a triazole and a disulfide bond. In this case, X1 acts as an adaptor to mediate the linkage of the different types of linking functional groups provided by the chelator to the nitrogen atom of the amino acid X2, since X1 provides the relevant complementary functional group for the linkage of the chelator.

[0975] However, the use of linkers is often purposeful. In some cases, it is necessary to separate the larger moiety from the bioactive molecule in order to maintain high biological activity. In other cases, the introduction of linkers provides the opportunity to adjust the physicochemical properties of the molecule by introducing polarity or multiple charges. In some cases, it may be an advantage and achievement if a chelating agent can be combined with a bioactive compound without the need for such a linker. In particular, in compounds of the present invention in which the chelating agent is attached to Yc of formula (X), the connection of the S atom of Xaa1 and the S atom of Xaa7 can generally be performed well without the use of any of the shown linkers, with the formation of two thioether bonds.

[0976] In one embodiment, the compounds of the invention comprise a chelating agent. Preferably, the chelating agent is part of the compounds of the invention, wherein the chelating agent is directly or indirectly (e.g., via a linker) attached to the compounds of the invention. Preferred chelating agents are those that form metal chelates, which preferably comprise at least one radioactive metal. The at least one radioactive metal is preferably useful or suitable for diagnosis and / or treatment and / or theranostic use, more preferably useful or suitable for imaging and / or radiotherapy.

[0977] In principle, chelating agents that can be used for and / or are applicable to the practice of the present invention (including diagnosis and / or treatment of disease) are known to those skilled in the art. Various corresponding chelating agents are available and have been reviewed, such as Banerjee et al. (Banerjee, et al., Dalton Trans, 2005, 24: 3886) and references therein (Price, et al., Chem Soc Rev, 2014, 43: 260; Wadas, et al., Chem Rev, 2010, 110: 2858). Such chelating agents include but are not limited to linear, cyclic, macrocyclic, tetrapyridine, N3S, N2S2 and N4 chelating agents, such as US 5,367,080 A, US 5,364,613 A, US 5,021,556 A, US 5,075,099 A and US 5,886,142 A.

[0978] Representative chelating agents and their derivatives include, but are not limited to, AAZTA, BAT, CDTA, DTA, DTPA, CY-DTA, DTCBP, CTA, cyclam, cyclen, TETA, Sarcophagine, CPTA, TEAMA, Cyclen, DO3A, DO2A, TRITA, DATA, DFO, DATA(M), DATA(P), DATA(Ph), DATA(PPh), DEDPA, H4octapa, H2dedpa, H5decapa, H2azapa, H2CHX DEDPA, DFO-Chx-MAL, DFO-p-SCN, DFO-1AC, DFO-BAC, p-SCN-Bn-DFO, DFO-pPhe-NCS, DFO-HOPO, DFC, Diphosphine, DOTA, DOTAGA, DOTA-MFCO, DOTAM-monobasic acid, nitro-DOTA, nitro-PA-DOTA, p-NC S-Bz-DOTA, PA-DOTA, DOTA-NCS, DOTA-NHS, CB-DO2A, PCTA, p-NH2-Bn-PCTA, p-SCN-Bn-PCTA, p-SCN-Bn-DOTA, DOTMA, NB-DOTA, H4NB-DOTA, H4TCE-DOTA, 3,4,3-(Li-1,2-HOPO), TREN(Me-3,2-HOPO), TCE-DOTA, DOTP, DOXP, p-NCS-DOTA, p-NCS-TRITA, TRITA, TETA, 3p-C-DEPA, 3p-C-DEPA-NCS, p-NH2-BN-OXO-DO3A, p-SCN-BN-TCMC, TCMC, 4-aminobutyl-DOTA, azido-monoamide-DOTA, BCN-DOTA, butyne-DOTA, BCN-DOTA-GA, DOA3P, DO2a2p, DO2A (trans-H2do2a), DO3A, DO3A-thiol, DO3AtBu-N-(2-aminoethyl)acetamide, DO2AP, CB-DO2A, C3B-DO2A, HP-DO3A, DOTA-NHS-ester, maleimide -DOTA-GA, maleimido-mono-amide-DOTA, maleimide-DOTA, NH2-DOTA-GA, NH2-PEG4-DOTA-GA, GA, p-NH2-Bn-DOTA, p-NO2-Bn-DOTA, p-SCN-Bn-DOTA, p-SCN-Bz-DOTA, TA-DOTA, TA-DOTA-GA, OTTA, DOXP, TSC, DTC, DTCBP, PTSM, ATSM, H2ATSM, H2PTSM, Dp44mT, DpC, Bp44mT, QT, hybrid thiosemicarbazone–benzothiazole, thiosemicarbazone–styrylpyridine tetradentate ligand H2L, 2–4 , HBED, HBED-CC, dmHBED, dmEHPG, HBED-nn, SHBED, Br-Me2HBED, BPCA, HEHA, BF-HEHA, Deferiprone, THP, HYNIC (2-hydrazinonicotinamide), NHS-HYNIC, HYNIC-Kp-DPPB, HYNIC-Ko-DPPB, (HYNIC)(tricine)2, (HYNIC)(EDDA)Cl, p-EDDHA, AIM, AIM A,IAM B, MAMA, MAMA-DGal, MAMA-MGal, MAMA-DA, MAMA-HAD, Macropa, Macropaquin, Macroquin-SO3, N x S 4-x, N2S2, N3S, N4, MAG3B, NOTA, NODAGA, SCN-Bz-NOTA-R, NOT-P(NOTMP), NOTAM, p-NCS-NOTA, TACN, TACN-TM, NETA, NETA-monoamine, p-SCN-PhPr-NE3TA, C-NE3TA-NCS, C-NETA-NCS, 3p-C-NETA, NODASA, NOPO, NODA, NO2A, N-Benzyl-NODA, C-NOTA, BCNOT-monoamine, maleimido-mono-amide-NOTA, NO2A-azide , NO2A-butyne, NO2AP, NO3AP, N-NOTA, oxo-DO3A, p-NH2-Bn-NOTA, p-NH2-Bn-oxo-DO3A, p-NO2-Bn-Cyclen, p-SCN-Bn-NOTA, p-SCN-Bn-oxo-DO3A, T RAP, PEPA, BF-PEPA, Pycup, Pycup2A, pycup1A1Bn, pycup2Bn, SarAr-R, Diamsar, AmBaSar-R, siamSar, Sar, Tachpyr, tachpyr-(6-Me), TAM A.TAM B. TAME, TAME-Hex, THP-Ph-NCS, THP-NCS, THP-TATE, NTP, H3THP, THPN, CB-TE2A, PCB-TE1A1P, TETA-NHS, CPTA, CPTA-NHS, CB-TE1K1P, CB-TE2A, TE2A, H2CB-TE2A, TE2P, CB-TE2P, MM-TE2A, DM-TE2A, 2C-TETA, 6C-TETA, BAT, BAT-6, NHS-BAT ester, SSBAT, SCN-CHX-A-DTPA-P, SCN-TETA, TMT-amine, p-BZ-HTCPP.

[0979] HYNIC, DTPA, EDTA, DOTA, TETA, bisaminobisthiol (BAT)-based chelators are disclosed in US 5,720,934; deferoxamine (DFO) is disclosed in (Doulias, et al., Free Radic Biol Med, 2003, 35:719), tetrapyridine and N3S, N2S2 and N4 chelators are disclosed in US 5,367,080 A, US 5,364,613 A, US 5,021,556 A, US 5,075,099 A, US 5,886,142 A, all of which are incorporated herein by reference in their entirety. 6-Amino-6-methylperhydro-1,4-diazepane-N,N′,N″,N″-tetraacetic acid (AAZTA) was disclosed in Pfister et al. (Pfister, et al., EJNMMI Res, 2015, 5:74), deferiprone, i.e., 1,2-dimethyl-3,4-hydroxypyridone, and hexadentate tris(3,4-hydroxypyridone)THP) were disclosed in Cusnir et al. (Cusnir, et al., Int J Mol Sci, 2017, 18), monoamine-monoamidedithiol (MAMA)-based chelators were disclosed in Demoin et al. (Demoin, et al., Nucl Med Biol, 2016, 43:802), MACROPA and its analogs were disclosed in Thiele et al. (Thiele, et al., Angew Chem Int Ed Engl, 2017, 56: 14712), 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N″,N″′,N″″,N″″′-hexaacetic acid (HEHA) and PEPA analogs were disclosed in Price and Orvig (Price, et al., ChemSoc Rev, 2014, 43: 260), Pycup and analogs were disclosed in Boros et al. (Boros, et al., Mol Pharm, 2014, 11: 617), disclosed in N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid (HBED), 1,4,7,10-tetrakis(carbamoylmethyl)-l,4,7,10-tetraazacyclododecane (TCM), 2-[(carboxymethyl)]-[5-(4-nitrophenyl-1-[4,7,10-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]pentan-2-yl)-amino]acetic acid (3p-C-DEPA), CB-TE2A, TE2A, TE1A1P, Diamsar, 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]-eicosane-1,8-diamine (SarAr), NETA, N,N0,N00 tris(2-mercaptoethyl)-1,4,7-triazacyclononane (TACN-TM), {4-[2-(bis-carboxymethyl-amino)-ethyl]-7-carboxymethyl-[1,4,7]triazanonan-1-yl}-acetic acid (NETA), diethylenetriaminepentaacetic acid (DTP), 3-({4,7-bis-[(2-carboxymethyl-ethyl)-hydroxy-phosphorylmethyl]-[1,4,7]triazacyclononane-1-yl}-acetic acid (NETA), Non-1-ylmethyl}-hydroxy-phosphoryl)-propionic acid (TRAP), NOPO, H4octapa, SHBED, BPCA, 3,6,9,15-tetraazabicyclo[9.3.1]-pentadecan-1(15),11,13-triene-3,6,9,-triacetic acid (PCTA) and 1,4,7,10,13-pentaazacyclopentadecan-N,N′,N″,N″′,N″″-pentaacetic acid (PEPA) were prepared in Price and Orvig (Price, et al. et al., Chem Soc Rev, 2014, 43:260), 1-hydroxy-2-pyridone ligand (HOPO) was disclosed in Allott et al. (Allott, et al., Chem Commun (Camb), 2017, 53:8529), [4-carboxymethyl-6-(carboxymethyl-methyl-amino)-6-methyl-[1,4]diazepan-1-yl]-acetic acid (DATA) was disclosed in Tornesello et al. (Tornesello, et al., Molecules, 2017, 22:1282), tetrakis(aminomethyl)methane (TAM) and the like were disclosed in McAuley 1988 (McAuley, et al., Canadian Journal of Chemistry, 1989, 67:1657), hexadentate tris(3,4-hydroxypyridone) (THP) and the like were disclosed in Ma et al. (Ma, et al., Dalton Trans, 2015, 44: 4884).

[0980] The prior art describes some of the diagnostic and / or therapeutic applications of the above-mentioned chelators. For example, 2-hydrazinonicotinamide (HYNIC) has been widely used to incorporate 99m Tc and 186,188 Re (Schwartz, et al., Bioconjug Chem, 1991, 2:333; Babich, et al., J Nucl Med, 1993, 34: 1964; Babich, et al., Nucl Med Biol, 1995, 22: 25); DTPA is used Sino-Israeli complex 111In, and some modifications are described in the literature (Li, et al., Nucl Med Biol, 2001, 28:145; Brechbiel, et al., Bioconjug Chem, 1991, 2:187); the use of DOTA-type chelators in radiotherapy is described by Tweedle et al. (US Pat 4,885,363); other polyaza macrocycles that chelate trivalent isotopes of metals are described by Eisenwiener et al. (Eisenwiener, et al., Bioconjug Chem, 2002, 13:530); N4-chelators such as 99m Tc-N4-chelates have been used for peptide labeling in the case of minigastrin targeting the CCK-2 receptor (Nock, et al., J Nucl Med, 2005, 46: 1727).

[0981] In one embodiment, the metal chelator is selected from but not limited to DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOTP, sarcophagine, FSC, NETA, H4octapa, Pycup, N x S 4-x (N4, N2S2, N3S), Hynic, 99m Tc(CO)3-chelating agents and analogs thereof, wherein:

[0982] DOTA stands for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.

[0983] DOTAGA stands for 1,4,7,10-tetraazacyclododecane, 1-(glutaric acid)-4,7,10-triacetic acid,

[0984] NOTA stands for 1,4,7-triazacyclononane triacetic acid,

[0985] NODAGA stands for 1,4,7-triazacyclononane-N-glutaric acid-N',N"-diacetic acid,

[0986] NODA-MPAA stands for 1,4,7-triazacyclononane-1,4-diacetic acid-methylphenylacetic acid,

[0987] HBED represents bis(2-hydroxybenzyl)ethylenediaminediacetic acid,

[0988] TETA stands for 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid,

[0989] CB-TE2A represents 4,11-bis-(carboxymethylmethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane,

[0990] DTPA stands for diethylenetriaminepentaacetic acid,

[0991] DFO represents the group of chelating agents of the Desferal or Desferrioxamine type, a non-limiting example of which is the chemical name N-[5-({3-[5-(acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-(5-amino-pentyl)-N'-hydroxy-succinamide,

[0992] Macropa stands for N,N'-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown,

[0993] HOPO represents an octadecylhydroxypyridone type chelating agent group, the structure of a non-limiting example is shown below,

[0994] TRAP stands for 3-({4,7-bis-[(2-carboxy-ethyl)-hydroxy-phosphorylmethyl]-[1,4,7]triazanonan-1-ylmethyl}-hydroxy-phosphoryl)-propionic acid,

[0995] THP stands for hexadentate tris(3,4-hydroxypyridone),

[0996] DATA stands for [4-carboxymethyl-6-(carboxymethyl-methyl-amino)-6-methyl-[1,4]diazepan-1-yl]-acetic acid,

[0997] NOTP represents 1,4,7-triazacyclononane-N,N′N″-tri(methylenephosphonic acid),

[0998] Sarcophagine means 3,6,10,13,16,19-hexaazabicyclo[6.6.6]eicosane,

[0999] FSC stands for 3,15,27-triamino-7,19,31-trihydroxy-10,22,34-trimethyl-1,13,25-trioxa-7,19,31-triaza-cyclohexatriacontane-9,21,33-triene-2,8,14,20,26,32-hexaone,

[1000] NETA, {4-[2-(bis-carboxymethyl-amino)-ethyl]-7-carboxymethyl-[1,4,7]triazanonan-1-yl}-acetic acid

[1001] H4octapa, N,N′-(6-carboxy-2-pyridylmethyl)-N,N′-diacetic acid-1,2-ethylenediamine,

[1002] Pycup represents 1,8-(2,6-pyridiniumdimethylidene)-1,4,8,11-tetraazacyclotetradecane,

[1003] N x S 4-x (N4, N2S2, N3S) represents a group of tetradentate chelating agents with N atoms (basic amines or non-basic amides) and thiol as donors, which stabilize Tc-complexes, especially Tc(V)-oxo complexes. The structure of a representative non-limiting example, MAG3, is shown below, and

[1004] MAG3 represents {2-[2-(3-mercapto-propionylamino)-acetylamino]-acetylamino}-acetic acid,

[1005] HYNIC represents 6-hydrazino-nicotinic acid,

[1006] 99m Tc(CO)3-chelating agents are bidentate or tridentate chelating agents which are capable of forming stable complexes with technetium tricarbonyl fragments.

[1007] Its chemical structure is shown below:

[1008]

[1009]

[1010] In a preferred embodiment, the metal chelator is selected from the group consisting of DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, CB-TE2A, DFO, THP, N4 and the like.

[1011] In a more preferred embodiment, the metal chelator is selected from the group consisting of DOTA, DOTAGA, NOTA, N4Ac and NODAGA and analogs thereof.

[1012] Those skilled in the art will appreciate that the chelators may in theory be used regardless of whether the compounds of the invention are used or suitable for use in diagnosis or therapy. This theory is outlined in International Patent Application WO 2009 / 109332 A1.

[1013] Those skilled in the art will further appreciate that, unless otherwise stated, the presence of the chelating agent in the compounds of the invention includes the possibility of the chelating agent being complexed with any metal complex partner (i.e., any metal that could theoretically be complexed by the chelating agent). Specific reference to a chelating agent of the compounds of the invention or the general term chelating agent in relation to the compounds of the invention refers to the uncomplexed chelating agent itself, or to a chelating agent bound to any metal complex partner, wherein the metal complex partner is any radioactive or non-radioactive metal complex partner. Preferably, the chelating agent metal complex, i.e., the chelating agent to which the metal complex partner is bound, is a stable chelating agent metal complex.

[1014] Non-radioactive chelating agent metal complexes have multiple applications, for example, for assessing properties that are difficult to determine, such as stability or activity. One aspect is that cold variants of the radioactive form of the metal complex partner (for example, non-radioactive gallium, lutetium or indium complexes described in the embodiments) can serve as substitutes for radioactive compounds. In addition, they are valuable tools for identifying metabolites and assessing the toxicity properties of the compounds of the invention in vitro or in vivo. In addition, chelating agent metal complexes can be used in conjunction with assays, utilizing some metal complexes (for example, europium salts) with different ligands for fluorescence properties.

[1015] Chelating agents can be synthetic or commercially available, with a variety of (possibly activated) groups conjugated to peptides or amino acids. Direct conjugation of a chelating agent to the amino nitrogen of a corresponding compound of the invention is entirely possible for a chelating agent selected from the group consisting of DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, DATA, sarcophagine, N4, MAG3, and Hynic, preferably DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, CB-TE2A, and N4. Preferred linkages in this regard are amide bonds.

[1016] Those skilled in the art are aware of functional groups on chelating agents that are ideal precursors for direct conjugation of the chelating agent to the amino nitrogen, including but not limited to carboxylic acids, activated carboxylic acids, for example active esters such as NHS-esters, pentafluorophenol-esters, HOBt-esters and HOAt-esters, isothiocyanates.

[1017] Those skilled in the art are aware of functional groups on chelators that are ideal precursors for direct conjugation of chelators to the carboxyl groups of peptides, including but not limited to alkylamino and arylamino nitrogens. Corresponding chelator reagents are for some commercially available chelators, such as DOTA with alkylamino or arylamino nitrogens.

[1018] The person skilled in the art will recognize that the radionuclide to be or to be linked to the compounds of the invention is selected taking into account the disease to be treated and / or the disease to be diagnosed and / or the characteristics of the patient and patient group to be treated and diagnosed, respectively.

[1019] In one embodiment of the present invention, the radioactive nuclide is also referred to as a radionuclide. Radioactive decay is the process by which the nucleus of an unstable atom loses energy by emitting ionizing particles (ionizing radiation). There are different types of radioactive decay. When an atom with one type of nucleus (called the parent radionuclide) transforms into a nucleus with a different state or containing a different number of protons and neutrons, energy decay or loss results. Any of these products is named a daughter nuclide. In some decays, the parent and daughter are different chemical elements, so the decay process results in nuclear transmutation (the production of atoms of new elements). For example, radioactive decay can be alpha decay, beta decay, and gamma decay. Alpha decay occurs when an atomic nucleus ejects an alpha particle (helium nucleus). This is the most common process of emitting nucleons, but in rarer types of decay, the atomic nucleus can eject protons, or specific nucleons of other elements (in this process is called cluster decay). In the process of protons turning into neutrons or vice versa, in the process of the atomic nucleus emitting electrons (beta decay), the nucleus emits electrons (beta decay). - - decay) or positron (β + Beta decay occurs when a nucleus is exposed to a combination of a proton (atom) and a type of neutrino. In contrast, there are radioactive decay processes that do not result in transmutation. The energy of the excited nucleus can be emitted as gamma rays in gamma decay, used to eject an orbiting electron through interaction with the excited nucleus in a process called internal conversion, used to absorb an internal atomic electron from an electron shell, thereby converting a nuclear proton into a neutron, resulting in the emission of an electron neutrino in a process called electron capture (EC), or emitted without changing the number of protons and neutrons in a process called isomeric transition (IT). One form of radioactive decay, spontaneous fission (SF), is found only in very heavy chemical elements and results in the spontaneous disintegration of the nucleus into smaller atomic nuclei and isolated nuclear particles.

[1020] In a preferred embodiment of the present invention, said radionuclides can be used to label the compounds of the present invention.

[1021] In one embodiment of the present invention, the radionuclide is suitable for complexing with a chelating agent to form a radionuclide chelate complex.

[1022] In another embodiment, one or more atoms of the compounds of the invention have an unnatural isotopic composition, preferably these atoms are radionuclides; more preferably radionuclides of carbon, oxygen, nitrogen, sulfur, phosphorus and halogens: these radioactive atoms are typically part of the amino acids (in some cases halogen-containing amino acids) and / or building blocks (in some cases halogenated building blocks) of the compounds of the invention.

[1023] In a preferred embodiment of the present invention, the radionuclide has a half-life that allows diagnostic and / or therapeutic medical use. Specifically, the half-life is from 1 minute to 100 days.

[1024] In preferred embodiments of the present invention, the radionuclide has a decay energy that allows for diagnostic and / or therapeutic medical use. Specifically, for gamma-emitting isotopes, for diagnostic use, the decay energy is 0.004 to 10 MeV, preferably 0.05 to 4 MeV. For positron-emitting isotopes, for diagnostic use, the decay energy is 0.6 to 13.2 MeV, preferably 1 to 6 MeV. For particle-emitting isotopes, for therapeutic use, the decay energy is 0.039 to 10 MeV, preferably 0.4 to 6.5 MeV.

[1025] In a preferred embodiment of the present invention, the radionuclide is industrially produced for medical use. In particular, the radionuclide is of GMP quality.

[1026] In preferred embodiments of the present invention, the daughter nuclides after radioactive decay of the radionuclide are compatible with diagnostic and / or therapeutic medical uses. Furthermore, the daughter nuclides are stable or further decay in a manner that does not interfere with, or even supports, the diagnostic and / or therapeutic medical uses. Representative radionuclides that can be used in conjunction with the present invention are summarized in Table 7.

[1027] Table 7: Key properties of relevant radionuclides – half-life, decay type and decay energy

[1028]

[1029]

[1030]

[1031]

[1032]

[1033]

[1034]

[1035]

[1036]

[1037]

[1038]

[1039]

[1040]

[1041]

[1042]

[1043]

[1044]

[1045]

[1046]

[1047]

[1048]

[1049]

[1050]

[1051]

[1052]

[1053]

[1054]

[1055]

[1056]

[1057]

[1058]

[1059]

[1060]

[1061] In one embodiment of the present invention, the radionuclide is used for diagnosis. Preferably, the radioisotope is selected from but not limited to 43 Sc, 44 Sc, 51 Mn, 52 Mn, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 94m Tc, 99m Tc, 111 In, 152 Tb, 155 Tb, 177 Lu, 201 Tl, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1. More preferably, the radionuclide is selected from 43 Sc, 44 Sc, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 99m Tc, 111 In, 152 Tb, 155 Tb, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 1. Even more preferably, the radionuclide is selected from 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 In, 18 F. 123 I and 124 However, those skilled in the art will also appreciate that the use of said radionuclides is not limited to diagnostic purposes, but includes use in therapy and theranostics when conjugated to the compounds of the invention.

[1062] In one embodiment of the present invention, the radionuclide is used for therapy. Preferably, the radioisotope is selected from 47 Sc,67 Cu, 89 Sr. 90 Y. 111 In, 153 Sm, 149 Tb, 161 Tb, 177 Lu, 186 Re、 188 Re、 212 Pb, 213 Bi, 223 Ra, 225 Ac, 226 Th, 227 Th, 131 I. 211 At. More preferably, the radioisotope is selected from 47 Sc, 67 Cu, 90 Y. 177 Lu, 188 Re、 212 Pb, 213 Bi, 225 Ac, 227 Th, 131 I. 211 Even more preferably, the radionuclide is selected from 90 Y. 177 Lu, 225 Ac, 227 Th, 131 I and 211 However, those skilled in the art will also appreciate that the use of said radionuclides is not limited to therapeutic purposes, but includes use in diagnosis and theranostic use when conjugated to the compounds of the invention.

[1063] In one embodiment, the compounds of the present invention are in the form of pharmaceutically acceptable salts.

[1064] "Pharmaceutically acceptable salts" of the compounds of the present invention are preferably acid or base salts generally recognized in the art as suitable for use in contact with human or animal tissue without undue toxicity or carcinogenicity, and preferably without irritation, allergic reactions, or other problems or complications. Such salts include inorganic and organic acid salts of basic residues such as amines, and alkali metal or organic salts of acidic residues such as carboxylic acids. The compounds of the present invention are capable of forming internal salts, which are also pharmaceutically acceptable salts.

[1065] Suitable pharmaceutically acceptable salts include, but are not limited to, salts of acids such as hydrochloric acid, phosphoric acid, hydrobromic acid, malic acid, glycolic acid, fumaric acid, sulfuric acid, sulfamic acid, sulfanilic acid, formic acid, toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid, ethanedisulfonic acid, 2-hydroxyethylsulfonic acid, nitric acid, benzoic acid, 2-acetoxybenzoic acid, citric acid, tartaric acid, lactic acid, stearic acid, salicylic acid, glutaric acid, ascorbic acid, pamoic acid, succinic acid, fumaric acid, maleic acid, propionic acid, hydroxymaleic acid, hydroiodic acid, phenylacetic acid, alkanoic acids such as acetic acid, HOOC-(CH2) n -COOH, wherein n is any integer from 0 to 4, i.e., 0, 1, 2, 3, or 4, etc. Similarly, pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium. One of ordinary skill in the art will recognize other pharmaceutically acceptable salts of the compounds provided herein. In general, pharmaceutically acceptable acid or base salts can be synthesized from parent compounds containing a basic or acidic moiety by any conventional chemical method. In short, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of a suitable base or acid in water, in an organic solvent, or in a mixture of the two. In general, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferably used.

[1066] A "pharmaceutically acceptable solvate" of a compound of the invention is preferably a solvate of a compound of the invention formed by the association of one or more solvent molecules with one or more molecules of the compound of the invention. Preferably, the solvent is one generally recognized in the art as suitable for use in contact with human or animal tissues without undue toxicity or carcinogenicity, and preferably without irritation, allergic reactions, or other problems or complications. Such solvents include organic solvents such as alcohols, ethers, esters, and amines.

[1067] A "hydrate" of a compound of the invention is formed by the association of one or more water molecules with one or more molecules of the compound of the invention. Such hydrates include, but are not limited to, hemihydrates, monohydrates, dihydrates, trihydrates, and tetrahydrates. Regardless of the hydrate composition, all hydrates are generally considered pharmaceutically acceptable.

[1068] The compounds of the present invention have high binding affinity for FAP and high inhibitory activity against FAP. Due to this high binding affinity, the compounds of the present invention are effective, useful, and / or suitable as targeting agents and, when conjugated to another moiety, as targeting moieties. As preferably used herein, a targeting agent is an agent that interacts with a target molecule, in this case, the FAP. With respect to cells and tissues to which the compounds of the present invention are targeted, any cell or tissue expressing the FAP is or can be targeted, respectively.

[1069] In one embodiment, the compound interacts with fibroblast activation protein (FAP), preferably human FAP having the amino acid sequence of SEQ ID NO: 1 or a homolog thereof, wherein the amino acid sequence of the homolog has an identity with FAP of at least 85% to the amino acid sequence of SEQ ID NO: 1. In a preferred embodiment, the identity is 90%, preferably 95%, 96%, 97%, 98% or 99%.

[1070] The identity between two nucleic acid molecules can be determined as known to those skilled in the art. More specifically, a sequence comparison algorithm can be used to calculate the percent sequence homology of a test sequence relative to a reference sequence, based on specified program parameters. The test sequence is preferably a sequence or protein or polypeptide that is said to be identical, or is tested for identity and, if so, to what extent, relative to a different protein or polypeptide, which is also referred to as a reference sequence and is preferably a wild-type protein or polypeptide, more preferably human FAP of SEQ ID NO: 1.

[1071] Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith & Waterman (Smith, et al., Advances in Applied Mathematics, 1981, 2:482), by the homology alignment algorithm of Needleman & Wunsch (Needleman, et al., J Mol Biol, 1970, 48:443), by the search for similarity method of Pearson & Lipman (Pearson, et al., Proc Natl Acad Sci USA, 1988, 85:2444), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection.

[1072] An example of an algorithm suitable for determining percent sequence identity is the algorithm used in the Local Alignment Search Basic Tool (hereinafter referred to as "BLAST"), see, for example, Altschul et al., 1990 (Altschul, et al., J Mol Biol, 1990, 215:403) and Altschul et al., 1997 (Altschul, et al., Nucleic Acids Res, 1997, 25:3389). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (hereinafter referred to as NCBI). McGinnis et al. (McGinnis, et al., Nucleic Acids Res, 2004, 32:W20) describe the default parameters for determining sequence identity using software from NCBI, such as BLASTN (for nucleotide sequences) and BLASTP (for amino acid sequences).

[1073] Within the scope of the present invention, the compounds of the present invention are used or intended for use in a method of treating a disease as disclosed herein. Such a method preferably comprises the step of administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention. Such a method includes, but is not limited to, curative or adjuvant cancer treatment. It is used as a palliative treatment in cases where a cure is not possible and the goal is local disease control or symptom relief, or as a therapeutic treatment in cases where the treatment has a survival benefit and can be curative.

[1074] The methods of treating the diseases disclosed herein include treating the diseases disclosed herein, including tumors and cancers, and can be used as primary therapy or as second-line, third-line, fourth-line or final therapy. It is also within the scope of the present invention to use the compounds of the present invention in combination with other therapeutic methods. It is well known to those skilled in the art that the precise treatment intent, including curative, adjuvant, neoadjuvant, therapeutic or palliative treatment, will depend on the tumor type, location and stage, as well as the patient's overall health status.

[1075] In one embodiment of the present invention, the disease is selected from the group consisting of: tumor nos, benign tumor, tumor of uncertain benign or malignant nature, malignant tumor, metastatic tumor, malignant tumor of uncertain primary or metastatic nature, benign tumor cells, tumor cells of uncertain benign or malignant nature, malignant tumor cells, small cell malignant tumor, giant cell malignant tumor, spindle cell malignant tumor, epithelial tumor nos, benign epithelial tumor, carcinoma in situ nos, carcinoma nos, carcinoma metastasis nos, carcinoma spread, benign epithelial tumor, malignant epithelial tumor, large cell carcinoma nos, undifferentiated carcinoma nos, anaplastic carcinoma nos, pleomorphic carcinoma, Giant cell and spindle cell carcinoma, giant cell carcinoma, spindle cell carcinoma, pseudosarcoma, polygonal cell carcinoma, spheroid cell carcinoma, microtumor, small cell carcinoma nos, oat cell carcinoma, small cell carcinoma, spindle cell type, papillary and squamous cell tumors, papilloma nos, papillary carcinoma in situ, papillary carcinoma nos, verrucous papilloma, verrucous carcinoma nos, squamous cell papilloma, papillary squamous cell carcinoma, inverted papilloma, papillomatosis nos, squamous cell carcinoma in situ nos, squamous cell carcinoma nos, squamous cell carcinoma metastasis nos, keratinizing type squamous cell carcinoma nos nos,), large cell nonkeratinizing squamous cell carcinoma, small cell nonkeratinizing squamous cell carcinoma, spindle cell squamous cell carcinoma, adenoid squamous cell carcinoma, squamous cell carcinoma in situ with indeterminate stromal invasion, minimally invasive squamous cell carcinoma, erythema of Queyrat, Bowen's disease, lymphoepithelial carcinoma, basal cell tumor, basal cell neoplasm, basal cell carcinoma nos, multicentric basal cell carcinoma, morphea-type basal cell carcinoma, fibroepithelial basal cell carcinoma, basosquamous carcinoma, carcinoma atypia, Jadassohn intraepidermal epithelioma, trichoepithelioma, folliculoma, pilomatricoma, transitional cell papilloma and carcinoma, transitional cell papilloma nos, urothelial papilloma, transitional cell carcinoma in situ, transitional cell carcinoma nos, Schneider papilloma, inverted transitional cell papilloma, Schneider carcinoma, spindle cell transitional cell carcinoma , basaloid carcinoma, cloacal carcinoma, papillary transitional cell carcinoma, adenoma and adenocarcinoma, adenoma nos, bronchial adenoma nos, adenocarcinoma in situ, adenocarcinoma nos, metastatic adenocarcinoma nos, scleral adenocarcinoma, leathery cystic stomach, superficial spreading adenocarcinoma, intestinal type adenocarcinoma, spreading type carcinoma, monomorphic adenoma, basal cell adenoma, islet cell adenoma, islet cell carcinoma, insulinoma nos, malignant insulinoma, glucagonoma, malignant pancreatic hyperglycemia Glucocortinoma nos, Gastrinoma nos, Malignant gastrinoma, Mixed pancreatic islet cell and exocrine gland carcinoma, Biliary adenoma, Biliary duct carcinoma, Biliary cystadenoma, Biliary duct cystadenocarcinoma, Hepatocellular adenoma, Hepatocellular carcinoma nos, Benign hepatobiliary cholangiocarcinoma, Hepatocellular carcinoma combined with bile duct carcinoma, Trabecular adenoma, Trabecular adenoma, Embryonic adenoma, Exocrine gland dermal cylindroma, Adenoid cystic carcinoma, Cribriform carcinoma, Adenomatous polyp nos, Adenocarcinoma in adenomatous polyp,tubular adenoma nos, tubular adenocarcinoma, adenomatous polyposis coli, adenocarcinoma in adenomatous polyposis coli, multiple adenomatous polyps, solid carcinoma nos, simple carcinoma, carcinoid tumor nos, malignant carcinoid tumor, carcinoid tumor silver nos, malignant carcinoid tumor silver, carcinoid tumor non-silver nos, malignant carcinoid tumor non-silver, malignant mucinous carcinoid, combined carcinoid, adenomatosis of the lung, bronchioalveolar adenocarcinoma, alveolar adenoma, alveolar adenocarcinoma, papillary adenoma nos, papillary adenocarcinoma nos, villous adenoma nos, adenocarcinoma in villous adenoma, villous adenocarcinoma, tubulovillous adenoma, chromophobe adenoma, chromophobe carcinoma, oncocytic adenoma, oncocytic carcinoma, mixed oncocytic-basophilic adenoma, mixed oncocytic-basophilic carcinoma , aerobic adenoma, aerobic adenocarcinoma, basophilic adenoma, basophilic carcinoma, clear cell adenoma, clear cell adenocarcinoma nos, renal tumor, renal cell carcinoma, clear cell adenofibroma, granular cell carcinoma, chief cell adenoma, water clear cell adenoma, water clear cell adenocarcinoma, mixed cell adenoma, mixed cell adenoma, lipoadenoma, follicular adenoma, follicular adenocarcinoma nos, well-differentiated follicular adenocarcinoma, trabecular follicular adenocarcinoma, microfollicular adenoma, macrofollicular adenoma, papillary and follicular adenocarcinoma, non-encapsulated sclerosing carcinoma, multiple endocrine neoplasia, juxtaglomerular tumor, adrenocortical adenoma nos, adrenocortical carcinoma, compact cell adrenocortical adenoma, heavily pigmented variant adrenocortical adenoma, clear cell adrenocortical adenoma, small kidney Globular cell adrenocortical adenoma, mixed cell adrenocortical adenoma, endometrioid adenoma nos, endometrioid adenoma, borderline malignant tumor, endometrioid carcinoma, endometrioid adenofibroma nos, endometrioid adenofibroma borderline malignant tumor, malignant endometrioid adenofibroma, adnexal and skin appendage tumors, skin appendage adenoma, skin appendage carcinoma, sweat gland adenoma, sweat gland tumor nos, sweat gland adenoma carcinoma, apocrine adenoma, apocrine carcinoma, eccrine apocrine spiradenoma, eccrine spiradenoma, sweat gland cystoma, papillary sweat gland cystoma, papillary sweat gland adenoma, syringoma nos, sebaceous adenoma, sebaceous gland carcinoma, wax adenoma, waxy adenocarcinoma, mucoepidermoid neoplasm, mucoepidermoid tumor, mucoepidermoid cystic carcinoma, mucus and serous tumors, cystadenoma nos, cystadenocarcinoma nos, serous cystadenoma nos, serous cystadenoma borderline malignant tumor, serous cystadenocarcinoma nos, papillary cystadenoma nos, papillary cystadenoma borderline malignant tumor, papillary cystadenocarcinoma nos, papillary serous cystadenoma nos, papillary serous cystadenoma borderline malignant tumor, papillary serous cystadenocarcinoma, serous surface papilloma nos, serous surface papilloma borderline malignant tumor, serous surface papillary carcinoma, mucinous cystadenoma nos, mucinous cystadenoma borderline malignant tumor, mucinous cystadenocarcinoma nos, papillary mucinous cystadenoma nos, papillary mucinous cystadenoma borderline malignant tumor, papillary mucinous cystadenocarcinoma, mucinous adenoma,Mucinous adenocarcinoma, pseudomyxoma peritonei, mucin-producing adenocarcinoma, signet ring cell carcinoma, metastatic signet ring cell carcinoma, ductal, lobular, and medullary tumors, noninvasive intraductal carcinoma nos, invasive ductal carcinoma, comedo carcinoma, noninvasive comedo carcinoma nos, juvenile breast cancer, intraductal papilloma, noninvasive intraductal papillary adenocarcinoma, intracystic papillary adenoma, noninvasive intracystic carcinoma, intraductal papillomatosis nos, subareolar ductal papillomatosis, medullary carcinoma nos, medullary carcinoma with amyloid stroma, medullary carcinoma with lymphoid stroma, lobular carcinoma in situ, lobular carcinoma nos, invasive ductal carcinoma, inflammatory carcinoma, Paget's disease of the breast, Paget's disease and invasive ductal carcinoma of the breast, extramammary Paget's disease, acinar cell neoplasms, acinar cell adenoma, acinar cell tumor, acinar cell carcinoma, complex epithelial tumor, adenosquamous carcinoma, adenolymphoma, adenocarcinoma with squamous metaplasia, adenocarcinoma with cartilaginous and bony metaplasia, adenocarcinoma with spindle cell metaplasia, adenocarcinoma with apocrine metaplasia, benign thymoma, malignant thymoma, specialized adenoma, sex cord-stromal tumor, theca cell tumor nos, theca cell carcinoma, luteoma nos, granular cell tumor nos, malignant granular cell tumor, granulosa cell theca cell tumor, benign androcyte tumor, androcyte tumor nos, malignant androcyte tumor, Leydig cell tumor, androcyte tumor, tubular androcyte tumor nos, Sertoli cell carcinoma, tubular androcyte tumor with lipid storage, benign Sertoli cell tumor, Sertoli cell tumor nos, malignant Sertoli cell tumor, hilum cell tumor, ovarian lipid cell tumor, renal adrenal rest tumors, paraganglioma and glomus tumor, paraganglioma nos, malignant paraganglioma, sympathetic paraganglioma, parasympathetic ganglioma, glomus jugulare tumor, aortic body tumor, carotid body tumor, extraadrenal paraganglioma nos, malignant extraadrenal paraganglioma, pheochromocytoma nos, malignant pheochromocytoma, glomus sarcoma, glomus tumor, glomus tumor, nevus and melanoma, pigmented nevus nos, malignant melanoma nos, nodular melanoma, balloon cell nevus, balloon cell melanoma, halo nevus, nasal fibrous papule, intradermal nevus, giant cell nevus, amelanotic nevus, amelanotic melanoma, junctional nevus, junctional nevus malignant melanoma, premalignant melanosis nos, malignant premalignant melanosis, Hutchinson melanotic freckle, malignant melanoma in Hutchinson melanotic freckle, superficial spreading melanoma, intradermal nevus, compound nevus, giant pigmented nevus, malignant melanoma in giant pigmented nevus, epithelioid and spindle cell nevus, epithelioid cell melanoma, spindle cell melanoma nos, spindle cell melanoma type a, spindle cell melanoma type b, mixed epithelioid and spindle cell melanoma, blue nevus nos, malignant blue nevus, cellular blue nevus, soft tissue tumors and sarcomas nos, soft tissue tumors, benign sarcoma nos, sarcoidosis nos, spindle cell sarcoma, giant cell sarcoma, small cell sarcoma, epithelioid cell sarcoma, fibromatous tumor, fibroma nos, fibrosarcoma nos, fibromyxoma, fibromyxosarcoma, periosteal fibroma,periosteal fibrosarcoma, fascial fibroma, fascial fibrosarcoma, infantile fibrosarcoma, fibroelastoma, aggressive fibromatosis, abdominal fibromatosis, fibroblastic fibroma, fibrous histiocytoma nos, atypical fibrous histiocytoma, malignant fibrous histiocytoma, fibroxanthoma nos, atypical fibroxanthoma, malignant fibroxanthoma, cutaneous fibroma nos, cutaneous fibroma protuberans, cutaneous fibrosarcoma nos, myxoma, myxoma nos, myxosarcoma, lipoma, lipoma nos, liposarcoma nos, fibrolipoma, well-differentiated liposarcoma, fibromyxolipomas, myxoid liposarcoma, round cell liposarcoma, pleomorphic liposarcoma, mixed liposarcoma, intramuscular lipoma, spindle cell lipoma, angioflat myolipomas, angiomyoliposarcomas, angiolipoma nos, infiltrating angiolipomas, myelolipomas, dormant lipomas, lipoblastomatosis, myomatic tumors, leiomyoma nos, intravascular leiomyoma, leiomyosarcoma nos, epithelioid leiomyomas, epithelioid leiomyosarcomas, cellular leiomyomas, bizarre leiomyomas, angiomyomas, angiosarcomas, myomas, sarcomas, rhabdomyomas nos, rhabdomyosarcoma nos, pleomorphic rhabdomyosarcoma, mixed rhabdomyosarcoma, fetal rhabdomyomas, adult rhabdomyomas, embryonal rhabdomyosarcomas, alveolar rhabdomyosarcoma, complex mixed and stromal tumors, endometrial stromal sarcoma, intralymphatic stromal myopathy, adenomyomas, pleomorphic adenomas, mixed tumors, malignant Mullerian Rian mixed tumor nos, mesodermal mixed tumor, mesoblastic nephroblastoma, Wilms tumor nos, epithelial Wilms tumor, mesenchymal Wilms tumor, hepatoblastoma, carcinosarcoma nos, embryonal carcinosarcoma, myoepithelioma, benign stromal tumor, stromal tumor nos, malignant mesenchymal tumor, embryonal sarcoma, fibroepithelial tumor, Brenner tumor nos, Brenner tumor, borderline malignant tumor, malignant Brenner tumor, fibroadenoma nos, intratubular fibroadenoma nos, peritubular fibroadenoma, adenofibroma nos, serous adenofibroma, myxoid adenofibroma, intratubular fibroadenoma, cystosarcoma phyllodes nos, malignant cystosarcoma phyllodes, juvenile fibroadenoma, synovial tumor, benign synovial tumor, synovial sarcoma nos, spindle cell synovial sarcoma , epithelial cell type synovial sarcoma, biphasic synovial sarcoma, clear cell tendon and aponeurosis sarcoma, mesothelioma, benign mesothelioma, malignant mesothelioma, benign fibrous mesothelioma, malignant fibrous mesothelioma, benign epithelioid mesothelioma, malignant epithelioid mesothelioma, biphasic benign mesothelioma, biphasic malignant mesothelioma, adenomatous tumor nos, germ cell tumor, dysgerminoma, seminoma nos, undifferentiated seminoma, spermatocytic seminoma, germ cell tumor, embryonal carcinoma nos, endodermal sinus tumor, polyembryonic tumor, gonadoblastoma, benign teratoma, teratoma nos, malignant teratoma nos, teratocarcinoma, undifferentiated malignant teratoma, intermediate malignant teratoma, dermoid cyst, malignantly transformed dermoid cyst, goiter-like ovarian tumor,Malignant goiter-like ovarian tumor, stromal carcinoid, trophoblastic tumor, hydatidiform mole nos, invasive hydatidiform mole, choriocarcinoma, choriocarcinoma with teratoma, malignant trophoblastic teratoma, mesonephroma, benign mesonephroma, mesonephroma tumor, malignant mesonephroma, fallopian tube endometrioma, vascular tumor, hemangioma nos, angiosarcoma, cavernous hemangioma, venous hemangioma, racemose hemangioma, Kupffer cell sarcoma, benign hemangioendothelioma, hemangioendothelioma nos, malignant hemangioendothelioma, capillary hemangioma, intramuscular hemangioma, Kaposi sarcoma, angiokeratoma, verrucous keratinizing hemangioma, benign hemangiopericytoma, hemangiopericytoma nos, malignant hemangiopericytoma, angiofibroma nos, hemangioblastoma, lymphangiogenic tumor, lymphangioma nos, lymphangiosarcoma, capillary lymphangioma, cavernous lymphangioma, cystic lymphangioma, lymphangioleiomyomatosis, lymphangioleiomyomatosis, lymphangioleiomyomatosis, angiolymphangioma, bone tumors and osteosarcomas, osteoma nos, osteosarcoma nos, chondroblastic osteosarcoma, fibroblastic osteosarcoma, telangiectatic osteosarcoma, osteosarcoma in Paget's disease of bone, juxtacortical osteosarcoma, osteoid osteoma nos, osteoblastoma, cartilage tumor, osteochondroma, osteochondromatosis nos, chondroma nos, chondromatosis nos, chondrosarcoma nos, juxtacortical chondroma, juxtacortical chondrosarcoma, chondroblastoma nos, malignant chondroblastoma, mesenchymal chondrosarcoma, chondromyxoid fibroma, giant cell tumor, giant cell tumor of bone nos, malignant giant cell tumor of bone giant cell tumor of soft tissue nos, malignant giant cell tumor of soft tissue, various bone tumors, Ewing's sarcoma, long bone amelinoma, ossifying fibroma, odontogenic tumor, benign odontogenic tumor, odontogenic tumor nos, malignant odontogenic tumor, odontoma, cementoblastoma nos, benign cementoblastoma, cementinizing fibroma, giant cementoblastoma, odontoma nos, combined odontoma, mixed odontoma, ameloblastic fibrous odontoma, ameloblastic odontosarcoma, adenomatous odontogenic tumor, calcifying odontogenic cyst, ameloblastoma nos, malignant ameloblastoma, odontogenic squamous cell tumor, odontogenic myxoma, odontogenic fibroma nos, ameloblastic fibroma, ameloblastic fibrosarcoma, calcifying epithelial odontogenic tumor Tumor, other tumors, craniopharyngioma, pinealoma, pineocytoma, pineoblastoma, melanin neuroectodermal tumor, chordoma, glioma, malignant glioma, glioma cerebri, mixed glioma, subependymal angioendomyoma, subependymal giant cell astrocytoma, choroid plexus papilloma nos, malignant choroid plexus papilloma, ependymoma nos, anaplastic ependymoma inter, papillary ependymoma, myxopapillary ependymoma, astrocytoma nos, anaplastic astrocytoma, protoplasmic astrocytoma, obese astrocytoma, fibrillary astrocytoma, pilocytic astrocytoma, glioblastoma nos, polar cavernosoma, astroblastoma, glioblastoma nos,giant cell glioblastoma, glioblastoma with sarcomatous component, primitive polarity glioblastoma, oligodendroglioma nos, anaplastic oligodendroglioma, oligodendroglioma, medulloblastoma nos, desmoplastic medulloblastoma, myeloblastoma, cerebellar sarcoma nos, weird cell sarcoma, neuroepithelioma-like tumor, ganglioneuroma, ganglioblastoma, gangliomatosis, neuroblastoma nos, medullary epithelioma nos, teratoid medulloepithelioma, neuroepithelioma nos, cavernous neuroblastoma, ganglioglioma, ganglioglioma, pacinian tumor, retinoblastoma nos, differentiated retinoblastoma, undifferentiated retinoblastoma, olfactory neurogenic tumor, sensory neurocytoma, olfactory neuroblastoma, sensory neuroepithelioma, meningioma, meningioma nos, meningiomatosis nos, malignant meningioma, meningiomatous meningioma, fibrous meningioma, psammomatous meningioma, angiomatous meningioma, hemangioblastic meningioma, hemangiopericytic meningioma, transitional meningioma, papillary meningioma, meningeal sarcoidosis, nerve sheath tumor, neurofibroma nos, neurofibromatosis nos, neurofibrosarcoma, melanotic neurofibroma, plexiform neurofibroma, neurothelia nos, neurothelia nos, malignant nerve sheath tumor, neuroma nos, granular cell tumor and alveolar soft tissue sarcoma, granular cell tumor nos , malignant granular cell tumor, alveolar soft tissue sarcoma, lymphoma nos or diffuse type, benign lymphoma tumor, malignant lymphoma nos, non-Hodgkin's malignant lymphoma, undifferentiated cell type malignant lymphoma nos, stem cell type malignant lymphoma, convoluted cell type malignant lymphoma nos, lymphosarcoma nos, lymphoplasmacytic type malignant lymphoma, immunoblastic type malignant lymphoma, mixed lymphocyte-histiocytic type malignant lymphoma nos, centroblast-centrocytic diffuse type malignant lymphoma, malignant lymphoma follicle center cell nos, lymphocyte well differentiated type malignant lymphoma nos, lymphocyte moderately differentiated type malignant lymphoma nos, centrocytic type malignant lymphoma, follicle center cell mitotic type malignant lymphoma nos s, lymphocytic poorly differentiated malignant lymphoma nos, prolymphocytic lymphosarcoma, malignant lymphoma centroblastic type nos, follicular center cell non-cleaved malignant lymphoma, reticulum cell sarcoma, reticulum cell sarcoma nos, pleomorphic cell type reticulum sarcoma, nodular reticulum sarcoma, Hodgkin's disease, Hodgkin's disease nos, lymphocyte-predominant Hodgkin's disease, mixed cellularity Hodgkin's disease, lymphocyte-depleted Hodgkin's disease nos, lymphocyte-depleted diffuse fibrosing Hodgkin's disease, lymphocyte-depleted reticular Hodgkin's disease, tuberous sclerosis Hodgkin's disease, tuberous sclerosis Hodgkin's disease cell stage, paragranuloma of Hodgkin's disease, granuloma of Hodgkin's disease, Hodgkin's sarcoma, nodular or follicular lymphoma, nodular malignant lymphoma nos,Mixed lymphocyte-histiocytic nodular malignant lymphoma, centroblast-centrocytic follicular malignant lymphoma, lymphocyte-well differentiated nodular malignant lymphoma, lymphocyte-moderately differentiated nodular malignant lymphoma, follicular malignant lymphoma with mitotic follicular cells, lymphocyte-poorly differentiated nodular malignant lymphoma, centroblastic follicular malignant lymphoma, follicular malignant lymphoma with non-mitotic follicular cells, mycosis fungoides, mycosis fungoides, Sezary disease, various reticuloendothelioma tumors, microglioma, malignant histiocytosis, histiocytic myeloid reticular cell plasma cell hyperplasia, Letterer-Siwe disease, plasma cell neoplasm, plasma cell myeloma, benign plasmacytoma, plasmacytoma nos, malignant plasmacytoma, mast cell neoplasm, mast cell tumor nos, mast cell sarcoma, malignant mastocytosis, burkitt tumor, burkitt tumor, leukemia, leukemia nos, acute leukemia nos, subacute leukemia nos, chronic leukemia nos, nonleukemic leukemia nos, combined leukemia, combined leukemia, lymphoid leukemia nos, acute lymphoid leukemia, sub Acute lymphocytic leukemia, chronic lymphocytic leukemia, nonleukemic lymphocytic leukemia, prolymphocytic leukemia, plasma cell leukemia, plasma cell leukemia, erythroleukemia, erythroleukemia, acute polycythemia, chronic polycythemia, lymphosarcoma cell leukemia, lymphosarcoma cell leukemia, myeloid leukemia, myeloid leukemia nos, acute myeloid leukemia, subacute myeloid leukemia, chronic myeloid leukemia, nonleukemic myeloid leukemia, neutrophilic leukemia, acute promyelocytic leukemia, basophilic leukemia, basophilic leukemia, eosinophilic Myeloproliferative and lymphoproliferative diseases, myelomonocytic leukemia ...

[1076] In one embodiment of the present invention, the disease is selected from the group consisting of pancreatic tumors, pancreatic adenocarcinoma, pancreatic head tumors, pancreatic body tumors, pancreatic tail tumors, pancreatic duct tumors, pancreatic islet tumors, pancreatic neck tumors, prostate tumors, prostate adenocarcinoma, prostate glands, neuroendocrine tumors, breast cancer, central breast tumors, upper inner quadrant of the breast, lower inner quadrant of the breast, upper outer quadrant of the breast, lower outer quadrant of the breast, axillary tail of the breast, overlapping lesions of the breast, adolescent breast cancer, parathyroid tumors, myeloma, lung cancer, small cell lung cancer, non-small cell lung cancer, main bronchial tumors, upper lobe lung tumors, middle lobe lung tumors, lower lobe lung tumors, colorectal cancer, ascending colon tumors, hepatic flexure colon tumors, transverse colon tumors, Intestinal tumors, splenic flexure tumors of the colon, descending colon tumors, sigmoid colon tumors, overlapping lesions of the colon, small bowel tumors, liver tumors, hepatocellular adenoma, hepatocellular carcinoma, hepatobiliary duct tumors, combined hepatocellular carcinoma and bile duct cancer, hepatoblastoma, ovarian cancer, sarcoma, osteosarcoma, fibrosarcoma, gastrointestinal stromal tumors, gastrointestinal tract, gastric cancer, thyroid cancer, medullary thyroid carcinoma, thyroid, renal cell carcinoma, renal pelvis tumors, bladder tumors, bladder cancer, tumors of the trigone, bladder dome tumors, bladder lateral wall tumors, posterior bladder wall tumors, ureteral orifice tumors, urachal tumors, overlapping lesions of the bladder, basal cell carcinoma, basal cell neoplasms, basal cell tumors, basal cell carcinoma , multicentric basal cell carcinoma, basaloid carcinoma, basal cell adenoma, squamous cell carcinoma, oral squamous cell carcinoma, laryngeal squamous cell carcinoma, cervical cancer, ectocervical tumor, overlapping lesions of the cervix, cervical tumor treatment, uterine isthmus tumor, uterine tumor, ovarian tumor, esophageal tumor, thoracic esophageal tumor, abdominal esophageal tumor, upper third esophageal tumor, middle third esophageal tumor, lower third esophageal tumor, overlapping lesions of the esophagus, endometrial cancer, head and neck cancer, lymphoma, malignant mesothelioma, mesothelioma, mesothelioma, fibromesothelioma, fibromesothelioma, epithelioid mesothelioma, epithelioid mesothelioma, duodenal cancer, neuroendocrine tumor, pulmonary neuroendocrine tumor Endocrine tumors, pancreatic neuroendocrine tumors, foregut neuroendocrine tumors, midgut neuroendocrine tumors, hindgut neuroendocrine tumors, gastroenteropancreatic neuroendocrine tumors, neuroendocrine carcinomas, breast neuroendocrine tumors, ovarian neuroendocrine tumors, testicular cancer, thymic cancer, gastric tumors, gastric fundus tumors, gastric body tumors, gastric antrum tumors, pyloric tumors, lesser curvature of the stomach tumors, greater curvature of the stomach tumors, gastric overlapping lesions, paraganglioma, ganglioma, melanoma, malignant melanoma, nodular melanoma, amelanotic melanoma, superficial spreading melanoma, epithelioid cell melanoma, spindle cell melanoma, mixed epithelioid and spindle cell melanoma.

[1077] In yet another embodiment, the aforementioned indications may occur in an organ or tissue selected from the group consisting of: outer upper lip, outer lower lip, outer lip nos, upper lip mucosa, lower lip mucosa, lip mucosa nos, lip commissure, lip overlap lesions, tongue base nos, dorsal side of tongue nos, tongue margin, ventral side of tongue nos, anterior 2 / 3 of tongue nos, lingual tonsils, tongue overlap lesions, tongue nos, upper gum, lower gum, gum nos, anterior floor of mouth, lateral floor of mouth, floor of mouth overlap lesions, floor of mouth nos, hard palate, soft palate nos, uvula, palatal overlap lesions, palatine nos, buccal mucosa, oral vestibule, retromolar area, overlap lesions in other and non-specific parts of the mouth, oral nos, parotid gland, submandibular gland, sublingual gland, major salivary gland overlap lesions, major salivary gland nos, tonsillar fossa, Tonsillar pillars, tonsillar overlapping lesions, tonsillar nos, epiglottic valley, anterior epiglottis, lateral oropharynx, posterior oropharynx, branchial clefts, overlapping lesions of the oropharynx, oropharynx nos, superior nasopharyngeal wall, posterior nasopharyngeal wall, lateral nasopharyngeal wall, anterior nasopharyngeal wall, overlapping lesions of the nasopharynx, nasopharyngeal nos, piriform recess, posterior region of the cricoid cartilage, aryepiglottic folds, laryngopharyngeal surface, posterior laryngopharyngeal wall, overlapping lesions of the laryngopharynx, laryngopharyngeal nos, pharyngeal nos, pharyngeal, pharyngeal lymphatic rings, overlapping lesions of the labial oral cavity and pharynx, cervical esophagus, thoracic esophagus, abdominal esophagus, upper third of the esophagus, middle third of the esophagus, lower third of the esophagus, overlapping lesions of the esophagus, esophageal nos, cardia, gastric fundus, gastric body, gastric antrum, pylorus, lesser curvature of stomach nos, greater curvature of stomach nos, overlapping lesions of the stomach, gastric nos, Duodenum, jejunum, ileum, Meckel's diverticulum, overlapping lesions of the small intestine, small intestine nos, cecum, appendix, ascending colon, hepatic flexure of the colon, transverse colon, splenic flexure of the colon, descending colon, sigmoid colon, overlapping lesions of the colon, colon nos, rectosigmoid junction, rectal nos, anal nos, anal canal, cloacal origin area, overlapping lesions of the rectum, anus and anal canal, liver, intrahepatic bile duct, gallbladder, extrahepatic bile duct, ampulla of the hepatopancreatic duct, overlapping lesions of the bile duct, bile duct nos, pancreatic head, pancreatic body, pancreatic tail, pancreatic duct, pancreatic islets, pancreatic neck, overlapping lesions of the pancreas, pancreatic nos, intestinal nos, overlapping lesions of the digestive system, gastrointestinal tract nos, nasal cavity, middle ear, maxillary sinus, ethmoid sinus, frontal sinus, sphenoid sinus, overlapping lesions of the paranasal sinuses, paranasal sinus nos, phonation Door, supraglottis, subglottis, laryngeal cartilage, overlapping lesions of the larynx, laryngeal nos, trachea, main bronchi, upper lobe of the lung, middle lobe of the lung, lower lobe of the lung, overlapping lesions of the lung, lung nos, thymus, heart, anterior mediastinum, posterior mediastinum, mediastinum nos, pleural nos, overlapping lesions of the heart, mediastinum and pleura, upper respiratory tract nos, overlapping lesions of the respiratory system and intrathoracic organs, respiratory tract nos, long bone joints of the upper limbs, short bone joints of the upper limbs, long bone joints of the lower limbs, short bone joints of the lower limbs, overlapping lesions of the limb bones and articular cartilage, limb bones nos, craniofacial bones, mandible, spine, ribs, sternum, clavicle, pelvis, overlapping lesions of the bone joints and articular cartilage, bone nos, blood, bone marrow, spleen, reticuloendothelial system nos, hematopoietic system, lip skin nos,Eyelid nos, external ear, facial skin, scalp and neck skin, trunk skin, upper limb skin, lower limb skin, peripheral nerves of the head and neck, peripheral nerves of the shoulder and arm, peripheral nerves of the leg, peripheral nerves of the chest, peripheral nerves of the abdomen, peripheral nerves of the pelvis, peripheral nerve trunks, overlapping lesions of the peripheral nerves and autonomic nervous system, autonomic nervous system nos, retroperitoneum, peritoneum, peritoneum nos, overlapping lesions of the retroperitoneum and peritoneum, connective tissue of the head, connective tissue of the arms, connective tissue of the legs, connective tissue of the chest, connective tissue of the abdomen, connective tissue of the pelvis, connective tissue of the trunk nos, overlapping lesions of the subcutaneous connective tissue and other soft tissues, connective tissue nos, nipple, central part of the breast, endometrium Upper quadrant, inner and lower breast quadrant, outer upper and lower breast quadrant, axillary tail of breast, overlapping lesions of breast, breast nos, labia majora, labia minora, clitoris, overlapping lesions of vulva, vulvar nos, vaginal nos, endocervix, exocervix, overlapping lesions of cervix, cervix, isthmus of uterus, endometrium, myometrium, fundus of uterus, overlapping lesions of uterine body, uterine body, uterine nos, ovary, fallopian tube, broad ligament, round ligament, parametrial tissue, uterine appendages, Wolffian body, overlapping lesions of female reproductive organs, female reproductive tract nos, foreskin, penis, corpus of penis, overlapping lesions of penis, penile nos, prostate, cryptorchidism, descended testis, testicular nos s, epididymis, spermatic cord, scrotal nos, tunica vaginalis, overlapping lesions of male reproductive organs, male reproductive organs nos, kidney nos, renal pelvis, ureter, bladder trigone, bladder dome, bladder lateral wall, bladder posterior wall, ureteral orifice, urachus, overlapping lesions of bladder, bladder nos, urethra, paraurethral glands, overlapping lesions of urinary organs, urinary system nos, conjunctiva, cornea, retina, choroid, ciliary body, lacrimal gland, orbital nos, overlapping lesions of eye and appendages, eye nos, meninges, spinal meninges, meningeal nos, cerebrum, frontal lobe, temporal lobe, parietal lobe, occipital lobe, ventricle, cerebellum nos, brainstem, overlapping lesions of brain, brain nos, spinal cord, cauda equina, olfactory nerve, optic nerve, auditory Nerve, cranial nerve nos, brain and central nervous system overlap lesions, nervous system nos, thyroid gland, adrenal cortex, adrenal medulla, adrenal nos, parathyroid gland, pituitary gland, craniopharyngeal duct, pineal gland, carotid body, aortic body, overlap lesions of endocrine glands and related structures, endocrine gland nos, head, face or neck nos, chest nos, abdomen nos, pelvic nos, upper limb nos, lower limb nos, other unspecified sites, overlap lesions of unspecified sites, head, face or neck lymph nodes, intrathoracic lymph nodes, intra-abdominal lymph nodes, axillary lymph nodes, leg lymph nodes, inguinal lymph nodes, pelvic lymph nodes, multiregional lymph nodes, lymph node nos, primary site unknown.

[1078] Individuals treated with the compounds disclosed and claimed herein can be treated in combination with other non-surgical anti-proliferative (e.g., anti-cancer) drug therapies. In one embodiment, the compound can be administered in combination with an anti-cancer compound, such as a cell growth inhibitory compound. A cell inhibitory compound is a compound (e.g., a small molecule, nucleic acid, or protein) that inhibits cell growth and / or proliferation. In some embodiments, the cell inhibitory compound is directed against malignant cells of a tumor. In other embodiments, the cell inhibitory compound is a compound that inhibits the growth and / or proliferation of vascular smooth muscle cells or fibroblasts.

[1079] Suitable antiproliferative or cytostatic compounds for use in combination with the compounds disclosed and claimed herein include anticancer drugs. Many anticancer drugs that can be used are well known and include, but are not limited to: Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; and Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride Hydrochloride);Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflornithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epipropidine; Epirubicin Hydrochloride Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Fluorocitabine; Fosquidone; Fostricin Sodium Sodium; Gemcitabine; Gemcitabine Hydrochloride; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta-I a; Interferon Gamma-I b;Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine; Meturedepa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid Acid; Niraparib; Nocodazole; Nogalamycin; Olaparib; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate; Perfosfamide; Pipobroman; Piposulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium;Porfiromycin; Prednimustine; Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Rucaparib; Safingol; Safingol Hydrochloride; Semustine; Simtrazene; Sparrosate Sodium; Sparsomycin; Spirogermanium Hydrochloride Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Sulofenur; Talazoparib; Talisomycin; Taxol; Taxotere; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride Hydrochloride; Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Tubulozole Hydrochloride; Uracil Mustard; Uredepa; Vapreotide; Velaparib; Verteporfin;Vinblastine Sulfate; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; and Zorubicin Hydrochloride.

[1080] Other anticancer drugs include, but are not limited to, 20-epi-1,25-dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; acylfulvene; adecypenol; adozelesin; ALL-TK antagonists; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; anagrelide; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiestrogens; antineoplastons; antisense oligonucleotides; glycine aphidicolin; glycinate; apoptosis gene regulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR / ABL antagonists; benzochlorins; benzoylstaurosporine; β-lactam derivatives; β-alethine; betaclamycin B; betulinic acid; bFGF inhibitors; bisaziridinylspermine; bisnafide; bistratene A; breflate; budotitane; buthioninesulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxamide triazole; CaRestM3; CARN 700; cartilage-derived inhibitors; casein kinase inhibitor (ICOS); castanospermine; cecropin B; cetrorelix; chlorins;Chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; clomifene analogs; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogs; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; dehydrodidemnin B; deslorelin; dexifosfamide; dexrazoxane; dexverapamil; didemnin B); didox; diethylnorspermin; dihydro-5-azacytidine; 9-dihydrotaxol; dioxamycin; diphenylspiromustine; docosanol; dolasetron; doxifluridine; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur; epirubicin; epristeride; estramustine analogs; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane;fotemustine; gadoliniumtexaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; glutathione inhibitors; hepsulfam; heregulin; hexamethylenediethylamide; hypericin; ibandronic acid acid; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulatory peptides; insulin-like growth factor-I receptor inhibitors; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; irinotecan; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellae triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate sulfate; leptolstatin; leukemia inhibitory factor; leukocyte interferon alpha; leuprolide + estrogen + progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogs; lipophilic disaccharide peptides; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptide; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrixysin inhibitor; matrix metalloproteinase inhibitor; merbarone;meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double-stranded RNA; mitoguazone; mitolactol; mitomycin analog; mitonafide; mitotoxin; fibroblast growth factor-saporin; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotropin; monophosphoryl lipid A+ mycobacterial cell wall sk; mopidamol; multidrug antibody gene inhibitor; multiple tumor suppressor 1-based therapy; nitrogen mustard anticancer compound; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone + pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidants; nitrul lyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducers; osaterone; oxaliplatin; oxaunomycin; paclitaxel analogs; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide;Perillyl alcohol; phenazinomycin; phenyl acetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitors; platinum complexes; platinum compounds; platinum-triamine complexes; porfimer sodium sodium); porfiromycin; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immunomodulators; protein kinase C inhibitors; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugates; Raf antagonists; raltitrexed; ramosetron; Ras farnesyl-protein transferase inhibitors; Ras inhibitors; Ras-GAP inhibitors; demethylated retelliptine; Re 186 rhenium etidronate; rhizoxin; ribozymes; RII retinamide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetic; senescence-derived inhibitor 1; sense oligonucleotide; signal transduction inhibitor; signal transduction regulator; single-chain antigen-binding protein; sizofuran; sobuzoxane; borcarbamate sodium; sodium phenylacetate; solverol; somatomedin-binding protein; sonermin; sparrosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem cell division inhibitor; stipiamide; stromelysin inhibitor; sulfinosine; potent endothelial peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycan; tallimustine;tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temozolomide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thalidomide; thiocoraline; thrombopoietin; thrombopoietin mimetics; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid-stimulating hormone; tinethyl etiopurpurin; titanocene dichloride dichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins (tyrosine phosphorylation inhibitors); UBC inhibitors; ubenimex; urogenital sinus growth inhibitors; urokinase receptor antagonists; variolin B; vector systems, erythrocyte gene therapy; velaresol; veramine; verdins; vinorelbine; vinxaltine; vitamin; zanoterone; zilascorb; and zinostatinstimalamer.

[1081] The compounds disclosed and claimed in this application may also be used in combination with any of the following treatments:

[1082] Combined treatment with poly (ADP-ribose) polymerase (PARP) inhibitors, a class of chemotherapy agents targeting cancers with defective DNA damage repair (Yuan, et al., Expert Opin Ther Pat, 2017, 27:363). Such PARP inhibitors include but are not limited to olaparib, rupacarib, velaparib, niraparib, talazoparib, pamiparib, iniparib, E7449 and A-966492.

[1083] Combined treatment with inhibitors of signaling pathways and mechanisms that lead to repair of single-strand and double-strand breaks in DNA, such as nuclear factor-κB signaling (Pilie, et al., Nat Rev Clin Oncol, 2019, 16: 81; Zhang, et al., Chin J Cancer, 2012, 31: 359). Such inhibitors include, but are not limited to, inhibitors of ATM and ATR kinases, checkpoint kinases 1 and 2, DNA-dependent protein kinases, and WEE1 kinases (Pilie, et al., Nat Rev Clin Oncol, 2019, 16: 81).

[1084] Combination immunomodulators (Khalil et al., Nat Rev Clin Oncol, 2016, 13:394), cancer vaccines (Hollingsworth et al., NPJ Vaccines, 2019, 4:7), immune checkpoint inhibitors (e.g., PD-1, PD-L1, CTLA-4 inhibitors) (Wei et al., Cancer Discov, 2018, 8:1069), cyclin D-kinase 4 / 6 inhibitors (Goel et al., Trends Cell Biol, 2018, 28:911), antibodies that bind to tumor cells and / or metastases and induce antibody-dependent cellular cytotoxicity (ADCC) (Kellner et al., Transfus Med Hemother, 2017, 44:327), T cell or NK cell engagers (e.g., bispecific antibodies) (Yu et al., J Cancer Res Clin Oncol, 2019, 145:941), cell therapy using expanded autologous or allogeneic immune cells (e.g., chimeric antigen receptor T (CAR-T) cells) (Khalil, et al., Nat Rev Clin Oncol, 2016, 13:394). Immune checkpoint inhibitors include, but are not limited to, nivolumab, ipilimumab, pembrolizumab, atezolizumab, avelumab, durvalumab, and cemiplimab.

[1085] According to the present invention, the compounds can be administered before, simultaneously with, or after the administration of other anti-cancer compounds. The administration schedule may include administering different agents in an alternating manner. In other embodiments, the compounds can be delivered before and during, or during and after, or before and after treatment with the other therapy. In some cases, the compounds are administered more than 24 hours before the administration of the other anti-proliferative therapy. In other embodiments, more than one anti-proliferative therapy may be administered to an individual. For example, an individual may receive a compound of the invention in combination with surgery and at least one anti-proliferative compound. Alternatively, the compounds may be administered in combination with more than one anti-cancer drug.

[1086] In one embodiment, the compounds of the present invention are used to detect cells and tissues that overexpress FAP, wherein such detection is achieved by conjugating a detectable label, preferably a detectable radionuclide, to the compounds of the present invention. In preferred embodiments, the cells and tissues detected are diseased cells and tissues and / or are the cause of a disease and / or symptoms of a disease, or are part of the underlying pathology of a disease. In further preferred embodiments, the diseased cells and tissues cause and / or are part of an oncological indication (e.g., a tumor, a tumour, and a cancer) or a non-oncological indication (e.g., an inflammatory disease, a cardiovascular disease, an autoimmune disease, and a fibrotic disease).

[1087] In another embodiment, the compounds of the present invention are used to treat cells and tissues that overexpress FAP. In a preferred embodiment, the cells and tissues being treated are diseased and / or are the cause of a disease and / or symptoms of a disease, or are part of the underlying pathology of a disease. In a further preferred embodiment, the diseased cells and tissues are responsible for and / or are part of an oncological indication (e.g., tumors, tumours and cancers), and the therapeutic activity is achieved by conjugating a therapeutically active effector, preferably a therapeutically active radionuclide, to the compounds of the present invention. In a further preferred embodiment, the diseased cells and tissues are responsible for and / or are part of a non-oncological indication (e.g., inflammatory diseases, cardiovascular diseases, autoimmune diseases and fibrotic diseases), and the therapeutic activity is achieved by inhibiting the enzymatic activity of FAP.

[1088] In another embodiment, particularly if the disease is a non-tumor disease or non-tumor indication (e.g., inflammatory disease, cardiovascular disease, autoimmune disease, and fibrotic disease), the compound of the present invention is administered in a therapeutically effective amount; preferably, the compound of the present invention does not contain a therapeutically active nuclide. An effective amount is a dose of the compound sufficient to provide a therapeutically or medically desirable result or effect in an individual to whom the compound is administered. The effective amount varies with the specific condition being treated, the age and physical condition of the subject being treated, the severity of the condition, the duration of treatment, the nature of simultaneous or combined treatment (if any), the specific route of administration, and similar factors within the knowledge and skill of the health practitioner. For example, for a method intended to treat an individual with a condition characterized by abnormal cell proliferation, an effective amount to inhibit proliferation is an amount sufficient to reduce or completely stop abnormal cell proliferation, thereby slowing or stopping the formation or progression of cell masses such as tumors. As used in the embodiments, "inhibition" includes all of the foregoing.

[1089] In other embodiments, a therapeutically effective amount is that amount required to prolong the dormancy of micrometastases or stabilize any residual primary tumor cells following surgery or drug treatment.

[1090] Typically, when using an unconjugated compound that does not contain therapeutically active radionuclides, the therapeutically effective amount varies with the age, condition, sex, and nature and extent of the individual's disease, all of which can be determined by one of ordinary skill in the art. The dosage can be adjusted by a doctor or veterinarian, particularly when any complications occur. A therapeutically effective amount is typically, but is not limited to, 0.1 μg / kg to about 2000 mg / kg, or 1.0 μg / kg to about 1000 mg / kg, or about 0.1 mg / kg to about 500 mg / kg, or about 1.0 mg / kg to about 100 mg / kg, administered daily in one or more doses for one or more days. If desired, the effective daily dose of the active compound can be administered as two, three, four, five, six or more sub-doses, for example, administered separately at appropriate intervals throughout the day, optionally in unit dosage form. In some embodiments, the compound is administered for more than 7 days, more than 10 days, more than 14 days, and more than 20 days. In other embodiments, the compound is administered over a period of weeks or months. In other embodiments, the compound is administered every other day. For example, the formulation is administered every two days, or every three days, or every four days, or every five days, or every six days, or every week, or every month.

[1091] In a preferred embodiment, the compounds of the invention are used for the treatment and / or prevention of diseases, wherein the treatment is radionuclide therapy.

[1092] Preferably, radionuclide therapy utilizes or is based on different forms of radiation emitted by radionuclides. Such radiation may be, for example, any of the following: photon radiation, electron radiation including but not limited to beta - -particle and Auger electron radiation, proton radiation, neutron radiation, positron radiation, alpha-particle radiation or ion beam. Depending on the type of particles or radiation emitted by the radionuclide, radionuclide therapy can be divided into, for example, photon radionuclide therapy, electron radionuclide therapy, proton radionuclide therapy, neutron radionuclide therapy, positron radionuclide therapy, alpha-particle radionuclide therapy or ion beam radionuclide therapy. All of these forms of radionuclide therapy are encompassed by the present invention, and all of these forms of radionuclide therapy can be achieved by the compounds of the present invention, preferably with the proviso that the radionuclide is attached to the compound of the present invention, more preferably as the effector of such radiation.

[1093] Radionuclide therapy preferably works by damaging the DNA of cells. The damage is caused by direct or indirect ionization of the atoms that make up the DNA chain by photons, electrons, protons, neutrons, positrons, α-particles, or ion beams. Indirect ionization is the result of water ionization, forming free radicals, particularly hydroxyl radicals, which then damage DNA.

[1094] In the most common radionuclide therapies, the majority of radiation effects are produced through free radicals. Because cells have mechanisms to repair DNA damage, disrupting double-stranded DNA has proven to be the most important technique for altering cellular properties. Because cancer cells are typically undifferentiated and stem-like, they reproduce more rapidly and have a diminished ability to repair sublethal damage compared to most healthy, differentiated cells. DNA damage is inherited through cell division, accumulating in cancer cells and leading to their death or slower reproduction.

[1095] Oxygen is a powerful radiosensitizer, increasing the effectiveness of a given dose of radiation by forming free radicals that damage DNA. Therefore, hyperbaric oxygen tanks, blood substitutes that carry increased oxygen, hypoxic cell radiosensitizers such as misonidazole and metronidazole, and hypoxic cytotoxins such as tirapazamine can be used.

[1096] Other factors considered when choosing a dose of radiation include whether the patient is receiving chemotherapy, whether the radiation therapy is given before or after surgery, and how successful the surgery was.

[1097] The total radioactive dose can be administered in fractions, that is, in divided doses over time during one or more treatments for important reasons. Fractionated administration allows normal cells time to recover, whereas tumor cells generally have a lower efficiency of repair between fractionated administrations. Fractionated administration also allows tumor cells that are in a relatively radioresistant phase of the cell cycle during one treatment to cycle to a more sensitive phase of the cycle before the next fractionated administration. Similarly, tumor cells that are chronically or acutely hypoxic and therefore more radioresistant may be reoxygenated between fractionated administrations, thereby increasing tumor cell lethality.

[1098] It's well known that different cancers respond differently to radiation therapy. A cancer's response to radiation is described by its radiosensitivity. Highly radiosensitive cancer cells are rapidly killed by moderate doses of radiation. These include leukemias, most lymphomas, and germ cell tumors.

[1099] It is important to distinguish between the radiosensitivity of a particular tumor, which is measured in part in the laboratory, and the "curability" of a cancer in actual clinical practice, as determined by the dose of radioactivity delivered internally. For example, leukemia is generally not curable with radiotherapy because it spreads throughout the body. Lymphoma can be essentially cured if it is confined to one part of the body. Similarly, many common moderately radioreactive tumors can be treated with curative doses of radioactivity if they are in an early stage. This applies, for example, to non-melanoma skin cancer, head and neck cancer, non-small cell lung cancer, cervical cancer, anal cancer, and prostate cancer.

[1100] A tumor's response to radiation therapy is also related to its size. For complex reasons, very large tumors respond less well to radiation than smaller tumors or microscopic disease. Various strategies are used to overcome this effect. The most common technique is surgical resection before radiation therapy. This is most common in the treatment of breast cancer with wide local excision or mastectomy followed by adjuvant radiation therapy. Another approach is to shrink the tumor with neoadjuvant chemotherapy before definitive radionuclide therapy. A third technique is to enhance the cancer's radiosensitivity by giving certain drugs during radiation therapy. Examples of radiosensitizing drugs include, but are not limited to, cisplatin, nimorazole, and cetuximab.

[1101] Intraoperative radiotherapy is a special type of radiation therapy that is given immediately after surgery to remove the cancer. This approach has been used for breast cancer (targeted intraoperative radiotherapy), brain tumors, and rectal cancer.

[1102] Radionuclide therapy itself is painless. Many low-dose palliative treatments cause minimal or no side effects. Higher-dose treatments may cause different side effects during treatment (acute side effects), months or years after treatment (long-term side effects), or after retreatment (cumulative side effects). The nature, severity, and duration of side effects depend on the organ being irradiated, the treatment (type of radionuclide, dose, fractionation, concurrent chemotherapy), and the patient's individual condition.

[1103] The methods of the present invention for treating disease may implement each and any of the above strategies known in the art within the scope of the present invention and, to this extent, constitute further embodiments of the present invention.

[1104] Also within the present invention are methods of using the compounds of the present invention for diagnosing a disease as disclosed herein. Such methods preferably comprise the step of administering to a subject in need thereof a diagnostically effective amount of a compound of the present invention.

[1105] According to the present invention, the imaging method is selected from scintigraphy, single photon emission computed tomography (SPECT) and positron emission tomography (PET).

[1106] In a preferred embodiment of the invention, compounds of the invention comprising a chelator from the N4 chelator family, more preferably chelating a Tc radionuclide, are particularly suitable for use in methods and procedures using SPECT. In an embodiment thereof, the chelator from the N4 chelator family is N4Ac.

[1107] In a preferred embodiment of the present invention, compounds of the present invention comprising the chelator NODAGA, more preferably chelating Ga radionuclides, are particularly useful in methods and procedures using PET.

[1108] Scintigraphy is a diagnostic test or method used in nuclear medicine in which a radiopharmaceutical is internalized by cells, tissues, and / or organs, preferably within the body, and the radiation emitted by the internalized radiopharmaceutical is captured by an external detector (gamma camera) to form and display a two-dimensional image. In contrast, SPECT and PET form and display three-dimensional images. Therefore, although SPECT and PET also use gamma cameras to detect internal radiation, they are classified as different techniques from scintigraphy. Scintigraphy is different from diagnostic X-rays in which external radiation passes through the body to form an image.

[1109] Single-photon emission tomography (SPECT) scanning is a nuclear imaging technique that uses gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. Before a SPECT scan, the patient is injected with a radioactively labeled chemical that emits gamma rays that are detected by the scanner. A computer collects the information from the gamma camera and converts it into two-dimensional cross-sections. These cross-sections can then be combined to form a three-dimensional image of the organ or tissue. SPECT involves detecting single and continuous gamma rays emitted by the radionuclide provided by the radioactively labeled chemical. To acquire SPECT images, the gamma camera rotates around the patient. During rotation, projections are acquired at defined points, typically every 3-6 degrees. In most cases, a full 360-degree rotation is used to obtain the best reconstruction. The time it takes to acquire each projection also varies, but is typically 15 to 20 seconds. This results in a total scan time of 15 to 20 minutes. Multi-head gamma cameras are faster. Because SPECT acquisition is very similar to planar gamma camera imaging, the same radiopharmaceuticals can be used.

[1110] Positron emission tomography (PET) is a non-invasive diagnostic imaging technique used to measure the biochemical state or metabolic activity of cells within the human body. PET is unique because it can produce images of the body's basic biochemistry or function. Traditional diagnostic techniques, such as X-rays, CT scans, or MRIs, produce images of the body's anatomy or structure. These techniques are premised on the ability to visualize any structural or anatomical changes associated with disease. Biochemical processes are also altered by disease, and this can occur before any significant anatomical changes occur. PET is an imaging technique that can visualize these early biochemical changes. PET scanners rely on radiation emitted by the patient to generate images. Each patient is administered a minute dose of a radioactive drug that closely resembles a natural substance used by the body or that binds specifically to a receptor or molecular structure. When a radioactive isotope undergoes positron-emitting decay (also known as positive-beta decay), it emits a positron, the antiparticle counterpart of the electron. After traveling a few millimeters, the positron encounters an electron and annihilates, producing a pair of annihilation (gamma) photons traveling in opposite directions. When they reach the scintillating material in the scanning device, they are detected, generating a burst of light that is detected by a photomultiplier tube or silicon avalanche photodiode. The technology relies on the simultaneous, or synchronous, detection of pairs of photons. Unpaired photons, i.e., those that do not arrive within a few nanoseconds of each other, are ignored. All synchronization is forwarded to the image processing unit, where image reconstruction procedures are used to produce the final image data.

[1111] SPECT / CT and PET / CT are combinations of SPECT and PET with computed tomography (CT). The main benefit of combining these modalities is increased reader confidence and accuracy. With traditional PET and SPECT, the number of photons emitted by an abnormal area is limited, producing a very low level of background, which makes it difficult to anatomically localize the area. Adding CT helps to anatomically determine the location of the abnormal area and classify the likelihood that it represents disease.

[1112] The methods of diagnosing disease of the present invention may implement each and any of the above strategies known in the art within the scope of the present invention and, to this extent, constitute further embodiments of the present invention.

[1113] The compounds of the present invention can be used to stratify patients, i.e., to create subsets within a patient population that provide more detailed information about how patients will respond to a given drug. By identifying the subset of the population most likely to respond to a new therapy, stratification can be a key component in shifting clinical trials from negative or neutral results to those with positive outcomes.

[1114] Stratification involves identifying a group of patients with a common “biological” profile, selecting the best management option for the patient, and achieving the best possible outcome in terms of risk assessment, risk prevention, and achieving the best possible treatment outcome.

[1115] The compounds of the present invention can be used to assess or detect a particular disease at an early stage (this is a diagnostic use), the risk of developing a disease (this is a susceptibility / risk use), the evolution of a disease including indolence versus aggressiveness (this is a prognostic use), and can be used to predict the response and toxicity to a given treatment (this is a predictive use).

[1116] The compounds of the present invention are also intended for use in theranostic methods. The concept of theranostics is to increase the clinical utility of therapeutic drugs by combining them with corresponding diagnostic tests. The concept of theranostics is becoming increasingly attractive and is widely recognized as a key to improving the effectiveness of drug treatments by helping physicians identify patients who may benefit from a particular treatment, thereby avoiding unnecessary treatment.

[1117] The concept of theranostics is to combine therapeutic agents with diagnostic tests, allowing physicians to determine which patients will benefit most from a given treatment. In one embodiment, and as preferably used herein, the compounds of the present invention are used for patient diagnostics, i.e., identification and localization of the primary tumor mass and potential local and distant metastases. In addition, tumor volume can be determined, particularly using three-dimensional diagnostic modalities such as SPECT or PET. Only those patients with FAP-positive tumor masses, and therefore likely to benefit from a given therapy, are selected for a specific therapy, thereby avoiding unnecessary treatment. Preferably, such therapy is FAP-targeted therapy using the compounds of the present invention. In a specific embodiment, chemically identical tumor-targeted diagnostics, preferably imaging diagnostics for scintigraphy, PET or SPECT, and radiotherapy, are used. Such compounds differ only in the radionuclide and therefore generally have very similar, if not identical, pharmacokinetic profiles. This can be achieved using a chelating agent and a diagnostic or therapeutic radiometal. Alternatively, this can be achieved using a precursor for radiolabeling and radiolabeling with a diagnostic or therapeutic radionuclide. In one embodiment, diagnostic imaging is preferably used by quantifying the radiation emitted by diagnostic radionuclides and subsequently determining the radiation dose and predicting the drug concentration in the tumor compared to organs susceptible to side effects, as known to those skilled in the art. Thus, truly personalized drug dosage therapy is achieved for the patient.

[1118] In one embodiment and as preferably used herein, the theranostic method is achieved with only one theranostically active compound, e.g., a compound of the invention labeled with a radionuclide that emits diagnostically detectable radiation (e.g., positrons or gamma rays) as well as therapeutically effective radiation (e.g., electrons or alpha particles).

[1119] The present invention also contemplates methods for intraoperatively identifying / revealing diseased tissue expressing FAP in an individual. Such methods utilize compounds of the present invention, wherein such compounds of the present invention preferably comprise a diagnostically active agent as an effector.

[1120] According to another embodiment of the present invention, the compounds of the present invention, particularly if complexed with a radionuclide, can be used in addition to or as an adjunct to any other tumor treatment method, including surgery as the primary treatment for most solitary solid cancers, radiation therapy involving the use of ionizing radiation to attempt to cure or ameliorate the symptoms of cancer by using sealed internal sources or external sources in the form of brachytherapy, chemotherapy such as alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors and other anti-tumor agents, hormonal therapies that modulate tumor cell behavior without directly attacking these cells, targeted agents that directly target molecular abnormalities in certain types of cancer, including monoclonal antibodies and tyrosine kinase inhibitors, angiogenesis inhibitors, immunotherapy, cancer vaccination, palliative care, including measures to reduce physical, emotional, spiritual and psycho-social hardship to improve the patient's quality of life, and alternative care, including various health care systems, practices and products that are not part of conventional medicine.

[1121] In one embodiment of the methods of the invention, the individual is a patient. In one embodiment, the patient is an individual who has been diagnosed with, is suspected of having, or is at risk of having or developing a disease, wherein the disease is a disease described herein, preferably a disease involving FAP.

[1122] Where a radionuclide is used, and more particularly is attached to or is part of a compound of the invention, the dosage used to practice the therapeutic and diagnostic methods, respectively, will vary depending on, for example, the specific condition to be treated, such as the known radiosensitivity of the tumor type, the volume of the tumor, and the treatment required. In general, the dosage is calculated based on the distribution of radioactivity per organ and the observed target uptake. The gamma-emitting complex can be administered once or multiple times for diagnostic imaging. In animals, a given dosage range may be 0.1 μg / kg to 5 mg / kg of the compound of the invention, which is combined with, for example, 1 to 200 MBq of 111 In or 89 Complexation of Zr. The beta-emitting complexes of the compounds of the invention can be administered at several time points, for example, over a period of 1 to 3 weeks or longer. In animals, a given dose range can be 0.1 μg / kg to 5 mg / kg of the compound of the invention, in combination with, for example, 1 to 200 MBq 90 Y or 177 In larger mammals, such as humans, the indicated dosage range is 0.1 to 100 μg / kg of the compound of the invention, which is combined with, for example, 10 to 400 MBq of 111 In or 89 In larger mammals, such as humans, the indicated dosage range is 0.1 to 100 μg / kg of the compound of the invention, in combination with, for example, 10 to 5000 MBq of 90Y or 177 Complexation of Lu.

[1123] In another aspect, the present invention relates to compositions, especially pharmaceutical compositions, comprising a compound of the present invention.

[1124] The pharmaceutical compositions of the present invention comprise at least one compound of the present invention and, optionally, one or more carrier substances, excipients, and / or adjuvants. The pharmaceutical compositions may further comprise, for example, one or more of the following: water, a buffer such as neutral buffered saline or phosphate buffered saline, ethanol, mineral oil, vegetable oil, dimethyl sulfoxide, a carbohydrate such as glucose, mannose, sucrose, or dextran, mannitol, a protein, an adjuvant, a polypeptide, or an amino acid such as glycine, an antioxidant, a chelating agent such as EDTA or glutathione, and / or a preservative. In addition, one or more other active ingredients may, but need not, be included in the pharmaceutical compositions of the present invention.

[1125] The pharmaceutical compositions of the present invention can be formulated for any suitable route of administration, including, for example, topical administration, such as transdermal or ocular, oral, oral mucosal, nasal, vaginal, rectal, or parenteral administration. The term parenteral as used herein includes subcutaneous, intradermal, intravascular, such as intravenous, intramuscular, intrathecal, and intraperitoneal injection, and any similar injection or infusion techniques. The preferred route of administration is intravenous administration.

[1126] In an embodiment of the present invention, the compounds of the present invention comprising radionuclides are administered by any conventional route, particularly intravenously, for example in the form of an injection or suspension. The compounds of the present invention can also advantageously be administered by infusion, for example by infusion over 30 to 60 minutes.

[1127] Depending on the location of the tumor, the compounds of the present invention may be administered as close to the tumor site as possible, for example, by catheter administration. Such administration may be directly to the tumor tissue, around the tumor tissue, or into a blood vessel. The compounds of the present invention may also be administered repeatedly, preferably in divided doses.

[1128] According to a preferred embodiment of the present invention, the pharmaceutical composition of the present invention comprises a stabilizer, such as a free radical scavenger, which inhibits the autoradiolysis of the compound of the present invention. Suitable stabilizers include, for example, serum albumin, ascorbic acid, retinol, gentisic acid or a derivative thereof, or an amino acid infusion solution, such as for parenteral protein intake, preferably without electrolytes and glucose, such as commercially available amino acid infusion solutions such as KE Nephro. Ascorbic acid and gentisic acid are preferred.

[1129] The pharmaceutical composition of the present invention may contain additional additives, such as agents for adjusting the pH between 7.2 and 7.4, such as sodium acetate or ammonium acetate or Na2HP04. Preferably, a stabilizer is added to the non-radioactive compound of the present invention, and the introduction of the radionuclide, such as complexation with the radionuclide, is carried out in the presence of the stabilizer at room temperature or preferably at 40 to 120°C. The complexation can be conveniently carried out in the absence of air, such as under N2 or Ar. Additional stabilizers may be added to the composition after complexation.

[1130] Excretion of the compounds of the invention, particularly when the effector is a radionuclide, occurs primarily through the kidneys. Further protection of the kidneys from radioactivity accumulation can be achieved by administering lysine or arginine or an amino acid solution having a high lysine and / or arginine content, for example, prior to injection of the compounds of the invention or injection together with the compounds of the invention, particularly when the effector is a radionuclide, using commercially available amino acid solutions, for example -14 or -10. As an alternative to or in addition to the infusion of amino acids, the administration of plasma volume expanders such as gelofusine can also achieve kidney protection. Kidney protection can also be achieved by using diuretics, which is a method of forced diuresis that can increase the rate of urination. Such diuretics include high-efficiency loop diuretics, thiazide diuretics, carbonic anhydrase inhibitors, potassium-sparing diuretics, calcium-sparing diuretics, osmotic diuretics and low-efficiency diuretics. In addition to the compounds of the present invention, the pharmaceutical composition of the present invention may contain at least one of these other compounds, which is intended or suitable for kidney protection, preferably kidney protection of the individual to whom the compounds of the present invention are administered.

[1131] Those skilled in the art will appreciate that the compounds of the present invention are disclosed herein for use in various methods. Those skilled in the art will further appreciate that the compositions of the present invention and the pharmaceutical compositions of the present invention can equally be used in the various methods. Those skilled in the art will also appreciate that the compositions of the present invention and the pharmaceutical compositions disclosed herein are used in various methods. Those skilled in the art will also appreciate that the compounds of the present invention can equally be used in the various methods.

[1132] Those skilled in the art will appreciate that the compositions and pharmaceutical compositions of the present invention may comprise one or more other compounds in addition to the compounds of the present invention. To the extent such one or more other compounds are disclosed herein as part of the compositions and / or pharmaceutical compositions of the present invention, it is understood that such one or more other compounds may be administered separately from the compounds of the present invention to an individual exposed to or undergoing the methods of the present invention. Administration of such one or more other compounds may occur before, simultaneously with, or after administration of the compounds of the present invention. Those skilled in the art will also appreciate that, in the methods of the present invention, one or more other compounds may be administered to an individual in addition to the compounds of the present invention. Such administration of such one or more other compounds may occur before, simultaneously with, or after administration of the compounds of the present invention. To the extent such one or more other compounds are disclosed herein as being administered as part of the methods of the present invention, it is understood that such one or more other compounds are part of the compositions and / or pharmaceutical compositions of the present invention. It is within the scope of the present invention that the compounds of the present invention and the one or more other compounds may be contained in the same or different formulations. It is also within the scope of the present invention that the compounds of the present invention and the one or more other compounds are not contained in the same formulation, but rather are contained in the same packaging having a first formulation comprising the compound of the present invention and a second formulation comprising the one or more other compounds, whereby the types of the formulations may be the same or different.

[1133] It is within the scope of the present invention that the compositions of the present invention and / or the pharmaceutical compositions of the present invention comprise more than one type of compound of the present invention. It is within the scope of the present invention that more than one type of compound of the present invention is used, preferably administered, in the methods of the present invention.

[1134] It will be appreciated that the compositions of the invention and the pharmaceutical compositions of the invention may be manufactured in conventional manner.

[1135] As a result of radioactive decay, radiopharmaceuticals have a radioactive content that decreases over time. The physical half-life of the radionuclide is generally a shortcoming of radiopharmaceutical diagnosis. In these cases, the final preparation must be completed shortly before being applied to the patient. This is especially true for positron-emitting radiopharmaceuticals (PET radiopharmaceuticals) used for tomography. This situation usually results in the use of semi-finished products, such as radionuclide generators, radioactive precursors, and medicine boxes.

[1136] Preferably, the kits of the present invention typically contain, in addition to one or more compounds of the present invention, at least one of the following: instructions for use, final preparation and / or quality control, one or more optional excipients, one or more optional reagents for labeling procedures, one or more optional radionuclides with or without a protective shielding container, and optionally one or more devices, wherein the devices are selected from labeling devices, purification devices, analytical devices, handling devices, radiation protection devices or administration devices.

[1137] Shielded containers, called "pigs," used for general handling and transport of radiopharmaceutical containers come in various configurations and are used to house radiopharmaceutical containers, such as bottles, vials, syringes, etc. One form typically includes a removable lid that allows access to the contained radiopharmaceutical container. When the pig lid is in place, radiation exposure is acceptable.

[1138] The labeling device is selected from the group consisting of an open reactor, a closed reactor, a microfluidic system, a nanoreactor, a cartridge, a pressure vessel, a vial, a temperature-controlled reactor, a mixing or shaking reactor, and combinations thereof.

[1139] The purification device is preferably selected from ion exchange chromatography columns or devices, size exclusion chromatography columns or devices, affinity chromatography columns or devices, gas or liquid chromatography columns or devices, solid phase extraction columns or devices, filtration devices, centrifuge bottle columns or devices.

[1140] The analytical device is preferably selected from the group consisting of test devices for determining the identity, radiochemical purity, radionuclide purity, radioactivity content and specific radioactivity of a radiolabeled compound.

[1141] The handling device is preferably selected from the group consisting of devices for mixing, diluting, dispensing, labeling, injecting and administering individual radiopharmaceuticals.

[1142] Radiation protection devices are used to protect physicians and other personnel from radiation exposure when using therapeutic or diagnostic radionuclides. The radiation protection device is preferably selected from devices having a protective barrier of radiation absorbing material selected from aluminum, plastic, wood, lead, iron, lead glass, water, rubber, plastic, cloth, devices that ensure a sufficient distance from the radiation source, devices that reduce the duration of exposure to the radionuclide, devices that limit the inhalation, ingestion or other means of entry of radioactive material into the body, and devices that provide a combination of these measures.

[1143] The administration device is preferably selected from the group consisting of a syringe, a shielded syringe, a needle, a pump, and an infusion set. The syringe shield is typically a hollow cylindrical structure that receives the cylindrical body of the syringe and is made of lead or tungsten with a lead glass window that allows the operator to view the syringe plunger and the volume of liquid in the syringe.

[1144] The invention will now be further illustrated by reference to the following figures and examples, from which further features, embodiments and advantages of the invention can be derived. BRIEF DESCRIPTION OF THE DRAWINGS

[1145] Figure 1 The results are shown in a formulation buffer containing 100 mg / mL ascorbate and 5 mg / mL L-methionine. 177 Radiochromatogram of Lu-3BP-3407 analyzed immediately after synthesis;

[1146] Figure 2 The results are shown in a formulation buffer containing 100 mg / mL ascorbic acid and 5 mg / mL L-methionine. 177 Radiochromatogram of Lu-3BP-3407 analyzed 6 days after synthesis;

[1147] Figure 3 The results are shown in a formulation buffer containing 100 mg / mL ascorbate and 5 mg / mL L-methionine. 177 Radiochromatogram of Lu-3BP-3554 analyzed immediately after synthesis;

[1148] Figure 4 The results are shown in a formulation buffer containing 100 mg / mL ascorbic acid and 5 mg / mL L-methionine. 177 Radiochromatogram of Lu-3BP-3554 analyzed 6 days after synthesis;

[1149] Figure 5 Shown is the expression of 1 hour, 3 hours, 6 hours and 24 hours after injection into the mouse model. 111 In-3BP-3105(A) and 111 (B) Percent injected dose per gram tissue (% ID / g) uptake of In-3BP-3168 in kidney, liver, blood pool, and HEK-FAP tumors as determined by SPECT imaging;

[1150] Figure 6 Shown is the expression of 1 hour, 3 hours, 6 hours and 24 hours after injection into the mouse model. 111 In-3BP-3320(A) and 111 (B) Percent injected dose per gram tissue (% ID / g) uptake of In-3BP-3321 in kidney, liver, blood pool, and HEK-FAP tumors as determined by SPECT imaging;

[1151] Figure 7 Shown is the expression of 1 hour, 3 hours, 6 hours and 24 hours after injection into the mouse model. 111 In-3BP-3275(A) and 111(B) Percent injected dose per gram tissue (% ID / g) uptake of In-3BP-3397 in kidney, liver, blood pool, and HEK-FAP tumors as determined by SPECT imaging;

[1152] Figure 8 Shown is the expression of 1 hour, 3 hours, 6 hours and 24 hours after injection into the mouse model. 111 In-3BP-3398(A) and 111 (B) Percent injected dose per gram tissue (% ID / g) uptake of In-3BP-3407 in kidney, liver, blood pool, and HEK-FAP tumors as determined by SPECT imaging;

[1153] Figure 9 Shown is the expression of 1 hour, 3 hours, 6 hours and 24 hours after injection into the mouse model. 111 In-3BP-3554(A) and 111 (B) Percent injected dose per gram tissue (% ID / g) uptake of In-3BP-3652 in kidney, liver, blood pool, and HEK-FAP tumors as determined by SPECT imaging;

[1154] Figure 10 Shown is the expression of 1 hour, 3 hours, 6 hours and 24 hours after injection into the mouse model. 111 In-3BP-3654(A) and 111 (B) Percent injected dose per gram tissue (% ID / g) uptake of In-3BP-3656 in kidney, liver, blood pool, and HEK-FAP tumors as determined by SPECT imaging;

[1155] Figure 11 Shown is the expression of 1 hour, 3 hours, 6 hours and 24 hours after injection into the mouse model. 111 In-3BP-3659(A) and 111 (B) Percent injected dose per gram tissue (% ID / g) uptake of In-3BP-3678 in kidney, liver, blood pool, and HEK-FAP tumors as determined by SPECT imaging;

[1156] Figure 12 Shown is the expression of 1 hour, 3 hours, 6 hours and 24 hours after injection into the mouse model. 111 In-3BP-3692(A) and 111 (B) Percent injected dose per gram tissue (% ID / g) uptake of In-3BP-3767 in kidney, liver, blood pool, and HEK-FAP tumors as determined by SPECT imaging;

[1157] Figure 13Shown are 1 hour, 3 hours, 6 hours, 24 hours and 48 hours after injection into mice bearing HEK-FAP tumors. 111 SPECT images of In-3BP-3554;

[1158] Figure 14 Figure 3 shows that 1 hour, 3 hours, 6 hours, 24 hours and 48 hours after injection into mice bearing HEK-FAP tumors. 111 SPECT images of In-3BP-3767;

[1159] Figure 15 A shows the use of carrier, cold compound nat Lu-3BP-3554, 30 MBq (low dose) 177 Lu-3BP-3554 and 60MBq (high dose) 177 Tumor growth over time in Lu-3BP-3554-treated mice bearing HEKFAP tumors.

[1160] Figure 15 B shows the use of carrier, cold compound nat Lu-3BP-3554, 30 MBq (low dose) 177 Lu-3BP-3554 and 60MBq (high dose) 177 Percent change in body weight over time in Lu3BP-3554-treated mice bearing HEK-FAP tumors;

[1161] Figure 16 A shows 60 MBq in mice with HEK-FAP tumors 177 Representative SPECT / CT images of Lu-3BP-3554 biodistribution over time;

[1162] Figure 16 B shows 30 MBq in mice with HEK-FAP tumors 177 Representative SPECT / CT images of Lu-3BP-3554 biodistribution over time;

[1163] Figure 17 A shows four different sarcoma PDX models administered 111 Representative SPECT / CT images 3 hours after In-3BP-3554;

[1164] Figure 17 B shows 3 hours after injection, 111 % ID / g uptake of In-3BP-3554 in four different sarcoma PDX models;

[1165] Figure 18 A shows the use of carrier, cold compoundnat Lu-3BP-3554, 30MBq 177 Lu-3BP-3554 or 60MBq 177 Tumor growth over time in Lu-3BP-3554-treated mice bearing Sarc4809 PDX tumors;

[1166] Figure 18 B shows the use of carrier, cold compound nat Lu-3BP-3554, 30MBq 177 Lu-3BP-3554 or 60MBq 177 Changes in body weight over time in Lu-3BP-3554-treated mice bearing sarcoma Sarc4809 PDX tumors; and

[1167] Figure 19 The amino acid sequences of human fibroblast activation protein (FAP) (SEQ ID NO: 1), human dipeptidyl peptidase 4 (DDP4) (SEQ ID NO: 2), and human prolyl endopeptidase (PREP) (SEQ ID NO: 3) are shown. DETAILED DESCRIPTION

[1168] The following examples are included to provide guidance for those of ordinary skill in the art to practice representative embodiments of the subject matter of the present disclosure. Based on the present disclosure and the general level of those skilled in the art, it will be understood that the following examples are merely exemplary and that various variations, modifications, and alterations may be employed without departing from the scope of the subject matter of the present disclosure. The following synthesis descriptions and specific examples are intended for illustrative purposes only and should not be construed as limiting in any way the preparation of the compounds of the present disclosure by other methods.

[1169] Example

[1170] The abbreviations used in this application and in particular in the following examples are as follows:

[1171] 4PL stands for four-parameter logistic curve fitting

[1172] Indicates

[1173] CAN stands for acetonitrile

[1174] Ahx stands for 6-aminohexanoic acid

[1175] AMC stands for 7-amino-4-methylcoumarin

[1176] amu stands for atomic mass unit

[1177] aq. means water

[1178] AUC inf represents the area under the curve extrapolated to infinity

[1179] BSA stands for bovine serum albumin

[1180] C0 represents the initial concentration of the compound

[1181] CAF stands for cancer-associated fibroblast

[1182] CL stands for clearance rate

[1183] CM stands for ChemMatrix TM

[1184] CT stands for computed tomography

[1185] Cy5 stands for Cyanine-5

[1186] DAD stands for diode array detector

[1187] DCM stands for dichloromethane

[1188] Dde represents N-(1-(4,4-dimethyl-2,6-dioxocyclohexylene)ethyl)

[1189] DEG stands for diethylene glycol dimethacrylate

[1190] DIC stands for N,N'-diisopropylcarbodiimide

[1191] DICOM stands for Digital Imaging and Communications in Medicine

[1192] DIPEA stands for diisopropylethylamine

[1193] DMF stands for N,N-dimethylformamide

[1194] DMSO stands for dimethyl sulfoxide

[1195] DOTA stands for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid

[1196] DOTA(tBu)3-OH stands for tri-tert-butyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate

[1197] DPP stands for dipeptidyl peptidase

[1198] EC stands for electron capture

[1199] EC 50 half-maximal excitatory concentration

[1200] ECACC stands for European Collection of Authenticated Cell Cultures; EDC stands for 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; EMEM stands for Eagle's Minimum Essential Medium.

[1201] eq or eq. means equivalent

[1202] ESI stands for electrospray ionization

[1203] Et2O represents diethyl ether

[1204] EtOAc means ethyl acetate

[1205] FACS stands for fluorescence-activated cell sorting

[1206] FAP stands for fibroblast activation protein

[1207] Fb represents the background fluorescence intensity

[1208] FBS stands for fetal bovine serum

[1209] FGF21 stands for fibroblast growth factor 21

[1210] FITC stands for 5(6)-fluorescein isothiocyanate

[1211] Fmoc stands for 9-fluorenylmethoxycarbonyl

[1212] FRET stands for Fluorescence Resonance Energy Transfer

[1213] Ft represents the fluorescence intensity

[1214] Gab stands for gamma-aminobutyric acid

[1215] GABA stands for gamma-aminobutyric acid

[1216] h represents hours

[1217] HATU represents O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; HBST represents SPR running buffer.

[1218] HEK-FAP represents human embryonic kidney 293 cells expressing human FAP

[1219] HEPES stands for 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

[1220] HFIP stands for hexafluoro-2-isopropanol

[1221] HOAc represents acetic acid

[1222] HOAt stands for 1-hydroxy-7-azabenzotriazole

[1223] HPLC stands for high performance liquid chromatography

[1224] HPLC / MS stands for high performance liquid chromatography / mass spectrometry

[1225] IC 50 half-maximal inhibitory concentration

[1226] ID / g represents the injected dose per gram

[1227] IS stands for isomeric transition

[1228] iTLC-SG stands for fast thin layer chromatography-silica gel

[1229] K2EDTA stands for dipotassium ethylenediaminetetraacetate

[1230] K D represents the dissociation constant

[1231] kDa means 1000 Dalton

[1232] K i Inhibition constant

[1233] k off Represents the dissociation rate

[1234] k on Indicates the binding speed

[1235] LC / TOF-MS stands for liquid chromatography / time of flight / mass spectrometry

[1236] LC-MS stands for high performance liquid chromatography coupled with mass spectrometry

[1237] LDH stands for lactate dehydrogenase

[1238] Leu represents leucine

[1239] LiOH represents lithium hydroxide

[1240] M stands for mole or mol / L

[1241] m / z represents mass divided by charge

[1242] max. means maximum

[1243] MeOH stands for methanol

[1244] MeV stands for mega-electron volts

[1245] min means minutes

[1246] MMP stands for matrix metalloproteinase

[1247] MRM stands for Multiple Reaction Monitoring

[1248] MTBE stands for methyl tert-butyl ether

[1249] Mtt represents methyltrityl

[1250] MTV stands for mean tumor volume

[1251] MW stands for molecular weight

[1252] nd means not determined

[1253] Na2SO4 represents sodium sulfate

[1254] NaCl stands for sodium chloride

[1255] NaHCO3 represents sodium bicarbonate

[1256] NCA stands for noncompartmental analysis

[1257] NHS stands for N-hydroxysuccinimide

[1258] NMP stands for 1-methyl-2-pyrrolidone

[1259] NOS stands for Not Specified

[1260] Oic stands for L-octahydroindole-2-carboxylic acid

[1261] pa means: for analytical purposes (quality level)

[1262] pi means post-injection

[1263] Pbf stands for 2,2,4,6,7-pentamethyl-2,3-benzodihydrofuran-5-sulfonyl

[1264] PBS stands for phosphate buffered saline

[1265] PDX stands for patient-derived xenograft

[1266] PET stands for Positron Emission Tomography

[1267] pIC50 represents the negative logarithm of the IC50 value when converted to molar values.

[1268] POP stands for prolyl oligopeptidase

[1269] ppm stands for parts per million

[1270] PREP stands for prolyl endopeptidase

[1271] prep. indicates preparation type

[1272] PS stands for polystyrene

[1273] Q-TOF stands for quadrupole time of flight

[1274] Ref means reference

[1275] RFU stands for relative fluorescence unit

[1276] RLB stands for radioligand binding assay

[1277] RMCE stands for recombinase-mediated cassette exchange

[1278] RP stands for reverse phase

[1279] R t Indicates retention time

[1280] RT stands for room temperature

[1281] RU stands for resonance unit

[1282] SAR stands for structure activity relationship

[1283] sat. means saturated

[1284] SCID stands for severe combined immunodeficiency

[1285] SCK stands for single-cycle kinetics

[1286] Sec or s means seconds

[1287] SF stands for spontaneous fission

[1288] SPECT stands for single photon emission computed tomography

[1289] SPPS stands for solid phase peptide synthesis

[1290] t 1 / 2 Terminal half-life

[1291] tBu represents tert-butyl

[1292] TFA stands for trifluoroacetate or trifluoroacetic acid

[1293] TG stands for TentaGel

[1294] TGI stands for tumor growth inhibition

[1295] THF stands for tetrahydrofuran

[1296] TIPS stands for triisopropylsilane

[1297] TLC stands for thin layer chromatography

[1298] TME stands for tumor microenvironment

[1299] t R Indicates retention time

[1300] UHPLC stands for ultra-high performance liquid chromatography

[1301] UV stands for ultraviolet light

[1302] V SS Steady-state volume of distribution

[1303] V Z Terminal volume of distribution

[1304] Example 1: Materials and Methods

[1305] Materials and methods and general procedures are further illustrated by the following examples.

[1306] Solvent:

[1307] Solvents were used as specified without further purification: acetonitrile (Super Gradient, HPLC, VWR, for analytical purposes; PrepSolv, Merck, for preparative purposes); dichloromethane (synthetic, Roth); ethyl acetate (synthetic grade, Roth); N,N-dimethylformamide (peptide synthesis grade, Biosolve); 1-methyl-2-pyrrolidone (peptide grade, IRISBioTech); 1,4-dioxane (extra pure, Roth); and methanol (pa, Merck).

[1308] Water: Milli-Q Plus, Millipore, demineralized.

[1309] Chemicals:

[1310] Chemicals were synthesized according to or analogously to literature methods or purchased from: Sigma-Aldrich-Merck (Deisenhofen, Germany), Bachem (Bubendorf, Switzerland), VWR (Darmstadt, Germany), Novabiochem (Merck Group, Darmstadt, Germany), Acros Organics (distribution company Fisher Scientific GmbH, Schwerte, Germany), Iris Biotech (Marktredwitz, Germany), Amatek Chemical (Jiangsu, China), Roth (Karlsruhe, Germany), Molecular Devices (Chicago, USA), Biochrom (Berlin, Germany), Peptech (Cambridge, MA, USA), Synthetech (Albany, OR, USA), Pharmacore (High Point, NC, USA), PCAS Biomatrix Inc (Saint-Jean-sur-Richelieu, Quebec, Canada), Alfa Reagents were obtained from Aesar (Karlsruhe, Germany), Tianjin Nankai Hecheng S&T Co., Ltd (Tianjin, China), CheMatech (Dijon, France), and Anaspec (San Jose, CA, USA) or other companies and used at the indicated mass without further purification.

[1311] Boc4N4Ac-OH was synthesized according to the literature method (Maecke et al. Chem. Eur. J., 2010, 16, 7, 2115):

[1312]

[1313] cell:

[1314] HT29 (ECACC Cat. No. 91072201) and WI-38 (ECACC Cat. No. 90020107) were purchased from ECACC, and HEK293 cells expressing human FAP (Q12884) were generated by recombinase-mediated cassette exchange (RMCE) by InSCREENeX GmbH (Braunschweig, Germany). The RMCE method is described by Nehlsen et al. (Nehlsen, et al., BMC Biotechnol, 2009, 9: 100).

[1315] HPLC / MS analysis:

[1316] HPLC / MS analysis was performed by injecting 5 μl of sample solution, using a 2-step gradient (5-65% B in 12 minutes, then 65-90% A (0.1% TFA in water) and B (0.1% TFA in ACN) in 0.5 minutes for all chromatograms. The RP column was from Agilent (Poroshell 120 model, 2.7 μm, EC-C18, 50×3.00 mm, flow rate 0.8 ml, HPLC room temperature); mass spectrometer: Agilent 6230 LC / TOF-MS, ESI ionization. MassHunter Qualitative Analysis B.07.00 SP2 was used as software. UV detection was performed at λ=230 nm. Retention time (R t ) is expressed in decimal (e.g., 1.9 minutes = 1 minute 54 seconds) and refers to the detection in the UV spectrometer. To assess the observed mass of the compound, the "Find Compounds by Formula" function was used. In particular, the individual "neutral mass of the compound (in Daltons)" values ​​and the corresponding isotopic distribution pattern were used to confirm the identity of the compound. The accuracy of the mass spectrometer is approximately ±5 ppm.

[1317] Preparative HPLC:

[1318] A reverse phase column (Kinetex 5μXB-C18 150×30mm, from Phenomenex, or RLRP-S 8μ, Preparative HPLC separations were performed using a 150×25 mm column (150×25 mm) stationary phase. 0.1% TFA (A) in water and 0.1% TFA (B) in ACN were used as mobile phases, mixed in a linear binary gradient. The gradient was described as follows: "10% to 40% B in 30 minutes," meaning a linear gradient from 10% B (and correspondingly 90% A) to 40% B (correspondingly 60% A) was run in 30 minutes. The flow rate was in the range of 30 to 50 ml / min. A typical gradient used to purify the compounds of the invention starts with 5-25% B and ends with 35-50% B after 30 minutes, with the difference between the B percentage at the end and the beginning being at least 10%. A commonly used gradient is "15% to 40% B in 30 minutes."

[1319] General procedure for automated / semi-automated solid phase synthesis:

[1320] Automated solid phase synthesis of peptides and polyamides was performed on a Tetras peptide synthesizer (Advanced ChemTech) at 50 μmol and 100 μmol scales. Manual steps were performed in plastic syringes equipped with glass frits (material PE, Roland Vetter Laborbedarf OHG, Ammerbuch, Germany). Unless otherwise stated, the reagent amounts in the protocols correspond to a 100 μmol scale.

[1321] Solid-phase synthesis was performed on polystyrene (crosslinked with 1,4-divinylbenzene (PS) or di(ethylene glycol) dimethacrylate (DEG)), ChemMatrix (CM), or TentaGel (TG) resins. Resin linkers were trityl, Wang, and Rinkamide.

[1322] Resin loading:

[1323] In the case of a trityl linker, the first building block was attached (resin loading) as follows. The resin (polystyrene (PS) trityl chloride, initial loading: 1.8 mmol / g) was swollen in DCM (5 ml) for 30 minutes and subsequently washed with DCM (3 ml, 1 minute). The resin was then treated with a mixture of the corresponding building block (0.5 mmol, 5 eq.) and DIPEA (350 μl, 3.5 mmol, 35 eq.) in DCM (4 ml) for 1 hour. The resin was then washed with methanol (5 ml, 5 minutes) and DMF (3 ml, 2 x 1 minute).

[1324] In the case of the Wang linker, pre-loaded resins (polystyrene (PS) and TentaGel (TG)) were used.

[1325] In the case of the Rink amide linker, attachment of the first residue of the resin (CM, DEG) was performed using the same procedure as for chain assembly, as described below.

[1326] Allyloxycarbonyl / allyl deprotection:

[1327] After swelling in DMF, the resin was washed with DMF and DCM. The DCM was deoxygenated by passing a stream of nitrogen through the stirred solvent. The resin was washed three times with an oxygen-free solvent. 2 ml of a 2M barbituric acid solution in oxygen-free DCM and 1 ml of a 25 μM tetrakis(triphenylphosphine)palladium(0) solution in oxygen-free DCM were then added to the resin. The resin was stirred for 1 hour and then washed with DCM, MeOH, DMF, 5% DIPEA in DMF, 5% dithiocarbamate in DMF, DMF, and DCM (each washing step was repeated 3 times, with 3 ml washing for 1 minute each time).

[1328] Fmoc-deprotection:

[1329] After swelling in DMF, the resin was washed with DMF and then treated with piperidine / DMF (1:4, 3 ml, 2 and 20 min) followed by washing with DMF (3 ml, 5 x 1 min).

[1330] Dde-deprotection:

[1331] After swelling in DMF, the resin was washed with DMF and then treated with hydrazine hydrate / DMF (2 / 98, 3 ml, 2 x 10 min) and subsequently washed with DMF (3 ml, 5 x 1 min).

[1332] Mtt-deprotection:

[1333] After swelling in DCM, the resin was washed with DCM and then treated with HFIP / DCM (7 / 3, 4-6 ml, 4 hours), followed by washing with DCM (3 ml, 3 x 1 minute), DMF (3 ml, 3 x 1 minute) and DIPEA (0.9 M in DMF, 3 ml, 1 minute).

[1334] Reagent solution:

[1335] Building block (0.3 M in DMF or NMP), DIPEA (0.9 M in DMF), HATU (0.4 M in DMF), acetic anhydride (0.75 M in DMF).

[1336] Coupling: Coupling of building blocks / amino acids (chain assembly):

[1337] Unless otherwise stated, the coupling of the building blocks was carried out as follows: After the subsequent addition of a solution of the corresponding building block (1.7 ml, 5 eq.), a DIPEA solution (1.15 ml, 10 eq.) and a HATU solution (1.25 ml, 5 eq.), the resin was shaken for 45 minutes. If necessary, the resin was washed with DMF (3 ml, 1 minute) and the coupling step was repeated.

[1338] Terminal acetylation:

[1339] After adding DIPEA solution (1.75 ml, 16 eq.) and acetic anhydride solution (1.75 ml, 13 eq.), the resin was shaken for 10 minutes and then washed with DMF (3 ml, 6 x 1 minute).

[1340] Cleavage Method A: Cleavage of Protected Fragments from Peracid-Labile Resins:

[1341] After the sequence assembly is complete, the resin is washed with DCM (3 ml, 4 x 1 min) and then dried in vacuo. The resin is then treated with HFIP / DCM (7 / 1, 4 ml, 4 hours) and the collected solution is evaporated to dryness. The residue is purified by preparative HPLC or used without further purification.

[1342] Cleavage method B: Cleavage of unprotected fragments (complete resin cleavage):

[1343] After the sequence assembly is complete, the resin is washed with DCM (3 ml, 4 × 1 minute), dried in vacuo overnight, and treated with TFA, EDT, water, and TIPS (94 / 2.5 / 2.5 / 1) for 2 hours (unless otherwise stated). The lysate is then poured into a cooled mixture of MTBE and cyclohexane (1 / 1, 10-fold excess compared to the volume of the lysate), centrifuged at 4 ° C for 5 minutes, and the precipitate is collected and dried in vacuo. The residue is lyophilized from water / acetonitrile before purification or further modification.

[1344] Cleavage method C: Cleavage of peptide protective groups in solution

[1345] The protected / partially protected compound was dissolved in TFA, water and TIPS (95 / 2.5 / 2.5) for 2 hours (unless otherwise stated). The cleavage solution was then poured into a cooled mixture of MTBE and cyclohexane (1 / 1, 10-fold excess compared to the volume of the cleavage solution), centrifuged at 4°C for 5 minutes, and the precipitate was collected and dried under vacuum. The residue was lyophilized from water / acetonitrile before purification or further modification.

[1346] More relevant Fmoc-solid phase-peptide synthesis methods are described in detail in "Fmoc Solid Phase Peptide Synthesis" Editors W. Chan, P. White, Oxford University Press, USA, 2000. Where appropriate, the names of the compounds were determined using MestreNova version 12 Mnova IUPAC Name plug-in (Mestrelab Research, SL) or AutoNom version 2.2 (Beilstein Informationssysteme 1988-1998, BeilsteinInstitut für Literatur der Organischen Chemie, licensed to Beilstein Chemiedaten andSoftware GmbH) as appropriate.

[1347] Preparation of compounds:

[1348] The following examples provide specific embodiments for preparing the compounds of the present invention. Unless otherwise noted, all starting materials and reagents were of standard commercial grade and used without further purification, or were readily prepared from such materials by conventional methods. Based on this disclosure, one skilled in the art of organic synthesis will recognize that the starting materials and reaction conditions may be varied, including additional steps, to produce the compounds encompassed by the present invention.

[1349] A general synthetic route for the compounds of the present invention comprises:

[1350] 1. Solid Phase Peptide Synthesis (SPPS) of a Linear Peptide Precursor with Two Thiol Moieties.

[1351] 2. The linear peptide precursor is cyclized site-specifically with the thiol of the following derivative:

[1352] a. bis(bromomethyl)benzene derivatives, or

[1353] b. Tris(bromomethyl)benzene derivatives.

[1354] 3. In the case of cyclization with a tris(bromomethyl)benzene derivative, the intermediate formed in the cyclization reaction is further reacted with a linker capable of attaching a chelating agent.

[1355] Example 2: Synthesis of Ac-Met-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Nmf-Arg-Asp-NH2(3BP-3188)

[1356] The sequence of the peptide (Ac-Met-Cys-Pro-Pro-Thr-Glu-Phe-Cys-Asp-His-Nmf-Arg-Asp-NH2) was assembled on a 50 μmol scale on Rink amide resin according to the "General procedure for automated / semi-automated solid phase synthesis". After performing the steps of "cleavage method B", the lyophilized crude peptide residue was dissolved in 60 ml of a 1:1 mixture of ammonium bicarbonate solution (50 mM, pH = 8.5) and acetonitrile. To this mixture was added a solution of 14.5 mg of α,α'-dibromo-m-xylene (55 μmol, 1.1 eq compared to the initial resin loading) in 0.5 ml of acetonitrile. After the cyclization reaction was complete, 50 μl of TFA was added and the solvent was removed by lyophilization. The residue was subjected to HPLC purification (15% to 45% B in 30 minutes, Kinetex) to produce 8.61 mg of pure title compound (9.8%). HPLC: R t =5.87 min. LC / TOF-MS: exact mass 1753.716 (calculated 1753.705). 79 H 107 N 19 O 21 S3 (MW = 1755.011).

[1357] Example 3: Synthesis of DOTA-Ttds-Leu-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Phe-Arg-Asp-NH2(3BP-3172)

[1358] The sequence of the peptide (DOTA-Ttds-Leu-Cys-Pro-Pro-Thr-Glu-Phe-Cys-Asp-His-Phe-Arg-Asp-NH2) was assembled on a 50 μmol scale on Rink amide resin according to the "General Procedure for Automatic / Semi-Automatic Solid Phase Synthesis". After carrying out the step of "Cleavage Method B", the lyophilized crude peptide residue was dissolved in a mixture of 60 ml of 1:1 ammonium bicarbonate solution (50 mM, pH = 8.5) and acetonitrile. To this mixture was added a solution of 14.5 mg of α, α'-dibromo-m-xylene (55 μmol, 1.1 eq compared to the initial resin loading). After the cyclization reaction was complete, 50 μl of TFA was added and the solvent was removed by lyophilization. The residue was purified by HPLC (20% to 45% B in 30 min, Kinetex) to yield 35.46 mg of pure title compound (29.8%). HPLC: R t = 5.9 min. LC / TOF-MS: exact mass 2368.091 (calculated 2368.087).107 H 157 N 25 O 32 S2 (MW = 2369.676).

[1359] Example 4: Synthesis of Hex-[Cys(3MeBn)-Pro-Pro-Thr-Glu-Phe-Cys]-Asp-His-Ppa-arg-Ttds-Lys...

Claims

1. A compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A connected to Xaa1, in: The peptide sequences are drawn from left to right in the direction of N-terminus to C-terminus. Xaa1 is the residue of an amino acid of formula (II), in: R 1a is –NH-, R 1b is H or CH3, n = 0 or 1, The N-terminal modification group A is covalently linked to the nitrogen atom of Xaa1, The carbonyl group of Xaa1 is covalently linked to the nitrogen of Xaa2. and the sulfur atom of Xaa1 is covalently linked to Yc as a thioether; Xaa2 is the residue of an amino acid of formula (III), (IV) or (XX), in: R 2a , R 2b , R 2c are each and independently selected from (C1-C2)alkyl and H, wherein the (C1-C2)alkyl may be substituted by a substituent selected from OH, NH2, halogen, (C5-C7)cycloalkyl, p = 0, 1, or 2 v = 1 or 2 w = 1, 2, or 3, and The amino acid of formula (IV) may be substituted at ring positions 3 and 4 as shown by one or two substituents selected from methyl, OH, NH2 and F; Xaa3 is the residue of an amino acid of formula (V) or (XX), in: X 3 Selected from CH2, CF2, CH-R 3b , S, O and NH, p = 1 or 2 v = 1 or 2 w = 1, 2 or 3, R 3a is H, methyl, OH, NH2 or F, R 3b is methyl, OH, NH2 or F; Xaa4 is the residue of an amino acid of formula (VI), in: R 4a Selected from H, OH, COOH, CONH2, X 4 and -NH-CO-X 4 , where X 4 is selected from (C1-C6)alkyl, (C5-C6)aryl and (C5-C6)heteroaryl, and X 4 may be substituted by one or two substituents selected from methyl, CONH2, halogen, NH2 and OH; q=1, 2 or 3, wherein optionally, one or two hydrogens of said 1, 2 or 3 CH2 groups are each and independently substituted by methyl, ethyl, (C5-C6)aryl or (C5-C6)heteroaryl, R 4b is methyl or H; Xaa5 is an amino acid residue of structure (VII), in: R 5 is selected from OH and NH2, and r = 1, 2 or 3; Xaa6 is an amino acid selected from aromatic L-α-amino acids and heteroaromatic L-α-amino acids; Xaa7 is an aminothiol or amino acid residue of formula (IX), in: R 7a It is -CO-, -COOH, -CONH2, -CH2-OH, -(CO)-NH-R 7b 、-(CO)-(NR 7c )-R 7b or H, where R 7b and R 7c are each and independently (C1-C4)alkyl, and t is 1 or 2; Yc is a structure of formula (X), It connects the S atom of Xaa1 and the S atom of Xaa7 while forming two thioether bonds, thereby forming a cyclic structure of formula (XXI), in: The substitution pattern of the aromatic group in formula (X) is ortho, meta or para, n = 0 or 1, t = 1 or 2, Y 1 is CH or N, Y 2 Is N or CR c1 , R c1 is H or CH2-R c2 ,as well as R c2 is a structure of formula (XI), (XII) or (XXII), in: R c3 and R c4 are each and independently selected from H and (C1-C4)alkyl, and u=1, 2, 3, 4, 5 or 6, x and y are each and independently selected from 1, 2 or 3, and X=O or S, Wherein in formula (XI) and (XXII), one of the nitrogen atoms is attached to R c1 -CH2-, and in formula (XII), -X- is connected to R c1 -CH2-; and wherein the N-terminal modification group A is a protecting group Abl or an amino acid Aaa; and wherein the protecting group Abl is selected from R a1 -C(O)-、R a1 -S(O2)-、R a1 -NH-C(O)- and R a1 -OC(O)-; Where R a1 is (C1-C8)alkyl optionally substituted by up to two substituents each and independently selected from OH, F, COOH, (C3-C8)cycloalkyl, aryl, heteroaryl and (C3-C8)heterocycle, and wherein in the (C1-C8)alkyl, 1 -CH2- group is optionally replaced by -S- or -O-.

2. The compound according to claim 1, wherein the amino acid Aaa is a D-amino acid residue or an L-amino acid residue, each of which has structure (XIV): in: R a2 is selected from (C1-C6)alkyl, modified (C1-C6)alkyl, (C1-C3)alkyl, modified (C1-C3), (C3-C8)carbocycle, aryl, heteroaryl and (C3-C8)heterocycle, wherein in the modified (C1-C6)alkyl, one -CH2- group is replaced by -S- or -O-, and in the modified (C1-C3)alkyl, one H is replaced by OH, F or COOH, or two H are replaced by F, and wherein R a3 It is H or acetyl.

3. The compound according to any one of claims 1 to 2, wherein Xaa2 is an amino acid residue selected from Pro, Gly, Nmg and derivatives thereof, wherein Xaa3 is an amino acid residue selected from Pro, Hyp, Tfp, Cfp, Dmp, Aze and Pip and derivatives thereof, wherein Xaa4 is an amino acid residue selected from Thr, Hse, Asn, Gln and Ser and derivatives thereof, wherein Xaa5 is an amino acid residue selected from Gln and Glu and derivatives thereof, wherein Xaa6 is an amino acid residue of any one of formula (VIIIa), (VIIIb), (VIIIc) and (VIIId): in: R 6a and R 6b are each and independently selected from H, methyl, ethyl, propyl and isopropyl, R 6c represents 0 to 3 substituents, each such substituent being individually and independently selected from Cl, F, Br, NO2, NH2, CN, CF3, OH, OR 6d and C1-C4 alkyl, R 6d is selected from the group consisting of methyl, ethyl, propyl and isopropyl, and s is 0 or 1, Preferably Xaa6 is an amino acid residue of any one of formulae (VIIIa), (VIIIb), (VIIIc) and (VIIId): in: R 6a and R 6b Each is H, R 6c represents 0 to 2 substituents, each such substituent being individually and independently selected from Cl, F, Br, NO2, NH2, CN, CF3, OH, OR 6d and methyl, R 6d is selected from the group consisting of methyl, ethyl, propyl and isopropyl, and s is 0, and / or wherein Xaa7 is an aminothiol residue selected from Cys, Cysol, AET, Hcy, cys and hcy.

4. The compound according to any one of claims 1 to 3, wherein the compound is a compound of formula (LI), (LII), (LIII) or (LIV):

5. A compound according to any one of claims 1 to 4, wherein Yc is a structure of formula (XIII): Preferably Yc comprises an NH group, preferably a reactive NH group, wherein the NH group allows a moiety to be conjugated to Yc, preferably the NH group is composed of the structure R c1 Provided, where R c1 It is CH2-R c2 , where R c2 is a structure selected from any one of formulae (XXIb), (XIc) and (XIIb): Where R c4 is H or methyl, and u=1, 2, 3, 4 or 5.

6. A compound according to any one of claims 1 to 5, wherein the compound comprises a Z group, wherein the Z group is covalently linked to Yc, preferably covalently linked to a structure of formula (X), wherein the Z group comprises a chelating agent and an optional linker, preferably the Z group is covalently linked to R c2 , forming a structure of any one of formula (XXIIc), (XId) and (XIId): Where R c4 is H or methyl, and u=1, 2, 3, 4 or 5.

7. A compound according to claim 6, wherein the linker is selected from Ttds, O2Oc, Apac, Gly, Bal, Gab, Mamb, Pamb, Ppac, 4Amc, Inp, Sni, Rni, Nmg, Cmp, PEG6, PEG12 and other PEG-amino acids, most preferably Ttds, O2Oc, Apac, 4Amc, PEG6 and PEG12, preferably the linker amino acid is selected from Ttds, O2Oc and PEG6.

8. The compound according to claim 6, wherein the chelating agent is selected from the group consisting of DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOTP, sarcophagine, FSC, NETA, H4octapa, Pycup, N x S 4-x (N4, N2S2, N3S), Hynic, 99m Tc(CO)3-chelating agent, more preferably DOTA, DOTAGA, NOTA, NODAGA, NODA-MPAA, HBED, CB-TE2A, DFO, THP, N4, and most preferably DOTA, DOTAGA, NOTA, NODAGA and N4.

9. A compound according to any one of claims 1 to 8, wherein the compound comprises a diagnostically active nuclide or a therapeutically active nuclide, wherein Preferably, the diagnostically active nuclide is a diagnostically active radionuclide, more preferably selected from 43 Sc, 44 Sc, 51 Mn, 52 Mn, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 94m Tc, 99m Tc, 111 In, 152 Tb, 155 Tb, 201 Tl, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 I, preferably 43 Sc, 44 Sc, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 99m Tc, 111 In, 152 Tb, 155 Tb, 203 Pb, 18 F. 76 Br, 77 Br, 123 I. 124 I. 125 I, most preferably 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 In, 18 F. 123 I and 124 I, and wherein the therapeutically active nuclide is a therapeutically active radionuclide, more preferably selected from 47 Sc, 67 Cu, 89 Sr. 90 Y. 153 Sm, 149 Tb, 161 Tb, 177 Lu, 186 Re, 188 Re, 212 Pb, 213 Bi, 223 Ra, 225 Ac, 226 Th, 227 Th, 131 I. 211 At, preferably 47 Sc, 67 Cu, 90 Y. 177 Lu, 188 Re, 212 Pb, 213 Bi, 225 Ac, 227 Th, 131 I. 211 At, and most preferably 90 Y. 177 Lu, 225 Ac, 227 Th, 131 I and 211 At.

10. A composition, preferably a pharmaceutical composition, wherein the composition comprises a compound according to any one of claims 1 to 9 and a pharmaceutically acceptable excipient; or A kit comprising a compound according to any one of claims 1 to 9, one or more optional excipients and optionally one or more devices, wherein the device is selected from a labeling device, a purification device, a manipulation device, a radiation protection device, an analysis device or an administration device.

Citation Information

Cited By

  • FAP-targeting compound and use thereof

    WO2026195063A1